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Abstract 
Neurodegenerative diseases such as the Alzheimer’s, Parkinson’s, multiple sclerosis etc., are 
typically characterised by the significant loss of neurons due to the activation of various 
signalling pathways including apoptotic mechanisms. However, though several natural 
inhibitors of apoptosis are being evaluated at pre-clinical and clinical levels none of them 
were reported to have strong neuroprotective activity. The primary aim of this project was to 
identify and apply the neuroprotector molecules that could rescue the neurons from a variety 
of insults associated with neurodegeneration. In addition, developing a nanoformulation of 
the neuroprotector to enhance the bioavailability and efficacy was the other aim of this study. 
Subsequently, survivin protein belonging to the inhibitors of apoptotic family (IAPs) was 
targeted as it exhibited bi-functional activities by regulating mitosis and apoptosis inhibition. 
These potentials of survivin ideally matched the neuroproliferation and neuroprotection 
strategy adopted for rescuing the neurons. Hence, survivin based neuroprotection is 
considered as a promising choice for developing the neurodegenerative therapeutics. Besides 
this, lactoferrin (Lf) an iron binding single chain glycoprotein protein was also used in this 
study after careful analysis of its multifunctional activities in vitro and in vivo. 
To begin with, a Baculovirus inhibitor of apoptosis protein repeat (BIR) motif mutant variety 
of survivin termed as the SurR9-C84A was used in this study obtained from the recombinant 
E.coli strain. This protein was identified to be different from the wild type possessing alanine 
instead of arginine at 84
th
 position and R9 peptide in its structure allowed rapid intracellular
permeation. Poly (lactic-co-glycolic acid) (PLGA) polymer was used to formulate the 
nanoparticles which showed the percentage encapsulation of (80.9 ± 2.12). The integrity of 
the protein remained intact post nano-encapsulation and showed enhanced stability. 
Surprisingly, the mutant protein showed differential actions against the undifferentiated    
SK-N-SH cells and the differentiated SK-N-SH neurons. 
iv 
The dominant negative action of the nano-encapsulated SurR9-C84A was evident post 
treating the undifferentiated neuroblastoma, expressing high endogenous pool of survivin 
where it exhibited a high percentage (84.8%) of cell death. However, the retinoic acid 
differentiated neurons with low endogenous survivin pool, showed proliferation evident with 
the significantly enhanced expression of proliferative markers PCNA (27.5%) and ki67 
(17%) respectively (p<0.05). In addition to this, SurR9-C84A also exhibited potent  anti-
autophagic activity contributing to a significant 2.3 folds reduction compared to the untreated 
group (p<0.05). 
Then the in vitro model of Alzheimer’s disease toxicity and its associated inflammatory insult 
was created by incubating the SK-N-SH neurons with β-amyloid plaques and activated       
THP-1 cell cytokine rich supernatants respectively. SurR9-C84A was found to have strong 
neuron rescuing activity against both these insults. With respect to β-amyloid toxicity          
SurR9-C84A showed a significant 6 fold reduction in the cytotoxicity along with a 1.5 fold 
increased neuronal integrity marker neurofilament 200 (NF 200) expression compared to the 
β-amyloid only treated group (p<0.05). In the instance of inflammatory insult, SurR9-C84A 
treated group showed 1.5 folds reduction in neuronal cell death followed by 3 folds increased 
expression of NF 200 (p<0.05). Further to this, the enhanced neuroprotective activity of 
SurR9-C84A was able to rescue the neurons from the D-Galactose induced senescence. 
SurR9-C84A significantly lowered the β-amyloid expression by 4.5 folds compared to 
untreated D-Gal insults (p<0.05). 
Finally, the differentiating actions of milk protein based bovine lactoferrin (bLf) and iron 
saturated lactoferrin (Fe-bLf) were investigated against the undifferentiated SK-N-SH 
neuroblastoma cells. The doses for bLf and Fe-bLf used in this study were way below the 
threshold dose known for their anti-cancer activity (a dose of 3200 µg is used in the lab for 
anti-cancer activity) and in addition the cells were treated cumulatively for 5 days. 
v 
Interestingly, both the proteins showed remarkable differentiating effects in the 
undifferentiated SK-N-SH tumor cells that were evident with the expression of neuron 
specific differentiating markers β-tubulin III and neurofilaments. 
Bovine Lf was able to enhance β-tubulin III and NF 200 expression by 45.7%, 40.6% 
respectively, while Fe-bLf showed increased expression of β-tubulin III  and NF 200 by 45% 
and 21.6% respectively (p<0.001). However, both the proteins shared a common ability in 
lowering the endogenous survivin expression that is highly essential for the proliferation, 
substantiating the fact that cells are undergoing differentiating. In addition, to this bLf and 
Fe-bLf influenced positively the expression of lactoferrin receptor and differentiation as 
observed with the miRNA 584-5p and miRNA 214-3p expression. This study revealed that 
bLf acts as a novel therapeutic molecule for treating a variety of neurological disorders. 
Hence, the differentiating effects would be beneficial in treating brain tumors and enhancing 
the neuronal strength in neurodegenerative diseases. 
To conclude both the neuroprotector compounds (SurR9-C84A and bLf) employed in this 
study showed significant neuronal rescuing activity and hold strong future neurotherapeutic 
application. The nanoformulated SurR9-C84A was able to induce proliferation in 
differentiated SK-N-SH neurons followed by saving them from the β-amyloid and 
inflammatory insults. On the other hand, bLf actions on the SK-N-SH neuroblastoma cells 
suggested its strong ability to induce differentiation in tumor cells and the same activity if 
tested will find valuable for strengthening the degenerating neurons. 
vi 
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Brain research in the 19
th
 century and at the beginning of 20
th
 has been focussed in different 
areas that varied in the methodology development and target identification. The latter had 
complex subcomponents of morphological, physiological and psychological aspects which 
made, understanding the brain a bit difficult. The average life span of an individual has 
significantly increased in the modern era due to the vast improvement in the quality of life. 
On the other hand, neurological disorders are also growing at an equal pace with the 
prolonged aging. Hence, a deeper understanding of the brain from molecular to behavioural 
level is necessary along with an increased scientific and technological research in an 
interdisciplinary way. To tackle the complex brain disorders, it would be fruitful only when 
the various scientific aspects are dealt in convergence rather than dealing them in isolation.   
1.1.Neurological disorders 
In the aging population, the frequency of neurological disorders like the Alzheimer’s, 
Parkinson’s, multiple sclerosis etc., including the primary brain tumors is significantly 
increasing [1]. The quality of life is again a critical factor for the incidence of these disorders 
and is highly influenced by the aging of the neurons in the central nervous system. These are 
increasing at a striking rate in the aging populations and contributing a major share of the 
disabilities. Neurological disorders can be divided into a variety of categories such as 
neurodegenerative, neuro-inflammatory and neoplastic diseases. Alzheimer’s disease (AD) is 
the most common of all the neurodegenerative diseases among the old age and following it 
are the Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), multiple sclerosis 
(MS) and Huntington’s disease [2].  
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In addition to these, HIV associated central nervous system (CNS) disease is prevailing as it 
turns out to be fertile for the replicating virus, where the virus reinfects and reactivates in the 
peripheral nerves through CNS [3]. Neoplasms of the brain are not to be neglected and they 
either originate from the neural elements or simply dissociate from the primary tumors and 
metastasize to the brain. Some of the primary tumors of the CNS are the gliomas and 
meningioma’s while the metastases from the other body parts like the breasts, lungs also 
contribute to the tumor generation [4].  
1.2. Neurodegenerative diseases 
The precise cause of neurodegeneration is not yet known but the evidences of past familial 
history and aging are considered to be posing high degree of risk. Age is significantly 
reflecting the abnormalities of neurodegeneration related to memory and motor symptoms 
thus driving the fact that more the age, more the risk of developing neurodegeneration.          
The other common causes of neurodegeneration are the excitotoxicity, mediated by the 
excitatory neurotransmitter glutamate where the deregulation of calcium homeostasis and 
generation of free radicals lead to neuronal death. Also, apoptotic mechanisms are hyper 
activated due to the generation of oxidative stress and mitochondrial dysregulation 
contributing to significant neuronal loss. In the case of neurodegeneration, neuropathological 
changes are strikingly evident in the form of neuronal loss, while the left out neurons show 
characteristic changes ranging from  changes in the cellular shape, size, nuclear 
defragmentation and intracellular protein accumulation. For instance, lewy bodies in PD [5]. 
Neurodegenerative diseases characterized by the abnormal aggregates of tau proteins are 






Alzheimer’s disease (AD) 
Alzheimer's disease is the commonest form of dementia primarily characterised by memory 
loss and loss of other intellectual abilities sufficient to worsen performance in daily life 
activities. The pathological hallmarks are the abnormal deposits of plaques and tangles that 
interfere with the viability of the nerve cells leading to degeneration. Plaques are amyloid 
deposits termed ‘Aβ’ and consist of 40-42 aminoacid long peptides formed by the abnormal 
segregation of amyloid precursor protein (APP). These plaques are deposited in the 
intercellular spaces and are detected using antibodies directed against amyloid plaques in the 
entire cerebral cortex region, hippocampus and in the arterial and capillary walls [6]. 
Neurofibrillary tangles are the twisted fibres of the abnormally phosphorylated microtubule-
associated protein called tau that is found intracellularly. Besides plaques and tangles,                
the pathological involvement of other proteins including presenelin 1 and 2, ApoE and           
α-synuclein have also been reported [7]. 
Progressive supranuclear palsy (PSP) 
Progressive supranuclear palsy (PSP) otherwise known as Steele-Richardson-Olszewski 
syndrome is a rare degenerative disease of the brain characterized histologically by the 
presence of neurofibrillary tangles. A constant loss of neurons and glial cells is seen in 
subcortical and cortical structures as well as in the pedunculopontine nuclei, the pretectal 
area, periaqueductal gray matter, superior colliculi, subthalamic nucleus, substantia nigra and 
nucleus dentatus [8]. Pathologically, the main distinction between PSP and AD is that the 
neurofibrillary tangles seen in PSP are not only restricted to neurons but are also seen in 






Frontotemporal dementia (FTD) 
FTD is characterized by the degeneration of neurons in the frontotemporal lobe and it is the 
second most important cause of dementia after AD. Abnormal deposition of 
hyperphosphorylated tau protein is detected in FTD like other tauopathies, but surprisingly, 
the rate of mutation and occurrence of tau protein abnormalities are seen only in less than half 
of FTD population [10]. 
Corticobasal degeneration (CBD) 
CBD is a rare and progressive neurodegenerative disease affecting the regions of the cerebral 
cortex and basal ganglia. It is characterized by the symptoms of Parkinsonism-like muscular 
rigidity, dystonia, akinesia and cognition defects, along with the abnormal tau protein 
deposits found in other degenerative diseases. The distinct pathology of CBD is the existence 
of gliosis and asymmetric distribution of large achromatic neurons in the cortical and 
subcortical regions affected [11]. 
Synucleinopathies 
Neurodegenerative disorders that are characterized by cytoplasmic inclusions of the 
presynaptic protein, alpha-synuclein in the neuronal and glial cell population are termed 
“synucleinopathies”. This group includes the following: 
Parkinson’s disease (PD) 
PD is classified as an age-related neurodegenerative disease that is progressive and 
characterised by the cardinal motor symptoms of rigidity, bradykinesia, tremors, akinesia and 
shuffling gait. It shows a striking pathological hallmark of degenerating dopaminergic 
neurons in the nigrostriatal region and is characterized by the inclusions of lewy bodies and 
lewy neuritis. These intraneuronal inclusions include ubiquitin, a regulatory protein that has 
the ability to recognise and destroy abnormal proteins aided by the proteasome and a 
presynaptic protein called α-synuclein.  
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The latter protein is altered under the influence of ubiquitin and hence, Parkinson’s disease is 
categorised as alpha synucleinopathy. In addition, genetic mutations in parkin, LRRK2, 
PINK1 genes contribute to the familial forms of PD [12, 13].  
Multiple system atrophy (MSA) 
MSA is characterized by the degeneration of central and autonomic nervous systems. Three 
neurodegenerative disorders namely striatonigral degeneration, olivopontocerebellar atrophy 
and Shy-Drager syndrome are integrated as MSA. The prominent histopathological feature of 
MSA is the occurrence of cytoplasmic inclusions in the glial cells with abnormal deposits of 
alpha synuclein [14].  
Dementia with lewy bodies (DLB) 
DLB is another variety of degenerative synucleinopathy characterized by abnormal 
aggregates of lewy bodies and its inclusions, ubiquitin and α-synuclein. The clinical features 
of DLB are manifested by impaired cognition, altered alertness and attention, depression, 
symptoms as seen in parkinsonism, autonomic failure and sleep abnormalities [15].
 
Huntington’s disease (HD)  
HD is a neurodegenerative disorder with striking effects on caudate nucleus. It shows an 
autosomal dominant pattern of inheritance and is characterized by choreiform moments and 
cognitive decline along with a presentation of psychic features [16]. 
Multiple sclerosis (MS)  
MS is a demyelinating disorder of the central nervous system characterized by inflammation 
and autoimmune attack. The pathology of demyelination process involves infiltration of 
lymphocytes mediating the degeneration of myelin sheaths of axons in the brain and spinal 
cord. The principle site of attack is the oligodendrocytes that synthesise myelin. The onset of 
disease is commonly in young adults and females are more commonly affected than males. 
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Neoplasms of the brain 
Brain tumors constitute the second most common cause of mortality among the CNS 
disorders next to stroke. Primarily, the classification of the brain tumors is based on the 
location and histological appearance. The common forms of the tumors include the gliomas 
accounting for 40% of the total CNS neoplasms and they arise from the glial tissues. It is 
further categorised to astrocytomas, oligodendrogliomas and ependymomas involving 
astrocytes, oligodendrocytes and ependymal cells respectively. These neoplasms frequently 
display loss of heterozygosity where the inactivation of tumor suppressor genes is evidently 
contributing to the development of tumors. Several other factors like the age, exposure to 
radiation, chemicals, environmental factors, infections etc., also contribute to the 
pathogenesis of the brain neoplasms [18]. 
Neuro-inflammation  
Inflammation is a host defence reaction against various insults and preliminarily designed to 
neutralize the noxious agents and their harmful effects. It has a complex network of cellular 
and molecular mechanisms to keep the insults under check. In the case of neurodegeneration, 
some of the potential triggers for generating inflammation could be the abnormally 
configured protein deposits (e.g. plaques in AD) or the signals generating from the injured 
neurons [19]. Unless cleared by the phagocytes, degenerating neuronal cells also provoke 
inflammation and this also depends on how the cell dies. The main effector cells mediating 
inflammation are the microglia and astrocytes that secrete an array of cytokines and execute 
the action. Microglia functions are of more generalised phagocytic type activating the 
complement cascade while astrocytes are involved in deletion of the individual synapses.  
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The neuronal damage always depends on the balance between the protective and destructive 
effects of microglia and astrocytes mediating neuro-inflammation. On account of the 
multifaceted roles played by these inflammatory mediators, it is rather difficult to conclude 
their specific role in the pathologic condition [20]. 
1.3. Research questions 
The research questions framed for this project were: 
1. How does the nanoformulated SurR9-C84A mutant targeting the wild type survivin 
exhibit dual actions against the normal and cancerous cells? 
2. What would be the effect of SurR9-C84A in the neurons subjected to degenerative 
insults, if it claims to have protective actions against the normal cells?   
3. How does it affect the neuroblastoma cells if the bovine and iron saturated lactoferrin 
















1.4. Aims and objectives 
The primary objective of this thesis was to develop a novel nanoformulation of cell 
permeable form of a BIR motif mutant of survivin (SurR9-C84A) and to evaluate its anti-
cancer and neuroprotective effects. To determine its differential actions against cancerous and 
non-cancerous cells, undifferentiated and differentiated SK-N-SH cell lines were studied 
respectively. Undifferentiated SK-N-SH cells, represent the neuronal tumor cells with high 
expression levels of the endogenous survivin while differentiated SK-N-SH behave like 
normal neurons. Differentiation of SK-N-SH cells was induced by retinoic acid for a period 
of two weeks and once differentiated they exit the cell cycle and exhibit neurite processes 
with relatively no or negligible levels of survivin [21]. Therefore, the aim of this study was to 
develop a novel dominant negative survivin treatment regimen which would selectively kill 
the brain tumor cells whilst protecting the differentiated neurons. Furthermore, 
neuroprotective functions of survivin mutant were also investigated against in vitro 
Alzheimer’s disease and its associated inflammation. The profound reason for targeting wild 
type survivin in this study is that its expression levels in cancer cells are relatively higher 
compared to the postmitotic cells like neurons. Based on the differential expression, the 
mutant form of survivin antagonises the wild type survivin in cancer cells exhibiting the 
dominant negative function. However, in the case of postmitotic neurons that are devoid of 
wild type survivin, it binds and stabilises the microtubule assembly promoting proliferation 
and protection [21]. A variety of survivin mutants have been introduced so far such as the 
survivin-C84A, survivin-D53A, survivin-T34A, survivin-T34A-C84A but the BIR motif 
mutant holds the unique ability to bind to the microtubule organising centre indistinguishable 
from wild type survivin [22]. Thus, the current approach is to employ the SurR9-C84A 
mutant (having potential involvement in mitosis) to protect the neurons, as it behaves 
indistinguishable to wild type in maintaining the microtubular dynamics.  
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In the broad spectrum of neurodegenerative diseases like the AD, PD, ALS, MS etc., neurons 
that are on the verge of  death express low or negligible endogenous pool of survivin and 
treatment in this condition with BIR mutant survivin would be highly effective. Finally, 
investigating the differentiating potential of the milk based proteins bovine lactoferrin (bLf) 
and iron saturated lactoferrin (Fe-bLf) on neuroblastoma cells was the conclusive study of 
this project. Lactoferrin exhibits a broad spectrum of physiological functions like the iron 
homeostasis, iron transportation and sequestration along with cytoprotective actions  such as 
anti-infective, anti-inflammatory and immunomodulatory functions [23]. Based on the multi-
functional activity and being a safe therapeutic (as it is a natural product) Lf entitles a potent 
therapeutic requiring attention. Hence, the project aimed to study its potential against 
neuroblastoma cells and this study is the first of a kind to investigate differentiating effects of 
bLf. 
To execute the research aims the experiments were set up as: 
 The void and mutant survivin loaded PLGA nanoparticles were prepared as per the 
modified double emulsion technique method. Complete characterization of the NPs 
was carried for shape, size, surface morphology, protein stability and release.                     
Surface modified NPs were also prepared by conjugating them with transferrin 









 The differential actions of survivin mutant were tested against the undifferentiated 
(cancerous) and differentiated (normal neuronal) SK-N-SH cells. As discussed, the 
SK-N-SH neuroblastoma cell line has a unique ability to undergo differentiation in the 
presence of retinoic acid. Preliminarily, the internalization of SurR9-C84A loaded 
PLGA nanoparticles were tested in both the cell lines. Following this, cell death and 
viability was tested using Live and Dead cell assay and CyQUANT assay.  
The apoptotic effects in undifferentiated SK-N-SH cells post treatments with              
SurR9-C84A were evaluated by propidium iodide staining, expression of caspase-3, 
Cyt-c (apoptotic markers). The neuroproliferative and protective effects in the  
differentiated SK-N-SH neurons were investigated by checking the expression of wild 
type survivin, proliferating cell nuclear antigen (PCNA) and Ki67 (cell proliferation 
markers) and Caspase-3, Cyt-c (apoptotic markers). 
 Post identifying the neuroproliferative and neuroprotective actions of survivin mutant 
light was thrown on to investigate its extended neuroprotection against the in vitro 
AD model and its associated inflammation. Initially, SurR9-C84A was tested for its 
neuroprotective activity against β-amyloid induced AD toxicity. To test its efficacy, 
the differentiated SK-N-SH neurons were pre-treated with SurR9-C84A followed by         
β-amyloid insults. Neuroprotective actions were investigated by a range of assays 
(Lactate dehydrogenase release assay, CyQUANT assay), flowcytometric analysis for 
PI staining, neuronal integrity marker expression (neurofilaments, β-tubulin III), gene 
expression study and finally with immune blotting. In addition to this, the 
neuroprotective actions of SurR9-C84A were also evaluated against the excitotoxicity 




 SurR9-C84A was then tested for its neuroprotective potential against the Alzheimer’s 
associated inflammation. To create the in vitro model of AD associated inflammation, 
microglial cells (THP-1) were differentiated and activated with the β-amyloid and 
bacterial lipopolysaccharides (LPS) insults. The cytokine rich supernatants were 
incubated with the differentiated SK-N-SH neurons pre-treated with SurR9-C84A. 
Then, the neuroprotective effects of survivin mutant were evaluated based on the 
reduced population of dead cells (PI staining), cells expressing lowered apoptotic 
markers (Caspase-3, Cyt-c) and cells expressing enhanced expression of neuronal 
integrity markers (neurofilaments).   
 Finally, the differentiating effects of low dose bovine Lactoferrin (bLf) and iron 
saturation lactoferrin (Fe-bLf) were tested on the SK-N-SH neuroblastoma cells 
(undifferentiated cancerous cells). bLf and Fe-bLf treated cells exhibited the 
differentiating effects post treatments with evident change in the morphology, and this 
was also confirmed with the expression of neuronal specific differentiating markers  
β-tubulin III, neurofilaments 68, 160 and 200 at the gene and protein levels. Thus, the 
milk protein based therapeutics were evaluated for the potential of differentiating the 











CHAPTER TWO   
LITERATURE REVIEW 
2.1. Introduction 
In the recent past, scientific understandings of the neurological diseases ranging from 
neurodegeneration to brain neoplasms has significantly improved. The term 
neurodegeneration often represents a pathological condition in which the neuronal cells tend 
to lose their structure or the ability to function normally. Diseases of the degenerative type 
share the common aetiology involving aggregation and deposits of abnormal protein misfolds 
along with a display of associated inflammation [24]. Being common to other cancer types, 
the brain neoplasms are equally harmful in inducing patient’s death. In the human body, brain 
occupies a privileged position and is constantly screened by the blood brain barrier from the 
toxins, chemicals and infections [25]. Hence, an ideal therapeutic should not only cross the 
BBB but also should be bioavailable for treating an ailment. In addition, neurons are unique 
from other cell types as they lack the ability to divide and self-repair further complicating the 
treatments. Precise mechanisms are yet to be identified to defend them against death and 
simultaneously preserve their integrity. Some of the past experimental findings were 
encouraging that suggested the inhibitors of apoptosis (IAP) could be potential candidates in 
resolving the neurological ailments [26]. As the current research project aims to target IAPs 
family, a decent effort is made to review the therapeutic potential and to target survivin 
protein. Along with that, detailed description of neurodegeneration pathophysiology in 
specific AD, current medications and the valuable future targets is provided. Last but not 
least, importance of nanodelivery in bypassing the BBB for brain delivery has also been 




2.2. Cell cycle in neurons 
Cell cycle is a carefully controlled process which is vital for the development, proliferation 
and differentiation of the neuronal cells. Improper regulation of the cell cycle is implicated in 
a variety of neurological disorders comprising both the acute damage and chronic 
degeneration leading to the death of the neurons. Activation of the cell cycle drive in the 
supporting astrocytes and microglia that usually associates the glial scar formation attracts the 
production of inflammatory factors that in turn play a key role in the CNS disease pathology.  
Thus, cell cycle regulation holds a central position in deciding the fate of the neurons that in 
turn provokes several disorders if deregulated [27]. The postmitotic nature of the neurons 
makes them unique from the rest of the body cells and these neurons continuously hold the 
cell cycle in check which would otherwise end up in huge cell loss. In the adult brain, the 
neural plate is comprised of hundreds of ectodermal cells which has the capacity to rapid cell 
division and give rise to the so called billion number of neurons. In the premature CNS, the 
polarised  epithelium known as the sub ventricular zone (VZ) arise from the stem cells and 
later on the second germinal region overgrows beyond it and termed as the sub ventricular 
zone (SVZ). As soon as the developing period ceases, VZ no longer supports the cell division 
and gets depleted of the mitotic cells whereas the SVZ shelters the precursor populations and 
takes charge of the neuronal cell production [28]. Once the adequate cell population is 
generated, the neurons migrate from this zone and permanently lose the ability to divide 
which makes them unique from other cells. To the researcher’s surprise, interesting questions 
need to be answered like what if the neurons exit their cell cycle and start dividing? However, 
several studies have proven that they die eventually. For instance, increased expression of 
cell cycle markers in neurons following the inactivation and subsequent release of 
transcription factor (E2F1) did not initiate the M-phase and culminated in the neuronal 
degeneration [29, 30].  
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The same concept applies in the case of degeneration, where some neurons were found to go 
through the G1/S checkpoint but failed to complete the G2/M transition and eventually ended 
up in cell death [31]. 
2.3. Blood brain barrier (BBB) 
The concept of BBB arose from the historical concepts where certain dyes administered 
through intravenous (i.v) route stained most of the body parts except the brain.
 
 While, the 
direct introduction of trypan blue into the CSF produced staining of majority of tissues in the 
central nervous system (CNS) [32]. Several other studies also proved that the brain capillary 
permeability is different from the peripheral tissues confirming the existence of a barrier 
strictly controlling the passages from the periphery to the brain. The BBB represents a triad 
of brain capillary endothelium, pericytes and the astrocytes along with several clusters of 
receptors, transporters, enzymes and efflux pumps. They form a complex and tightly 
regulated network screening the access of several molecules gaining entry to the CNS [4]. 
This highly regulated array of blood vessels poses a major hurdle for the treatment of 
neurological disorders and hence, exploring ways to deliver the drugs into the distinct areas 
of the brain is of paramount importance. However, on account of the rich vasculature inside 
the brain, molecules if once permeabilised become distributed throughout it. Based on this 
principle, a novel method sorted for delivering the therapeutics was via the vascular 
distribution, considering the extensive vasculature of the brain that constituted a surface area 
of 12 m
2
 [33]. Thus, if a drug is distributed in the blood compartment, there are more chances 
of the drug reaching the brain. However, this isn’t the case due to the existence of BBB 
comprising of tight layers of brain capillary endothelial cells along with astrocytes foot 
processes and the pericytes. Therefore, the prime focus of research is to identify the brain 
specific markers and develop the targeted therapeutics which would ensure the target specific 
delivery avoiding the unwanted drug disposition.  
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These brain specific targeting agents can be a variety of antibodies, transporters, or the drug 
enriched nanoparticles [34]. For example, the iron transporter transferrin receptor is more 
specific to the brain capillary endothelium and hence constitutes a potential delivery target 
for drug transport to the CNS [35]. Few other considerations for enhancing the brain delivery 
of therapeutics are: enhancing the lipophilicity of drug compounds, designing carriers for 
transporting the therapeutics or modifying the drugs that resemble the substrates of a normal 












Figure 2.1 Blood brain barrier and its components. Blood brain barrier is formed by the 
triad of pericytes, astrocytes and the brain capillary endothelium forming tight junctions 
regulating the brain traffic. The limited capacity of the brain penetration is to protect the brain 
from exogenous compounds such as toxins, infections and xenobiotics. Only the small 
molecules, less than the size of 400 Daltons and highly lipophilic substances have the 
privilege of brain permeation. This image is modified from the review published by       














Blood brain barrier 
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2.3.1. Transport mechanisms across BBB 
Diffusion: It is defined as a very simple transport  mechanism based on the concentration 
gradient principle. The key regulators that influence this transport mechanisms are the size 
and lipophilicity of the molecules. 
 
Carrier mediated transport: This process involves the transport of the molecules mediated by 
the carriers and can be either active or passive. This transport mechanism is vital in 
transporting the essential components like glucose, aminoacids, nucleosides and carboxylic 
acids.
 
Receptor mediated endocytosis: High molecular weight molecules are usually transported by  
this energy driven transport mechanism across the BBB. Insulin, albumin, etc., are some of 
the essential endogenous peptides driven through this mechanism and is highly suitable for 
developing targeted brain delivery therapeutics. 
Adsorption mediated transport: This process basically allows the movement of charged 
particles and favours the positive charged molecules transport across the capillary 
endothelium that is negatively charged. This unique feature of brain endothelium grabbed the 













Figure 2.2. Transport mechanisms across the blood brain barrier. 1) Passive diffusion: 
lipophilic substances dissolve in the cell membrane and cross the BBB. 2) Paracellular 
transport facilitates the transport through the intercellular spaces. 3) Carrier mediated 
transport across the BBB (e.g. Glucose transport). 4) Energy driven receptor mediated entry 
of the ligands for e.g. Insulin transport through insulin receptor. 5) The positively charged 
particles are transported through the negatively charged brain endothelium through the 
adsorptive mediated transport. This image is modified from the review published by     













Various transport mechanisms 
19 
 
2.4. Nanodelivery and targeted therapeutics 
In general, nanoparticles (NPs) are typically regarded as the colloidal drug delivery systems 
with a restricted size ranging in between 1-100 nm accomplished with a significant potential 
of therapeutic delivery. The added beauty of this technology is that they can deliver the active 
drug molecules to the desired tissues overcoming limitations of the membrane barriers        
(for e.g. brain) with improved localised delivery and maintaining its stability [5]. In addition, 
a huge surface area offered by the NPs on account of their smaller size also enables them to 
adsorb/bind the therapeutics and facilitate the drug bioavailability. Hence, due to the 
restricted solute moment imposed by the BBB, NPs mediated drug delivery could be a 
potential application for not only improving drug pharmacokinetics but also its dynamics.  
2.4.1. Nanotechnology in neurological diseases 
In a study, an improved brain delivery of rivastigmine an anti-AD drug was developed by 
Wilson and colleagues where the polymeric poly(n-butylcyanoacrylate) (PBCA) NPs  were 
employed. Comparatively, the nano formulated form of the drug showed improved patient 
outcome than the drug only treated patient group. In addition, the study has also improvised 
BBB penetration by modifying the surface of the NPs with a surfactant,  polysorbate-80 that 
improved the therapeutic availability of tacrine [38]. In an another study, magnetic chitosan 
NPs were used for the delivery of tacrine that helped in an improved ablation of the 
amyloidal plaques in the presence of a magnet [39].
 
The anti-Parkinson’s drug, 
bromocryptine upon encapsulation in solid lipid NPs showed enhanced bioavailability and 
efficacy when administered through intraperitoneal route compared to the free drug [40].                         
Also, improvisation in the delivery methods were made by coating the surface of 
tristearin/tricarpin suspended bromocriptine crystals with poloxamer-188 that displayed 
enhanced permeation into the brain [41].  
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Improved therapeutic outcome was noted in MS against oxidative damage and inflammation 
by incorporating an agonist of N-methyl-D-aspartic acid (NMDA) receptor in a 
nanoformulation [42]. Further, efforts are needed to develop a cutting edge NPs with 
specificity and precision. For e.g. it has been proven in vivo that, in experimental autoimmune 
encephalomyelitis (EAE) lymphocytes interact with their surface receptors α4β7, α4β1,  
LFA-1 with the corresponding mucosal vascular addressin cell adhesion molecule-1 
(MAdCAM-1), vascular cell adhesion molecule (VCAM) and intercellular adhesion molecule 
(ICAM) on the endothelial cells of BBB. This interaction facilitates easy migration and 
trafficking into the CNS and induces autoimmune diseases [26, 43]. Thus, decorating the NPs 
with targets specific to either of these molecules would be highly beneficial in treating the 

















Table 2.1. Nanotechnology applications for various neurological disorders 
Nano Application Function Ref 
Drug delivery 
Increased bioavailability   
Polysorbate 80 coated tacrine PBCA NPs. 
Polysorbate 80 coated gemcitabine PBCA NPs.   
Polysorbate 80 coated rivastigmine PBCA NPs. 







Improved Gene delivery 
Branched polyethyleneimine plasmid DNA delivery in vivo 
delivery.  








Protect and condense gene 
Biotinylated peptide nucleic acid conjugated with OX26-
streptavidin delivery to the brain. 
Matixmetalloproteinase (MMP) siRNA quantum dots for 
silencing MMP-9. 
Gene expression enhancement                                                                   
Chitosan oligomers employed for enhanced Green fluorescent 
















Iron oxide NPs for tracking macrophages using MRI. [49] 
Hippocampal neural cell growth detection using gold NPs.  [50] 
Tissue engineering 






Fe2O3 magnetic NPs employed for destroying cancer cells. 








Coupled photon dye TMPyP (Tetramethyl Pyridyl Porphyrin) 









FGFR, fibroblast growth factor receptor; 
2





PBCA, polybutylcyanoacrylate. The table is modified form the review 
published by Kanwar JR, Sun X, Punj V, Sriramoju B et al., 2012 [1]. 
2.4.2. Brain targeted nanodeliveries 
Considering the unique permeability characteristics of the BBB conventional therapeutics 
suffer serious resistance offered by it and end up with inadequate penetration. However, it is 
often possible to overcome this resistance either by disturbing the BBB integrity or by 
modifying the surface of NPs decorating them with brain specific targets. For instance, 
administration of bradykinin analogues generated enough osmotic pressure to open up the 
tight junctions of the BBB thus allowing the paracellular drug transport. This principle was 
adopted to enhance the permeation of hyperosmotic solution of arabinose when administered 
through the intracarotid route [55].
 
Though the former phenomenon allows rapid delivery of 
therapeutics, it is not always a safer practice to follow as there are also chances of undesired 
and toxic molecules gaining entry along with the therapeutics causing potential toxicities. 
Hence, the method of targeted delivery has gained significant attention and has been the 
prime focus of research. The potential benefits of targeted delivery are the enhanced 
therapeutic bioavailability, reduced non-specific distribution and ultimately reduced dosage 






MT-4 and Jurkat cells (human T-cell leukemia) were targeted by 




2.4.3. Surface modifications 
Antibody conjugation  
Understanding the physiology and anatomy of BBB would certainly facilitate the effective 
targeting and one such approach is to modify the NP surface with brain specific receptor. 
Transferrin receptor belongs to one such class and is widely studied for its high expression on 
the brain capillary endothelium [57]. Conjugation with transferrin receptor reported to 
enhance the brain transport of chemotherapeutic drugs like methotrexate and some proteins 
like fibroblast growth factor (FGF) and nerve growth factor (NGF) [58]. Starr et al 2005., 
patented megalin ligands that are specific to the brain and can be adopted for decorating the 
NPs [59]. Another attractive modification tried was the conjugation of NPs with human 




 [60].  
Modification by surfactants 
NP surface functionality highly influences the interaction of biological cells with the 
nanoparticulate system and hence their surface can be modified by surfactant coating [61, 
62].
 
Polyvinyl alcohol (PVA) is regarded as a bio-adhesive surfactant and can certainly 
influence the adhesion followed by adsorption in the intestinal cells. Reports were published 
earlier, coating the NP surface with polysorbate 80 (T-80) for brain specific delivery of 
doxorubicin and gemcitabine loaded PBCA NPs [44]. Other surfactant reported effective for 
the brain delivery was F68 modified PLGA NPs [63] and the mechanism behind the 
enhanced brain permeation is that surfactants inhibit the efflux protein actions and also 
solubilise the brain endothelial cell membrane lipids easing their entry. In addition to this, 
NPs surface modified with T-80 and F-68 adsorb lipoproteins ApoE or ApoB or both and 





Table 2.2. Appealing novel targets for brain specific delivery 
S.NO Targeting ligand Mechanism Result Ref 
1 Bovine serum albumin 
Adsorptive BBB delivery Specific uptake by the 
brain endothelial cells 
[64] 
2 Myristic acid 
Lipophilicity assisted 
transport 
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BBB, Blood brain barrier; 
2
GLUT1, glucose transporter; 
3
LRP1, low density lipoprotein 
receptor related protein 1; 
4
LDLR, low density lipoprotein receptor; 
5
MMP2, matrix 




Figure 2.3. Brain targeted delivery of neuroprotector compounds. Neuroprotector-loaded 
nanoparticles can be surface modified with a variety of brain specific targets.                      
(For e.g. transferrin receptors present on the brain capillary endothelium). In addition, the 
nanoparticle surface can be modified with efflux inhibitor for surpassing reduced drug 
availability and incorporated with +Ve charge for enhanced permeation. Once inside the 
brain, the NP releases the neuroprotectors and alleviates the existing ailment. The image is 
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2.4.4. Toxicity issues 
Though the targeted NPs represent the future treatment hope, it shouldn’t be ignored that 
BBB imposes a strong mechanism of defence against neurotoxic compounds including NPs. 
However, the application of targeted NPs is at a nascent stage studies convey that initial 
convincing results might not be acceptable later on. For instance, the much hyped quantum 
dots and carbon nanotubes were proved toxic in vivo [75] along with SiO2 and MNO NPs 
[76]. Another cause of potential neurotoxicity arose from the NPs functionalised with 
cationised proteins [77]. Contrarily, in regards to the safety, the most reliable NPs were 
presumed to be liposomes that are usually made of naturally occurring lipids [78] and iron 
oxide NPs [79]. In addition to this, the immune responses might develop towards the 
nanoencapsulated formulations and it is recommended to coat the nanoparticle surface with a 
hydrophilic coating to shield the immune recognition [80]. Considering these issues, the risk-
benefit ratio must always be outweighed for careful evaluation of engineered NPs.  
2.5. Brain neoplasms 
According to the world health organisation’s (WHO) estimate, the incidence ratio of 
malignant brain tumors is 3.5/100,000 worldwide. Tumors of the brain are rather difficult to 
diagnose and control, on account of their location in a more complex brain region and thus 
pose higher health risks [81]. For example, glioblastoma multiforme, the most common of all 
the CNS tumors represents the second most cause of cancer in individuals aging in the range 
of 35 years or less [82]. Due to the highly aggressive nature, invasion of the surrounding 
tissues of the brain is common eventually suppressing the normal brain tissue. This leads to 





The clinical presentation of these tumors can be either focal or generalised and include 
elevated intracranial pressure consisting of headache and with increased disease severity 
nausea, vomiting and sixth-nerve palsy are common. The diagnosis of brain tumors is rather 
tricky and magnetic resonance imaging (MRI) with gadolinium enhancement is the gold 
standard technique adopted for the detection. This is because other techniques such as 
computed tomography (CT) can miss out structural lesions and the non-proliferating low 
grade gliomas [84]. As per the WHO, three main types of brain tumors are categorised as 
astrocytomas, oligodendrogliomas and mixed oligoastrocytomas based on the four main 
features of nuclear atypia, microvascular proliferation, mitoses and necrosis. Astrocytomas 
further are classified based on the dedifferentiation potential into grade I pilocytic 
astrocytoma, grade II diffuse astrocytoma, grade III anaplastic and finally the grade IV 
glioblastoma which is the most common and aggressive of all [85]. Pilocytic astrocytomas 
mostly are seen in children and young adults and are confined to the optic tracts, 
hypothalamus or basal ganglia and the posterior fossa. The typical diagnostic features include 
the presence of high contrast tumors with cysts or mural nodule patterns upon imaging. 
Treatments include surgical resection for long term survival, along with radiotherapy and 
carboplatin based chemotherapy [86]. Diffuse astrocytomas, oligodendrogliomas and mixed 
oligo-astrocytomas represent the low-grade gliomas sharing several characteristics in 
common. They usually affect young adults (mean age 35-45 years) with a characteristic 
clinical presentation of partial or generalised seizures [87]. Radio and chemotherapy 
treatment should be considered separately for astrocytomas and oligodendrogliomas because 
the former respond profoundly with radiotherapy while the latter treatment needs both radio 
and chemo. Glioblastoma represents the high-grade or malignant astrocytoma and is the most 
common tumors of the brain affecting men more frequently than the women.  
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The mean age group for the onset is observed to be 53 years and unfortunately, treatment is 
available for symptomatic relief. The  primary aim of the treatment is to prolong the life of 
the patient improving neurological deficits and quality of life [86].  
2.5.1. Meningioma 
Meningiomas arise from the meningothelial cells that form the outermost membranous 
covering of the brain and hence not considered as absolute brain tumors. However, they are 
included in brain tumor category because they arise intracranially and present symptoms of 
neurological deficit [88]. These tumors are usually slow growing and occur primarily in the 
skull region reflecting the symptoms relative to the location. Headache is a common 
prognostic feature irrespective of the tumor site and is associated with the compression of 
nearby neural structures. Coming to the treatment, chemotherapy with hydroxy urea and 
doxorubicin were tried initially but were not encouraging in tumor reduction. Surgical 
removal is often found to be beneficial with a majority of the meningioma’s being benign but 
again it depends on the location of the tumor. This is because tumors found at the skull base 
are difficult to be removed as they intertwine with very vital organs increasing the 
complication [84].  
2.5.2. Primary central nervous system lymphoma 
They constitute 1% or less of all the primary brain tumors affecting majorly men over women 
and the significant risk factor associated with these tumors is the immunosuppression [89]. 
Considering the treatment, chemotherapy is the first choice and include methotrexate as the 








Neuroblastoma is an embryonal tumor, originating from the primitive cells of the autonomic 
nervous system and represents the most common childhood solid tumors affecting 10.2 cases 
per million children below the age of 15 years. Pathologically, the tumors arise in 
sympathetic nervous system tissues most commonly in the para-spinal ganglia or adrenal 
medulla, presenting the symptoms of mass lesions in the neck, chest, abdomen, or pelvis.  
The clinical presentation is often unnoticed at a primary tumor stage but poses striking illness 
upon invasion and metastatic spread of the tumor [91].  Interestingly, infants respond well to 
the minimal treatment showing complete regression while elder patients show aggressive 
metastatic disease and are difficult to treat even with multimodality therapy. Some of the 
unique features of neuroblastoma that have correlated with the therapeutic outcome are the 
oncogene amplification, allelic loss or the ploidy status. For instance, tumors with the near 
triploidy have shown a positive outcome, while those showing MYCN oncogene 
amplification or allelic loss at chromosome 1p, were found to be highly aggressive with poor 
prognosis. Similarly, tumors expressing neurotrophin receptor TrkA (NTRK1) end up 
showing apoptosis or differentiation while those expressing TrkB (NTRK2) show aggressive 
proliferation, particularly those associated with MYCN amplification [92]. Current treatment 
regimens for neuroblastoma include the high dose chemotherapy followed by secondary 
surgical extirpation, myeloablative therapy and biologic response modifiers. Among the 
chemotherapeutics, topotecan (topoisomerase I inhibitor) alone or in combination with 
cyclophosphamide were found fruitful [93]. Radiation therapy with meta-
iodobenzylguanidine (MIBG) is found beneficial where it is taken up and concentrated in 
secretory granules of the neuroblastoma cells [94].  
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Biologic response modifiers tried were retinoids (natural and synthetic vitamin-A derivatives) 
that showed a reduction in the growth inducing differentiation, targeted immunotherapeutics 
against disialoganglioside (GD2) which is specific to neuroblastoma. Other promising 
immunotherapies included were cytotoxic T-lymphocytes, trained dendritic cells, 
recombinant IC-2, granulocyte-macrophage colony stimulating factor (GM-CSF) 
and interleukin-2 (IL-2) [93]. 
2.6. Alzheimer’s disease  
Alzheimer’s disease (AD) is a chronic neurodegenerative disease with the pathological 
formation of neuritic plaques and neurofibrillary tangles that are respectively related to the 
abnormal accumulation of amyloid-beta (Aβ) peptide and hyperphosphorylation of 
microtubule associated protein called Tau. AD mostly affects the neocortical structures such 
as the hippocampus and medial temporal lobes thereby significantly affecting the memory 
and cognition. According to the amyloid hypothesis, deposition of Aβ is due to the abnormal 
cleavage of the amyloid precursor protein (APP). APP is a transmembrane, integral 
glycoprotein representing the class of most abundant and ubiquitously expressed CNS 
proteins. Aβ species vary in the number, aminoacid sequence and the fragments with 40 and 
42 aminoacids (Aβ40 and Aβ42) are exclusively abundant in the brain [95]. Cell biology 
studies have revealed that full length soluble Aβ originate predominantly in the Golgi/trans-
Golgi network and packed into secretory vesicles while the pathologic truncated Aβ are 
generated preferably in the endoplasmic reticulum. The truncated forms are rather insoluble 
posing problems for secretion and therefore remain accumulated [96].  The overproduction 
of Aβ is a result of dysregulated proteolytic cleavage of APP. Physiologically, it is 
metabolised by the secretory pathway (non amyloidogenic) which involves preliminary 
cleavage by α-secretase followed by γ-secretase.  
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In this pathway, the aminoacid sequences pertaining to the Aβ peptide are also cleaved  by α-
secretases thereby preventing the Aβ formation [97].  In the event of pathologic conditions, 
genetic, age-related and environmental factors drive the metabolic shift favouring the 
amyloidogenic pathway where the β-secretase enzyme alternatively cleaves APP. This 
generates a smaller N-terminal fragment (sAPPβ) and a longer C-terminal fragment (C99) 
where γ-secretase cleaves the amyloidogenic sequence yielding amyloid-β peptides (Aβ).    
Aβ species aggregate eventually forming dimers, trimers, oligomers and fibrils to generate 
the plaques and among these Aβ42 species is highly susceptible to aggregate posing severe 
neurotoxicity [98]. These plaques culminate the neuronal death activating the pro-
inflammatory cascades, increased oxidative stress, mitochondrial dysfunction [99] and impair 
intracellular signalling, tau phosphorylation, synaptic plasticity, calcium metabolism leading 
to the massive neuronal apoptosis [95]. Tau is a microtubule associated protein most 
abundantly expressed in both the peripheral and central nervous systems. In the neurons, it 
represents an important component of the cytoskeleton interacting with α and β-tubulins and 
its phosphorylation state is critical in maintaining the stability of the tubulins. It is a known 
fact that the microtubules regulate the structure, axonal transport of organelles, 
neurotransmitters and neuronal plasticity. Hence, dysregulation of tau phosphorylation 
negatively affects the microtubule structure affecting the cytoskeleton while   
hyperphosphorylation impairs axonal transport and synaptic metabolism [100]. The insoluble 
form of tau proteins are abundant in the paired helical filaments and represent the 
neurofibrillary tangles (NFTs). Thus, abnormal phosphorylation of tau proteins cause the 
cytoskeleton remodelling, microtubule instability, loss of cell viability and eventually end up 
in neuronal death [101]. Altogether, both these pathologic hallmarks result in significant 
neuronal loss, particularly of the cholinergic type where the neurotransmitter acetylcholine 
(Ach) plays a profound role in maintaining memory and cognition [102].  
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2.6.1. Inflammation in AD 
In AD, Aβ and NFTs represent the highly intractable structures are surrounded by the 
reactive microglia, activated astrocytes and the abnormal neurites of the degenerating neurons 
[103]. Though the brain is immune privileged, in the instance of abnormal plaque deposition, 
it initiates the immune response activation involving the microglial cells (resident 
macrophages) and the astrocytes. In addition, these depositions induce the nitric oxide (NO), 
reactive oxygen species (ROS) generation, alongside produce pro-inflammatory cytokines 
such as IL-1β, TNFα etc., thus initiating acute and chronic inflammatory responses [104]. All 
the Inflammatory participants and stressful events in turn provoke the APP processing and 
Aβ42 production stimulating the amyloidogenic pathway. All considerable neuroprotective 
events are abrogated including the formation of soluble APP that otherwise would support the 
neurons. In addition, Aβ plaques induce pro-inflammatory cytokines in glial cells, activate 
complement cascades and induce pathologic enzyme systems such as COX-2. All these 
events either alone or in concert with the abnormal deposits are highly detrimental and 






Figure 2.4. Alzheimer’s disease pathology. A) In a healthy brain, amyloid precursor protein 
is metabolised by the α-secretase enzyme following secretory pathway yielding soluble 
monomers and the microtubule associated tau protein regulates the intracellular homeostasis. 
B) In the event of the AD, APP is abnormally cleaved by the γ-secretase enzyme following 
the amyloidogenic pathway giving rise to insoluble Aβ plaques. Tau protein is abnormally 
phosphorylated leading to disturbed microtubule dynamics and the intracellular homeostasis.  
C) The Aβ plaques attract the microglia and astrocytes thus harbouring a potential source of 
the inflammatory cascade generation. The microglia and astrocytes turn reactive and amplify 
the inflammation secreting cytokines and finally culminate in neuronal death. The figure is 




















2.6.2. Treatment options 
Conventional therapy for AD is primarily symptomatic focussing to restore the cognition and 
improve the quality of life. Therefore, the mainstay of therapeutics used are the acetylcholine 
esterase inhibitors such as the donepezil, rivastigmine and galantamine that prevent the 
breakdown of Ach enhancing its half-life [106]. Drugs such as memantine were also being 
tried, as they protect the neurons from N-methyl D-aspartate (NMDA) receptor mediated 
excitotoxicity [107]. As oxidative stress and inflammation were evident from AD pathology, 
drugs possessing potent anti-oxidant properties such as α-tocopherol (vitamin-E) [108], 
ginkgo biloba extracts [109] and anti-inflammatory drugs such as ibuprofen, indomethacin, 
sulindac sulphide were used [110]. However, future therapeutics principally focuses either to 
prevent Aβ plaque formation or solubilize them soon after the formation. Semagacestat,         
a γ-secretase inhibitor is in trials for AD therapy and it acts by inhibiting Aβ plaque formation 
[111]. Some of the future therapeutics in trials include the vaccines for Aβ plaques, 
immunoglobulin antibodies against the tau proteins [112], humanized monoclonal antibodies, 
bapineuzumab [113] and solanezumab [114] for plaque solubilization, dimebolin 
hydrochloride, an antihistamine drug with strong neuroprotector activity [115] and finally 









Table 2.3. Various therapeutic options available for AD 





Acetylcholine esterase inhibition [106] 
2 Memantine 
N-methyl D-aspartate (NMDA) receptor 
mediated excitotoxicity inhibition 
[107] 
3 
α-Tocopherol    
(vitamin E); ginkgo 
biloba extracts 







Anti-inflammatory activity [110] 
5 Semagacestat γ-secretase inhibition and Aβ plaque formation [111] 
6 
Vaccines for Aβ 
plaques and Tau 
protein 












Strong neuroprotector activity [115] 
9 Bexarotene Aβ plaque solubilization [116] 
1
Aβ, amyloid beta. The table is modified from the review published by Kanwar RK, Sun X, 
Punj V, Sriramoju B et al., 2012 [1]. 
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2.6.3. In vitro aging associated neurodegeneration 
Aging is a continuous biological process associated with alteration in the physiological 
processes including pathological changes such as the formation of advanced glycation end 
products (AGEs) and oxidative stress [117]. In addition, aged individuals are reported to be 
much more susceptible to many of the chronic diseases such as the neurodegenerative type 
(AD, PD, MS etc.,) and the mitochondrial free radical toxicity [118]. A theory is also in 
existence, which states that aging and its associated disorders are a result of the free radical 
induced damage to the cellular components and that there exists no defence machinery with 
them to counteract this stress [119]. Eventually, the damaged mitochondria losses its integrity 
and becomes inefficient progressively secreting more of the free radicals as it is well known. 
Adding to it, the gradual aging always amplifies this condition further deteriorating the 
condition resulting in mitochondrial deoxyribonucleic acid (DNA) mutations, disturbed 
calcium homeostasis and abnormal mitochondrial structures [120]. Ultimately, increased 
susceptibility of aging to mitochondrial damage, oxidative stress, free radical generation 
leads to neuronal damage accelerating neurodegeneration [121]. AGEs are a group of 
heterogeneous compounds formed from the non-enzymatic catalysis of the reducing sugars 
(glucose, fructose etc.,) with the aminoacids present in proteins, DNA or lipids [122]. These 
AGEs were found to accumulate as the aging progresses and are associated with a number of 
age related diseases such as neurodegeneration [123, 124]. D-Galactose is one such 
compound obtained as a nutrient (e.g. Lactose in milk) and synthesised in the body, where it 
forms glycolipids and glycoproteins. In general, it is metabolised by D-galactokinase and 
galactose-1-phosphate uridyltransferase to non-toxic compounds [125] but at levels above the 
normal range it is metabolised to galactitol by aldose reductase that reacts abnormally with 
the aminoacids forming AGEs [126].  
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In the present study, D-Galactose (200 mM) was employed to induce neuronal injury 
mimicking the aging associated AD and the neuroprotector activity of SurR9-C84A is 
evaluated against it. 
2.7. Neuroprotection 
2.7.1. Neuroprotection through apoptotic inhibitors  
In general, brain usually responds to the stressful events adapting and responding to the 
unnatural habitat even up to the level of 50% of the cellular destruction. This phenomenon of 
survival in the milieu of harmful events is termed as preconditioning and is evident in the 
brain [127]. Apoptosis is an event of programmed cell death that is negatively regulated by a 
series of inhibitors namely Bcl-2 and IAPs that bind to the activated caspases and nullify 
them. The IAPs are unique molecules constituting at least one BIR domain in their structure 
containing 70 aminoacids. So far, this family was identified to contain 8 members which 
include X-linked inhibitor of apoptosis (XIAP), cellular IAP1 (cIAP1), cellular IAP2 
(cIAP2), survivin, livin/melanoma-IAP (ML-IAP), Bruce (apollon), ILP-2 and neuronal 
apoptosis inhibitory protein (NAIP) [128]. Among them cIAP1, cIAP2, XIAP and survivin 
were found to be overexpressed in a majority of the human malignancies [129, 130] while 
there is a lack of substantial data explaining their role and expression levels in 
neurodegenerative diseases. However, few reports indicated that AD patients showed lowered 
levels of NIAP with a slight upregulation of XIAP [131] while survivin showed initial 
suppression followed by an increase in the advanced stage amyotrophic lateral sclerosis and 
cerebral ischemia [132]. As discussed, strenuous efforts have been made in developing 
various inhibitors of survivin ranging from mutant varieties to gene silencing therapies for 




In contrast to this, members of IAP family such as XIAP that showed elevated levels in 
transgenic mice showed enhanced protective activity in them against the middle cerebral 
artery (MCA) occlusion compared to the non-transgenic controls [133]. Added to this, NAIP 
levels were elevated in rat hippocampus and an add on adenoviral delivery of NAIP showed 
enhanced protective activity against transient forebrain ischemia [134]. Similarly, adenoviral 
mediated delivery of NAIP, IAP1 and IAP2 protected the rats against sciatic axotomy. 
Furthermore, TAT (membrane transport peptide) sequence tagged BH4 domain of Bcl-XL 
protein protected the endothelial cells and neurons post hypoxia/ischemic insults [135]. 
Coming to the role of survivin and its partners, it has been well established that brain 
development is in absolute need of survivin and its interaction with XIAP. Survivin has 
multifunctional roles regulating cell division, development and apoptosis and a slight 
disturbance in its expression levels will result in brain hypoplasty and embryonic deaths.       
It has also been reported that in addition to neurodevelopmental defects, there were 
associated cardiogenic and angiogenic malfunctioning post depletion of Birc5a (human 
survivin homologue in zebra fish) [136]. Additionally, survivin was found to accumulate in 
the nucleus and co-localise with the cleaved Caspase-3 in the reactive astrocytes as a result of 
excitotoxicity in the cortex and its adjacent areas [137]. To conclude, the bottom line is 
survivin plays a crucial role in neuronal generation, growth, development and differentiation. 
Considering the potential of survivin in cell proliferation, it attracted lot of attention as a 
potential target for cancer therapy and no significant attempts were made to evaluate its role 







Table 2.4. Neuroprotective activity of various IAPs 
IAP molecule Mechanism Protection towards Ref 
NAIP 




Inhibition of oxidative 
stress 


















and its inhibition 














Survivin belongs to the family of inhibitor of apoptotic proteins (IAPs) bearing a molecular 
mass of 16.5 KDa and consists of single IAP repeat domain along with an α-helical coiled-
coil domain in the carboxyl-terminal. It has a unique feature as compared to the other IAPs, 
in lacking the RING-finger domain [139]. In humans, the location of survivin is on the 
telomeric position of chromosome 17 and is transcribed from the TATA-less, GC-rich 
promoter region generating the wild type and splice variants [140]. Physiologically, survivin 
exhibits dual actions regulating both the processes of cell division and apoptosis. However, 
its activity is in turn regulated by the several post-translational modifications such as 
phosphorylation by p34cdc2 and aurora-B-kinases and ubiquitylation [141]. 
2.8.1. Survivin and neuronal cell division 
During the embryonic stage soon after the initiation of neurogenesis, neuronal lineage has a 
capacity of undergoing 11 cell divisions before the neuronal production is halted. Most of the 
mitotic divisions take place in the ventricular zone (VZ) of the brain and eventually the cell 
divisions stop after the developmental period is terminated. However, in the adults, the supra 
ventricular zone (SVZ) harbours the stem cell precursors and takes the role of germinating 
new cells for the final division [142, 143]. The developing brain desperately needs survivin 
on account of its strong interaction with intracellular networks that mediate the mitosis and 
the microtubular dynamics [144]. Survivin in association with the other activating subunits, 
INCENP and Borealin/Darsa B forms the chromosomal passenger complex (CPC) that is 
critical for the initiation of mitosis and meiosis. Initially, survivin dimerises with Borealin 
proceeding towards the central spindle and thereby guides the aurora-B-kinase to its 
phosphorylation site [145]. Another unique feature attributed to survivin is due to the lack of 
intact BIR motif (Baculovirus inhibitor of apoptosis protein repeat) rendering improper CPC- 
central spindle localisation.  
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Thus, it is concluded that the regulatory and dimerization domains of survivin are different to 
each other. The same is also substantiated form our previous studies, where the BIR motif 
mutant of survivin was able to induce cell division in differentiated neuronal cells indicating 
the regulatory role of survivin-aurora-B-kinase for proper chromosomal segregation and 
mitosis [21].     
 
Figure 2.5. Regulation of survivin in neuronal cell division. Survivin dimerises with 
Borealin/DARSA initially followed by INCENP and thereby guides the aurora kinase 
phosphorylation. Thus, survivin organises the chromosomal passenger complex formation 
and stabilises the microtubule dynamics at kinetochores. An independent pool of survivin 
also favours the spindle formation thereby allowing the proper chromosomal alignment and 
therefore the cell division. Hence, survivin is very vital for the initiation and mitosis 
progression. The image is modified from the reviews published by Altieri DC, 2006 [146] 
and Baratchi et al, 2010 [324].  
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2.8.2. Survivin and microtubules 
Microtubules (MT) represent the cellular cytoskeleton and regulate the dynamic stability 
intracellularly. They possess some of the key prognostic features in the neurons facilitating 
the processes of cell division, migration, intracellular transport and differentiation. With 
respect to the association survivin in addition to forming the CPC, interacts and binds with 
the polymerised microtubules and attributes stability to them [146]. The mutual interaction 
between them was studied by Si et al 2009., where the increased expression of survivin and 
microtubule associated protein-2 (MAP-2) was found to improve the motor function recovery 
[147]. In contrast, MT dynamics are strongly influenced negatively upon forceful expression 
of survivin which would lead to the reduced pole-pole distance at metaphase, suppressed MT 
growth and stability and eventually end up in cell death [148]. On the other hand, survivin is 
highly essential for proper chromosomal alignment on the microtubule spindle apparatus and 
bio-orientation of them prior to anaphase [149]. 
2.8.3. Survivin and the intracellular balance 
In all the cells including neurons, the intracellular nuclear-cytoplasmic transport of survivin is 
facilitated by the transport receptors following specific signals through the nuclear pore 
complexes. This dynamic process of survivin transport is regulated by a series of signals 
termed as the nuclear export signals (NESs) and dimerize with XPO1 (human homolog of 
yeast Crm1) for effective functioning [150]. NES signals strictly confine the cytoplasmic 
location of survivin, while the nuclear import of survivin is mediated through the short basic 
aminoacid sequences known as nuclear localization signals (NLSs) that in association with 
cytoplasmic import receptors execute the function. However, on account of its low molecular 
weight a majority of the nuclear survivin import occurs through passive diffusion rather than 
NLS activity [151]. This nuclear-cytoplasmic transport is highly important in determining the 
role of survivin in nucleus for cell division or in the cytoplasm for apoptosis.  
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It is observed that in tumor cells, a majority of survivin is located in the subcellular locations 
and therefore the cytoplasmic fraction of survivin was rendered for cytoprotective actions 
while the nuclear actions of it were impaired [151]. Several studies have also proved the same 
where a majority of patients with higher nuclear survivin fractions had poor survival rates 
[152, 153]. Thus, it provides a useful clue for future neurodegeneration therapy where the 
cytoprotective cytoplasmic fraction and proliferative nuclear fraction can be studied.  
2.8.4. Survivin variants and mutants 
Human wild type survivin is encoded by 4 exons constituting 142 aminoacids and till date  14 
different variants of it are reported of which only four varieties Sur2α, Sur2B, SurΔEx3, 
Sur3B are extensively studied for their anti and pro-apoptotic actions [154]. In contrast to the 
wild type survivin, Sur2B and SurΔEx3 show reduced affinity for Borealin and therefore 
cannot proceed for the CPC formation and in addition a 23-aminoacid insertion in Sur2B 
variant interrupts the Smac/Diablo interaction domain [155]. However, some similarities exist 
for Sur2B and wild-type Survivin in that both can exist in nucleus and the cytoplasm while 
SurΔEx3 is exclusively located in nucleus regulating the proliferation and no sign of its 
existence is observed in G0/G1 arrested cells. Comparing the activity Sur2B and SurΔEx3 
contradict each other where the former has no anti-apoptotic activity despite localised in the 
cytoplasm with NES domain existence, while the latter shows anti-apoptotic activity despite 
lacking nuclear localization and NES domain [156, 157]. With respect to the expression, wild 
type survivin, Sur2B and ΔEx3 are predominant in the embryonic stage, while mature brain 
shows traces of ΔEx3 alone [158]. The Sur3B variant shows an intact BIR and the 
Smac/Diablo interaction domains along with the zinc coordinating aminoacids. However, 
when compared to wild type, Sur3B has a C-terminal and the BIR motif is significantly 
interrupted because of the deletion of exon 3. But surprisingly, it still exhibited the anti-
apoptotic effect where an otherwise action was anticipated [159, 160].  
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Interestingly,  Sur2B and 3B are the only variants that satisfy the requirements for dimerising 
with the wild type but for unknown reasons the other two varieties ΔEx3 and 2α were also 
found to have this activity [159]. After the characterization of various survivin variants, 
several mutant forms of wild type survivin have been developed with the prime aim of 
structural evaluation and later evaluated for therapeutic applications. Hence, attention has 
been focussed on developing macromolecules for targeting survivin and thus the survivin 
mutants became popularised. These mutants were referred as the dominant-negative survivin 
mutants differing form wild type in one aminoacid and this single aminoacid substitution 
made them act as competitive antagonists. The first survivin mutant to be introduced was 
SurC84A where arginine replaced cysteine at 84
th
 position and named as the survivin BIR 
mutant. The alteration in aminoacid sequence rendered the mutant variety with potent 
apoptotic activity along with the hydrolysis of aminoacid sequence DEVD, target for 
Caspase-3 [22]. Another mutant introduced was the Δ106 lacking the C-terminal and 
exhibiting localisation neither to kinetochores during metaphase nor the spindle midbody 
during telophase [161].  Later H80A, a zinc binding site mutant, E51A and L64A mutants 
with no known effects on HeLa cells were discovered. In addition, H80, E76 and G66 
mutants with pro-apoptotic effects and D71A mutant with pro-apoptotic effects on account of 
the changes in survivin dimeric organization and its negative charge were also introduced 
[162]. Chakravarti et al 2004., reported the T34A mutant where it suppressed TRAIL induced 
extrinsic apoptosis by blocking the phosphorylation at T34 position in cancer cells but was 
also found to induce sensitivity to X-rays in glioma cells [163]. Recently, it has been reported 
that the D53A mutant showed actions similar to wild type showing cytoplasmic localisation 




The mechanism by which it induced apoptosis was by binding to the wild type and making it 
unavailable for interacting with Smac/DIABLO complex thereby activating p53 mediated 
apoptosis [164]. Finally, DD70-71AA mutant was developed that has the ability to localize to 
the CPC complex during metaphase but has the inability of binding to the kinetochore 
midbody. When tested in vitro, it showed abnormal cytokinesis resulting in multinucleated 
















Figure 2.6. Map of pGEX-2T vector and survivin mutant construct 
The cell penetrating survivin mutant (SurR9-C84A) was constructed by fusing the 9             
N-terminal arginine residues (R9, cell-permeable peptide carrier) with the dominant negative 
survivin. Then, the cDNA of a pcDNA3 plasmid expressing the SurR9-C84A protein, where 
cysteine was replaced with alanine at 84
th
 position was amplified and subsequently sub-
cloned into pGEM-T. Following this, it was digested with BamHI, cloned into the pGEX-2T 
expression vector and then incorporated into the E.coli (BL421 strain) for SurR9-C84A 
expression. This figure is modified from the thesis entitled “Proliferative and protective 
effects of survivin mutant on differentiated neuroblastoma” submitted by Sara Baratchi 2010 




SurR9-C84A mutant construct 
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2.8.5. Small molecule inhibitors and peptidomimetics 
YM155, chemically termed as monobromide (1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-
(pyrazin-2-ylmethyl)-4,9-dihydro-1H naphtho[2,3-d]imidazolium bromide) is a novel small 
molecule survivin inhibitor evaluated for its potent anti-cancer activity both at pre-clinical 
and clinical stages. It shows anti-cancer activity by binding to the SP1 rich region of survivin 
promoter region and was found to be effective against several in vitro cancer cell lines [166-
168]. FL118, is an another small molecule survivin gene inhibitor and chemically known as 
(7-ethyl-7-hydroxy-(7S)-7,8,11,13-tetrahydro-10H-[1,3]-dioxolo[4,5-g] pyrano[30,40:6,7] 
indolizino[1,2-b]quinoline-8,11-dione). Structurally it resembles irinotecan (DNA Top1 
inhibitor) but exhibits anti-tumor activity inhibiting survivin in a p53 independent manner 
along with an activity against the survivin associated genes such as XIAP, Mcl-1 and clAP2. 
It showed potent anti-tumor activity against HCT116 (colon), A549 (lung), MCF7 (breast) 
and PC-3 (prostate) cancer cell lines in nano molar concentrations in vitro [169]. Shepherdin 
is a peptidomimetic analogue designed to act against survivin and its mechanism is explained 
as: Shepherdin binds to the ATP pocket of HSP90 and thereby physically interrupts the 
association of HSP90 and wild type survivin which is vital for survivin stability. Based on 
this principle, it was tested against the in vitro and in vivo tumor models and was found to 
have significant anti-tumor activity with least toxicity [170]. 5-deazaflavin analogue was an 
another survivin inhibitor demonstrated by Oikawa et al., where it was found to dissociate the 
Survivin–Smac/DIABLO interaction thereby rendering the interactions weaker [171].           
In addition to targeting survivin by small molecule inhibitors, antisense oligonucleotides such 
as the oligonucleotide 4003 constituting the sequence (5’-CCCAGCCTTCCAGCTCCTTG-
3’) were also developed. It basically acts by silencing the mRNA (nucleotide 232–251) of 
survivin thereby inhibiting its activity and the same was also observed upon testing in A549 
and HepG2 cancer cells in vitro [172].  
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LY2181308 is a modified second generation antisense oligonucleotide bearing                      
2’-O-methoxyethyl modified 18-mer structure (5’-TGTGCTATTCTGTGAATT-3’) with 
more enhanced stability and  half-life compared to the conventional RNA/DNA based 
therapeutics. It acts by binding to the 3’-untranslated region of the survivin transcript and 
causes the RNase H mediated degradation of survivin RNA [173].  SPC3042 (also called as 
EZN-3042) is another antisense 16-mer locked nucleic acid (LNA) oligonucleotide bearing 
the following sequence (5’-CTCAATCCATGGCAGC-3’).  It acts by binding to the exon 4 
of the survivin transcript and the same was demonstrated in vitro where a dose of nanomolar 
concentration induced severe toxicity in 15PC3, a prostate cancer cell line [174]. The 


















Table 2.5. Various survivin mutants and inhibitors 
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This table is modified from the thesis entitled “Proliferative and protective effects of survivin 
mutant on differentiated neuroblastoma” submitted by Sara Baratchi 2010 under the guidance 
of Prof. Jagat Kanwar.  
2.8.6. Survivin, apoptosis and autophagy 
Apoptosis in the CNS is categorised as the pathologic hallmarks of acute and chronic 
neurological disease condition. In acute disease states, apoptosis is usually seen in the areas 
that are seriously affected by the injury for instance, the lesioned site in the ischemic brain 
while in the chronic disease condition apoptosis is the predominant mode of cell death [179]. 
Considering the role of survivin, as discussed it has an important role to play regulating the 
intracellular balance, MT dynamics and stability and cell division. Above all, it also evades 
the cellular apoptosis and is explained as follows: Survivin exhibits dominant anti-apoptotic 
activity, a feature commonly observed in the rapidly proliferating cancer cells. It renders this 
activity, initially by binding to the hepatitis-B-X-interacting protein (HBXIP) and forms a 
complex. The survivin-HBXIP complex then attracts the pro-caspase 9 driving it away from 
the mitochondrial Cyt-c pathway thus avoiding the apoptosis [180]. In addition, the cytosolic 
fraction of survivin dimerises with the X-inhibitor of apoptotic protein (XIAP) and protects it 
against ubiquitination/ proteasomal destruction. Thus, survivin enhances its ability to bypass 
apoptosis evading the activation of Caspase-3 although this dimerization can be destabilised 
by survivin phosphorylation at Ser20 mediated by cyclic AMP-dependent protein kinase-A 
(PKA) [181]. Contradictorily, nuclear survivin complex regulates cytokinesis without having 
much to stop the apoptosis. Survivin is predicted to display antagonistic actions towards the 







Figure 2.7. Survivin and apoptosis inhibition. In response to cell-death stimuli, 
cytoplasmic fraction of survivin is localised in the mitochondria and finally released into the 
cytoplasm. The mitochondrial fraction of survivin interacts with the co-factor molecules 
HBXIB and XIAP to inhibit the apoptosome formation and reduces the availability of free 
levels of Caspase-3. Thus, survivin acts against the apoptosis through the mitochondrial 








However, antagonising the wild type survivin actions by employing small interfering RNA 
and dominant negative mutants have been found to be associated with mitotic arrest and 
apoptosis based on the cell type [26, 183]. Interestingly, some studies showed that survivin 
has the ability to bind directly with caspase-3 and caspase-7 with nanomolar affinity and 
confirmed through immunoprecipitation studies [184]. Several contradictory results were also 
reported on the structural modifications and their relation to apoptosis. For instance, wild 
type survivin was observed to bind with caspase-9 in cancer cells, while the mutant SurT34A 
lacking the phosphorylation site showed absolutely null binding [185]. Another study 
reported interesting results, where survivin phosphorylation at threonine 34 by cdk1 
promoted its cytoprotective activity in cancer cells avoiding mitosis [186] while Plk1 kinase 
dependant  phosphorylation at serine 20 prompted it to accurately align the chromosomes 
[187]. In addition to these, there are growing evidences of survivin interference with the 
cellular autophagy process showing an inverse relation where survivin downregulation 
provoked autophagy-dependent apoptosis. Several studies have tried to elucidate the relation 
of survivin and autophagy and interesting results have been reported. Niu et al 2010., 
conducted a study where knock down of autophagy regulator beclin-1 promoted TRAIL-
induced apoptosis in glioma cells and introduction of survivin antagonized this activity [188]. 
Other reports include the evasion of autophagic cell death in human PC3 prostate cancer cells 
treated with CCL2 (chemokine motif) following the phosphatidylinositol-3-kinase 
(PI3K)/Akt/ survivin pathway [189] and autophagy-mediated apoptosis induction in prostate 







2.8.7. Survivin and mitochondria 
Mitochondria are the vital organelles regulating the power consumption in the cells but can 
also execute the cell death mechanisms in response to the stress signals particularly in 
neurodegenerative diseases. The whole phenomenon is explained as deviations in the 
mitochondrial trans- membrane potential generate free radicals depleting ATP levels and then 
release vital apoptotic factors such as Cyt-c [191]. In contrast, mitochondria can also evade 
apoptosis through the mediation of mitochondrial pool of survivin (Fig 2.6). The release of 
survivin from the mitochondrial pool occurs in response to the activation of checkpoint 
kinase 2 (ChK2) and cell death signal generation where it prevents the DNA damage and 
apoptosis respectively [181]. In general, the putative mitochondrial pool of survivin is 
associated with tumor formation but what remains unclear till date is how survivin 
internalizes into mitochondria. However, there are speculations about the involvement of 
chaperone proteins HSP90 and apoptotic inhibitor protein (AIP) in facilitating the survivin 
transport [192]. It should also be noted that cytosol synthesizes the necessary mitochondrial 
proteins and are transported via the outer membrane transport proteins such N-terminal motif 
of precursor proteins or the TOM20/TOM70 receptor proteins [193].  One of the noticeable 
actions of survivin is its ability to block the apoptosis and this property is accomplished by 
the post translational phosphorylation modification by tyrosine kinase-A (TKA) at survivin 
ser20 position. This whole process cannot be executed in mitochondria due to the absence of 
TKA and eventually survivin binds to the SMAC/DIABLO complex, activates XIAP and 







2.8.8. Survivin and neuroprotection   
The neuronal genesis has always been fascinating supporting the fact that neurons are 
generated from the locally existing neuronal progenitor cells (NPCs). However, the neuronal 
generation is a complex and highly controlled process regulated by the NPCs 
microenvironment. The study conducted by Miranda et al 2012., evidenced for the first time 
that astrocytes influence the NPCs microenvironment by regulating the Wnt signalling and 
this cellular cross talk reduced  the proliferation of the NPCs and thereby the neuronal 
genesis. The intracellular events evidenced were that astrocytes downregulated the expression 
of survivin, the mitotic regulator in NPCs and this was responsible for reduced proliferation. 
As a proof of concept, it was also observed that the introduction of survivin restored the NPC 
proliferation in the brain. Thus, the conclusive results can be summarised as neurogenesis in 
the adult is possible either by modulating the survivin expression or the Wnt signalling [194]. 
The neuroprotector activity of survivin was confirmed in an in vitro model of multiple 
sclerosis where mouse brain astrocytes were insulted with BeAn strain of TMEV. Interesting 
results were reported with the upregulation of survivin expression confirmed by the RT-PCR 
and qPCR. The upregulated survivin was found to form a complex with caspase-3 enzyme 
nullifying the apoptotic events to be followed. Also, the enzymatic activity of caspase-3 was 
not detected in the colorimetric studies conducted further confirming the fact that astrocytes 
were being protected by survivin and its complexation with caspase-3 [195]. Reports have 
also been published that neuronal death can be avoided by employing the principles of 
neuroprotection and neuroproliferation proposing that anti-apoptotic molecules (for e.g.     
Bcl-2) and IAPs such as survivin appropriately suit the condition [196].
 
Likewise, the 
survivin mutant, SurR9-C84A was found to exhibit neuroproliferative activity by elevating 
the expression of cell division markers in the differentiated SK-N-SH neurons [21].  
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Also, its potential as a neuroprotective compound was tested against the H2O2 and T-cell 
mediated neurotoxicity and interestingly, SurR9-C84A rescued the neurons in both the 
occasions [138, 197].  
2.9. Lactoferrin 
Lactoferrin (Lf) belongs to the family of glycoprotein and is an iron binding single chain 
protein molecule consisting of 690 aminoacid residues with an average size of 70-80 KDa. 
Innately, it possesses natural defence mechanisms and is present in a majority of the body 
secretions. Structural analysis of Lf revealed that internally it is folded in the homologous   
N- and C-terminal lobes and independent domains were found to enclose the binding sites for 
iron. The internal lobes of natural Lf are not completely saturated with iron and 
approximately only 15% of iron saturation is observed in unmodified pure Lf. It exhibits a 
high iron binding capacity as the protein ligands in its structure offer the desired negative 
charge essential for strong Fe
3+ 
binding creating hostile conditions for iron release. Therefore, 
the release of iron is only possible either by the receptors or when the pH levels are lowered 
to the level enough to destabilise the protein. The affinity of Lf is not only limited to Fe
3+
 





. In contrast to this binding, Lf can also be made metal free and this free form of Lf is 
called as the apo-Lf [198]. Though reversible, Lf shows a tight high affinity binding to two 
Fe
3+ 
ions and is regarded as one of its unique physicochemical feature. Comparing the other 
members of transferrin family, Lf shows specificity in iron binding and release where a lower 
pH (~3) tends to bind and a pH higher than 5.5 tends to release Fe
3+
ions. On the basis of this 
feature, it was presumed earlier that the prime function of Lf was to absorb the iron but 




Some of the noticeable actions of Lf other than iron absorption are augmentation of intestinal 
cell growth, exerting defensive reactions against microbial infections, regulation of immune 
responses and myelopoiesis [201]. Added to this, the protective actions of Lf are confirmed 
with some previous studies reporting the elevated levels of it in pathological conditions of 
neurodegeneration [202], inflammatory diseases such as asthma, arthritis [203] and intestinal 
bowel diseases [204]. In all of these ailments, levels of Lf were seemed to be elevated 
suggesting its protective role. Several reports also exist supporting the Lf anti-inflammatory 
actions of against airway obstruction and hyper-responsiveness collagen-induced arthritis
 
and 
contact allergen induced inflammation [205]. In addition to this, bovine Lf (bLf) was found to 
exhibit profound anti-cancer activities in the tumor model of mice challenged with chemical 
carcinogen along with a negative regulation of tumor metastasis [201, 206]. Interesting 
advancements were also made where oral administration of recombinant human lactoferrin 
(talactoferrin) was found to effectively regress the human squamous carcinoma developed in 
the immune compromised nude mice [207]. Thus, considering the multi-functional activities 





Figure 2.8. Lactoferrin and its multi-functional activities. In addition to preliminary 
evaluation of a role in iron absorption, Lf exhibits actions against inflammation and cancer. 
Further to this, it also has a role in promoting the intestinal cell growth, myelopoiesis and 











MATERIAL AND METHODS 
3.1. Cell lines and culture conditions 
All the cell lines used in this study were obtained from the American type culture collection 
(ATCC). SK-N-SH neuroblastoma cell lines were grown as a monolayer in Eagle’s minimum 
essential medium (EMEM, Invitrogen) supplemented with 10% of foetal bovine serum, 1% 
penicillin and streptomycin at 37
o
C in a saturated humid atmosphere with 5% CO2. 
Undifferentiated SK-N-SH cells are generated from the bone marrow metastasis and are 
subdivided into neuroblasts (N) cells, substrate adherent non-neuronal (S) cells and the  
intermediate (I) cells. N-type cells exhibit the short neuronal processes while the S-type are 
rather flat and strongly bound to the substrate. The T-type cells display intermediate 
properties of both N and S cells with or without neuronal processes and substrate adherence. 
In order to induce the differentiation, SK-N-SH cells were treated with 20 µM retinoic acid 
(Sigma Aldrich) in EMEM media with periodical replacement every 48 hr for 10 days. 
Differentiation in the cells was confirmed post observation of neurite processes longer than 
their cell bodies [208]. CCF-STTG1 cells were grown in Dulbecco’s modified eagles medium 
(DMEM, Invitrogen) supplemented with 10% foetal bovine serum. THP-1 cells are cultured 
in Rosewell park memorial institute (RPMI, Invitrogen) 1640 medium supplemented with 
10% heat inactivated foetal bovine serum and 2 µM mercaptoethanol. To prevent bacterial 







3.2. Dominant negative survivin preparation and purification 
The mutant dominant negative survivin (SurR9-C84A) construct as described previously 
[183] was used in this study, where cysteine was replaced with alanine at 84
th
 position in the 
zinc co-ordination site. Also, the protein was endowed with enhanced cellular permeability as 
the amino terminus of the protein was modified with nine arginine (R9) residues and hence 
the name SurR9-C84A. E.coli BL21strain was transfected with the SurR9-C84A bearing 
plasmid and the protein expression was induced by incubating the E. coli bacteria in the LB 
broth media containing 0.01% w/v ampicillin at 37
o
C. The incubation was terminated once 
the OD of the broth medium reaches 0.7 at 620 nm. Then the protein expression was induced 
with 0.7 mM isopropylthiogalactoside (IPTG) by incubating for 3 hr. After this period, the 
bacterial cells were collected by centrifugation at 4500 RPM for 45 min at 4
o
C. The protein 
was collected by lysing the cell walls of the bacteria after treatment with the freshly prepared 
lysis buffer composed of (milliQ, 150 mM Nacl, 20% SDS, 50 mM Tris, lysozyme             
0.1 mg/ml, 1% Triton-X-100 and protease inhibitor) followed by sonication at 40 sec pulse 
and   70 amplitude for 7 min. The crude protein was collected after centrifugation and then 
purified using the glutathione agarose column. The purification of the protein is based on the 
principle of affinity chromatography where the glutathione-S-transferase (GST) tagged 
protein bound to the column was eluted by running the elution buffer composed of 10 mM 
reduced glutathione in 50 mM Tris-Hcl pH 7.5. The pure protein collected was frozen at        
-80
o




Figure 3.1. Preparation and purification of SurR9-C84A. A) Recombinant E.coli 
expressing SurR9-C84A was grown in LB broth media. B) The crude protein was collected.         
C) Protein extraction using lysis buffer and sonication. D) Purification of SurR9-C84A using 
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3.3. Cell cytotoxicity assay 
3.3.1. Lactate dehydrogenase (LDH) release assay  
Lactate dehydrogenase (LDH) is a fairly stable oxidoreductase enzyme that that is expressed 
by all the cells. After tissue damage, cells release LDH into the bloodstream or in the culture 
dishes and when incubated with the cytotoxicity detection kit (Roche), the tetrazolium salt 
INT is reduced to formazan which is water soluble and quantified at an absorption 
wavelength of 500 nm. The procedure is explained as: cells were seeded at a concentration of 
10
4
 cells/well in 96 well plates and grown as a monolayer. Post treatments for 24 hr the assay 
medium were collected (LDH from the cells is released into the culture media) and proceeded 
as follows: 
 Back ground control : 200 µl assay medium 
 Low control  : 100 µl/well cell suspension to triplicate wells 
 High control  : 100 µl/well cell suspension previously treated with            
Triton-X 100 
 Test control  : 100 µl/well cell suspension treated with respective test 
substances 
All the above fractions were incubated for 4 hr at 37
o
C, 5%CO2, 90% humidity and carefully 
transferred into an optically clear 96 well plate. Later they were incubated with the freshly 
prepared reaction mixture for 30 min at 25
o
C and the absorbance of the samples was 





 which later transfers the H/H
+
 to tetrazolium salt 
converting it to formazan. Formazan formation yields a coloured reaction which is 
proportionate to the LDH release. The percentage cytotoxicity was calculated using the 
following equation: 
% Cytotoxicity= (experiment value-low control) / (high control-low control) X 100. 
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3.4. Cell viability assays 
3.4.1 3-(4,5-dimehtylthiazol-2yl)-2,5-diphenyltetrazoliumbromide (MTT) assay 
To determine the level of cell viability, a simple and accurate colorimetric MTT 3-(4,5- 
dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide) assay was performed. The principle 
involved is that the mitochondrial dehydrogenases of viable cells catalyse the tetrazolium 
ring, forming purple formazan crystals that are water insoluble. Spectrophotometric 
measurement of this coloured solution measures the cell viability with the degree of 
cytotoxicity being proportionate to the intensity of the coloured reaction. The assay was 
performed as: post treatments the cultured cells were added with freshly reconstituted MTT 
vial (M-5655) constituting 10% volume of the cultured cells. Then incubated for 4 hr at 37
o
C 
allowing the formation of formazan crystals and later they were dissolved in MTT 
solubilization solution (M-8910). The intensity of the absorbance was detected 
spectrophotometrically using a microplate reader at 570 nm. 
3.4.2. Bromo deoxyuridine (BrdU) labelling assay 
In order to determine the cell proliferation in differentiated SK-N-SH cells post SurR9-C84A 
treatment’s, BrdU assay was performed using the BrdU labelling and detection kit (Roche 
Cat#11647229001). For this, 10
4 
cells were cultured in 96 well microplate with 100 µl media 
per well and the conditions were kept constant for both the untreated controls and treated 
wells. Following that, a 10 µl (final concentration of 10 µM) BrdU labelling solution was 
added to each well and incubated for 6 hr at 37
o
C. Post incubation period, the labelling 
solution from the culture medium was removed by pipetting and washed a couple of times 
with 250 µl of wash buffer (prepared as per the instructions) containing 10% serum per well. 
Soon after washing the wash buffer was removed the cells were immediately fixed with          





The washings were repeated with wash buffer for three times post fixing and then incubated 
with 100 µl of nuclease working solution for 30 min at 37
o
C. Similarly, washings were 
continued and the cells were then incubated with 100 µl of anti-BrdU-POD fragments at 37
o
C 
for 30 min. After the specified time the unbound fragments were washed away using the 
wash buffer and finally incubated with 100 µl of peroxidase substrate and substrate enhancer 
provided with the kit. Then the cells were allowed to incubate for 30 min and the extinction 
readings were collected using an Asys microplate reader at 405 nm with a reference 
wavelength of 490 nm. 
3.4.3. CyQUANT assay 
The proliferative potential of SurR9-C84A in the differentiated SK-N-SH cells was detected 
by using the CyQUANT assay as per the manufacturer’s instructions (CyQUANT cell 
proliferation assay kit, Invitrogen Cat# C7026). The principle behind this assay is that 
CyQUANT GR dye binds to the nucleic acids of the dividing cells and emits strong 
fluorescence. The DNA content possessed by each individual cell is constant and hence, 
measurement of DNA fluorescence intensity represents the cell number and therefore 
quantifies cell proliferation. The procedure is followed as: Cells were seeded in 96 well 
microplates and treated with test compounds as per the study requirements for a specific 
duration. Post treatments cells were washed with sterile 1X PBS and frozen overnight at          
-80
o
C followed by the addition of 200 µl/well of freshly prepared CyQUANT dye reaction 
mixture. Using a microplate reader the readings were taken at 480 nm excitation and 520 nm 
emission and results were analyzed in Microsoft excel software. 20% FBS treated            







SK-N-SH cells were seeded at a density of 2X10
4
 cells per well in the 8-well chamber slides 
(BD Falcon, Australia) and were differentiated by incubating with 20 µM retinoic acid 
(Sigma Aldrich, Cat# R-2625). Following differentiation for 10 days, cells were treated as per 
the study design. Post treatments cells were washed with sterile PBS, fixed for 15 min with 
freshly prepared 4% paraformaldehyde, washed with PBS and then permeabilised with 0.1% 
Triton-X-100 prepared in PBS. Then the cells were blocked in 3% bovine serum albumin 
(BSA) for 25 min at 37
o
C followed by incubations with mouse anti-Neurofilament 200 
(1:100, Sigma Aldrich) and mouse anti-myelin basic protein (1:100, Sigma Aldrich). The 
corresponding secondary antibody used was the anti-mouse IgG horse radish peroxidase     
(1:500, Sigma Aldrich). Cell nucleus was stained with methyl green and the slides were 
mounted with mounting media.  
3.6. FITC Annexin V staining 
Loss of plasma membrane integrity is one of the early indications of apoptotic cells where the  
membranous phospholipid phosphatidylserine (PS) is translocated from the inner to the 
outermost plasma membrane. The principle behind this assay is that annexin V, a 35-36 KDa 
Ca
2+
 dependent phospholipid-binding protein shows high affinity for PS and thereby binds to 
it. Thus conjugating annexin to fluorochromes such as FITC serves as a sensitive probe for 
detection of cells undergoing apoptosis. To identify the early stage of apoptosis annexin V, 
staining is normally used in conjunction with vital dyes such as propidium iodide (PI). PI is 
highly membrane permeable in the case of dead and damaged cells while impermeable in 






 Annexin-V-FITC positive and propidium iodide staining as apoptotic cells 
 Annexin-V-FITC and propidium iodide negative staining as viable cells 
 Annexin-V-FITC and propidium iodide positive staining as late apoptotic or dead 
cells 
The staining protocol was performed using the Annexin-V-FITC apoptosis detection kit I 
(Roche) following the manufacturer’s specifications. On the day of the experiment, post 
treatments cells were washed twice with sterile PBS and then resuspended in 1X binding 
buffer at a concentration of 1x10
6 
cells/ml. Next, 100 µl of the solution (1X10
5 
cells) was 
taken into a 5 ml culture tube followed by the addition of 5 µl of Annexin V-FITC and 5 µl 
PI to the cell suspension. Then the cells were gently vortexed and incubated for 15 min at 
25˚C in the dark. Later, the stained cells were suspended in 400 µl of 1X binding buffer and 
were analysed using flow cytometry within 1 hour. Fluorescence was recorded in BD FACS 
canto TM II analyser using a 488 nm laser light for Annexin V-FITC and PI. The emission 
signals were captured using band pass filters set at 530±30 and 613±20 nm for Annexin-V-










3.7. Quantitative real time-PCR 
3.7.1. RNA extraction 
RNA was extracted from the total cell lysates using the Trizol reagent (Invitrogen Cat# 
15596-026) method. Cells were treated with various treatments as per the study designs and 
following that cells were washed with ice-cold sterile PBS and proceeded for RNA isolation. 
1 ml of Trizol reagent was added to the cells grown in each well of a standard 6 well plate 
and were lysed with repeated pipetting up and down several times. Then 0.2 ml of chloroform 
was added for every 1 ml of Trizol reagent used and the reaction was allowed to incubate for        
2-3 min at room temperature with occasional shaking. Then the samples were centrifuged at 
12,000xg for the phase separation of lower phenol–chloroform and upper RNA aqueous 
phase. Then the aqueous phase was carefully separated and transferred to a fresh eppendorff 
tube while the interphase and phenol–chloroform were stored for DNA extraction. For RNA 
precipitation, 0.5 ml of 100% isopropanol was added to each tube and incubated for 10 min at 
RT followed by centrifugation at 12,000 g at 4
o
C. The RNA pellet obtained is then proceeded 
for washing in 1 ml of 75% ethanol followed by resuspension in RNase free water.            
The collected RNA was stored at -80
o












3.7.2. cDNA preparation 
cDNA preparation was further proceeded using the prepared RNA and the SUPERSCRIPT 
III reverse-transcriptase (Invitrogen). In brief, the following components were added to 
prepare the reaction mix in nuclease free microcentrifuge tubes: 
 1 µl of oligo(dT)20 (50 µM) 
 5 µg prepared RNA  
 1 µl of 10 mM nucleotide (dNTP) mix  
(10 mM each dATP, dGTP, dCTP and dTTP) 
 Sterile, RNAse free water to 13 µl 
The above reaction mixture was heated to 65
o
C for 5 min on TAKARA PCR machine 
followed by rapid incubation on ice for 1 min. Then the contents in the tubes were collected 
by centrifugation and further preparation is continued by the addition of following 
components to each tube: 
 4 µl 5X first strand buffer 
 1 µl 0.1M DTT 
 1 µl RNaseOUTTM recombinant RNase inhibitor (Cat# 10777-019) 
 1 µl of SuperscriptTM III RT (200 units/µl) 
The above reaction mixture was incubated for 1 hr at 50
o 
C followed by stopping the reaction 
at 70
o









3.7.3. Quantitative real time PCR 
For the gene analysis studies, quantitative real time PCR studies were performed on the 
iCycler (Bio-Rad) PCR machine with a reaction mixture volume of 25 µl prepared using 
SYBR green master mix. The components of the mixture were added to a low bind 
eppendorff tubes as follows: 
 1X iQ SYBR green super mix         12.5 µl 
 Forward primer (100 nM)   1.0 µl 
 Reverse primer (100 nM)   1.0 µl 
 Nuclease free sterile water   9.5 µl 
 Prepared DNA template   1.0 µl 
The reaction mixture was prepared as above for all the genes studied with corresponding 
annealing temperatures following 36 PCR amplification cycles that consisted of: 
 60sec at 94oC 
 60sec at 60oC 
 90sec at 72oC 
 
All the samples were run in triplicates and a mean Ct value was used for gene quantification 
using the 2
-∆∆Ct
 method [209]. For the amplification specificity, melt curve analysis was 
adopted and further confirmed by imaging the PCR products post agarose gel electrophoresis. 














































































































































































NSE, neuron specific 
enolase; 
7
PI3K, phosphotidyl ionositol-3-kinase; 
8








3.7.4. Multiplex RT-PCR 
Multiplex RT-PCR was performed for survivin and the house keeping gene β-actin using the 
Ex Taq DNA polymerase premix (Takara). The reaction mixture prepared consisted of the 
following components (Table 3.2). 
Table 3.2. RT-PCR protocol and reaction mixture composition 






 DNA polymerase   
(5 units/µl) 
25 1.25 units/50 µl 
2 10X Ex Taq buffer (Mg
2+
 plus) 5 1X 
3 dNTP mix (2.5 mM) 4 200 µM 
4 DNA template 1 2.5 ng/50 µl 
5 Primers 1 0.2 µM 
6 Sterile ddH20 




The 36 PCR amplification cycle was used for both survivin and actin genes consisting of: 
 60 sec at 94oC 
 60 sec at 60oC 
 90 sec at 72oC 
The PCR products and their integrity was confirmed by running them on 1% agarose gel to 





3.8. miRNA isolation and preparation of cDNA 
The miRNA isolation was performed using the mirPremier

 microRNA isolation kit (Sigma 
Aldrich, cat# SNC50) following the protocol described as follows. Cells were plated in a         
6 well culture plate and post treatments, they were washed with Hanks balanced salt solution 
to remove the traces of media that would interfere with the miRNA isolation. Then the lysis 
mix (700 µl miRNA lysis buffer + 300 µl binding solution + 10 µl 2-mercaptoethanol) was 
added to each treatment (300 µl/well) and incubated for 7 min with gentle swirling following 
which, the lysates were centrifuged as 16,000xg to remove the cell debris. The clear 
supernatant was transferred into a 2 ml tube without disturbing the pellet and added with 1.1 
volumes of 100% ethanol followed by vigorous mixing. Then the miRNA was bound to the 
column following the centrifugation of this mixture at 16,000xg for 30 sec. To enhance the 
purity the column was washed once with 100% ethanol and twice with wash solution. Each 
washing step was followed by centrifugation at 16,000xg for 30 sec. After washing, the 
column was dried for 30 sec and pure miRNA was eluted by running the elution solution 
through the column. 
3.8.1. Preparation of miRNA cDNA 
cDNA synthesis is a two-step reaction and is prepared following the manufacturers protocol 
(MystiCq™ microRNA cDNA Synthesis Mix, Catalog# MIRRT). This is described as: 
Step 1: Poly-adenylation of isolated miRNAs 







Table 3.3. miRNA-cDNA preparation reaction mixture composition 
S.No Reagent Volume in µl 
1 
Poly (A) tailing buffer  5X 
concentration 
2 
2 miRNA 6* 
3 Poly (A) polymerase enzyme 1 
4 Nuclease free water 1 
Total 10 
                    *Varies according to the concentration  
Then the reaction mixture was proceeded for incubation at 37
o
C for 40 min and at 70
c
C for 5 
min on TAKARA PCR machine. 
Step 2: First strand cDNA is synthesized according to the Table 3.4. 
Table 3.4. First strand cDNA preparation reaction mixture composition 
S.No Reagent Volume in µl 
1 
Poly (A) tailing reaction mix  
(obtained from step 1) 
10 
2 








Then the reaction mixture was mixed appropriately and incubated at 42
o
C for 20 min and at 
85
o
C for 5 min. The cDNA is ready for qRT-PCR gene analysis described as follows. 
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3.8.2. Amplification of microRNAs using the real time SYBR green RT-PCR 
The amplification of desired miRNAs was performed following the manufacturers protocol 
(Sigma Aldrich, Cat#MIRRMO3). The reaction mixture required for RT-PCR miRNA 
amplification is given in the following Table 3.5. 
 





MystiCq microRNA SYBR green qPCR 
ready mix (2X) 
12.5 
2 
MystiCq microRNA qPCR assay primer 
(10 μM) 
0.5 
3 MystiCq universal PCR primer (10 μM) 0.5 
4 miRNA cDNA 1 
5 Nuclease free water 10.5 
Total 25 
 
The 40 PCR amplification cycle was used for miRNA amplification consisting of: 
 2 min at 95oC  (Activation)  
 5 sec at 95oC   (Denaturation) 
 60 sec at 60oC (Annealing) 
The qPCR products and their integrity were confirmed by running on 1% agarose gel 
followed by imaging. 
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3.9. Western blotting (WB) 
The protocol for Western blot was followed according to the well-established procedure in 
the lab and also from the Abcam company. 
3.9.1. Preparation of cell lysates 
The cell lysates were collected post treatments that were designed specifically for various 
study requirements. Soon after the treatments, the cells were washed with ice cold sterile PBS 
and culture dishes were placed in ice followed by the addition of RIPA (radio immuno 
precipitation assay) buffer. The constituents of it are: 
Table 3.6. RIPA buffer composition for cell lysate preparation 
S.NO Reagent used Concentration 
1 Sodium chloride 150 mM 
2 Triton-X-100 1% 
3 Sodium deoxycholate 0.5% 
4 Sodium dodecyl sulphate 0.1% 
5 Tris buffer pH 8 50 mM 
 
The adherent cells were scraped off using a cell scraper and carefully transferred to           
pre-cooled low bind centrifuge tubes. The cells were allowed to interact with the lysis buffer 
for 30 min at 4
o
C and occasional pipetting was done for uniform mixing. Then the lysed cells 
were centrifuged at 12,000 RPM for 30 min at 4
o





3.9.2. Estimation of protein concentration 
Bradford assay was used for determining the concentration of protein samples. Initially,         
a standard curve was plotted using BSA as the protein standard prepared in serial dilutions. 
The concentration of test samples were obtained from the standard curve prepared.   
3.9.3. Test sample preparation for gel loading  
Before loading the samples on to the gel, they were added with the loading dye in a ratio of 
1:1 concentration and were denatured by heating the samples at 95
o
C for 5 min. The principle 
behind this is that the antibodies used during staining, recognize and bind to a small portion 
on the protein of interest. This binding site might reside within the 3D configuration of the 
protein making it inaccessible to the antibodies. Hence, the test samples were denatured to 
expose the binding sites for optimal antibody binding.   
3.9.4. Electrophoresis 
3.9.4.1. SDS-PAGE gel preparation 
The SDS-gels were prepared following the polymerization of 40% acrylamide and           
N,N-methylenebisacrylamide with ammonium persulphate and N,N,N´,N´-
tetramethylethylenediamine (TEMED). The detailed recipe for SDS-PAGE gel preparation is 























Reagent Volume in mL 












0.3 1.2 1.6 2 2.5 3 
20% 
SDS(µl) 
15 40 40 40 40 40 
10% 
APS9 (µl) 
15 40 40 40 40 40 
TEMED  
(µl) 





Different gel strengths were used for eluting the proteins of various sizes and the same is 
given in Table 3.8. 
Table 3.8. SDS-PAGE gel strength for various protein sizes 
S.NO Protein Size KDa % Gel strength 
1 4-40 20 
2 12-45 15 
3 10-70 12.5 
4 15-100 10 














3.9.4.2. Test sample loading  
A minimum protein concentration of 50 µg per well was loaded and the gel was run at       
200 volts for 1 hr. 
3.9.4.3. Protein visualization for SDS and western blot 
For SDS gels: After running the gel, it was stained with staining solution composed of    
(40% distilled water, 10% acetic acid, 50% methanol and 0.25% coomassie brilliant blue     
R-250) for 30 min at room temperature. Then the gel was destained by soaking it in a high 
destain solution composed of 67.5% water, 7.5% acetic acid and 25% methanol until the gel 
is free of excess dye and then it is imaged. 
For Western blot: After the gel is run, the proteins were transferred onto the activated PVDF 
membrane followed by overnight incubations with primary antibodies at 4
o
C and the 
corresponding secondary antibodies at RT for 1 hr. Then the blots were washed adequately 
and developed using the ECL (GE health care) reagents. A list of primary and secondary 










Table 3.9. List of primary and secondary antibodies used 
S.NO 1
o 
antibody used Dilution 2
o 






































3.10. Microarray studies 
3.10.1. Cytokine array  
The cytokine array kits (R&D systems, Cat# ARY005) were used in order to determine the 
presence of cytokines in the secretions of differentiated THP-1 cells subjected to various 
insults. All the reagents were prepared according to the instructions provided by the 
manufacturer R&D systems. The following procedure was adopted: 
 The blotting membranes were blocked with 2.0 ml of block buffer supplied in the 
4-well multi-dish for 1 hr RT.   
 1 mL of the test samples were added with 0.5 ml of blocking buffer and 15 μl of 
reconstituted cytokine antibody cocktail and incubated for 1 hr at RT. 
 The membranes were then incubated with the prepared test sample mix overnight 
at 2-8°C.   
 Following incubation, each membrane was thoroughly washed with the wash 
buffer provided and then incubated with the streptavidin-HRP for 30 min RT. 
 Then the membranes were washed and then added with 1 ml of the prepared 


















3.10.2. Apoptotic array  
The apoptotic array kits (R&D systems, Cat#ARY009) were used in order to determine the 
protective ability of SurR9-C84A against the cytokine induced inflammation in the SK-N-SH 
neurons. As described above, all the reagents were prepared according to the instructions 
provided by the manufacturer R&D systems. The following procedure was adopted: 
 The blotting membranes were blocked with 2.0 ml of block buffer supplied in the 
4-well multi-dish for 1 hr RT.   
 The test samples were added with 1.25 ml of blocking buffer and mixed 
thoroughly. A maximum of 250 µl of the test sample mix is used for each of the 
membrane used. 
 The membranes were then incubated with the prepared test sample mix overnight 
at 2-8°C on a rotating shaker.   
 Following incubation, each membrane was thoroughly washed with the wash 
buffer provided and then incubated with the apoptotic antibody cocktail for 1 hr 
at RT. 
 Then the membranes were washed followed by incubation with the streptavidin-
HRP for 30 min RT. 
Then the membranes were washed and then added with 1 ml of the prepared chemi reagent 







DOMINANT SURVIVIN MUTANT NANOFORMULATION FOR NEUROLOGICAL 
DISORDERS: NEUROBLASTOMA TO NEURODEGENERATION 
Abstract 
In this study, the differential actions of dominant negative survivin mutant (SurR9-C84A) 
against the cancerous SK-N-SH neuroblastoma cell lines and the differentiated SK-N-SH 
neurons were investigated. In both cases, the mutant protein displayed dual actions where its 
effects were cytotoxic towards cancerous cells and proliferative towards the differentiated 
neurons. This is explained as, tumorous (undifferentiated SK-N-SH) cells have high 
endogenous survivin pool and upon treatment the survivin mutant causes forceful expression 
of survivin.  These events significantly lower the microtubule dynamics and stability 
eventually leading to apoptosis. In the case of differentiated SK-N-SH neurons that express 
negligible wild type survivin, the mutant indistinguishably behaves like wild type and 
encourages the cell cycle progression forming the chromosome passenger complex (CPC) 
and stabilizing the microtubule organizing center. Thus, the mutant SurR9-C84A entitles a 
novel therapeutic target aiming a variety of neurological disorders (protective proliferative 
effect) including brain cancers (apoptotic effects). A novel nanoparticulate formulation is also 
developed for the delivery of SurR9-C84A to surmount the hurdles associated with protein 









Neurotherapeutics has always been a fascinating area of research on account of the limited 
proliferation potential of the neuronal cells for along with a deficit regenerative ability. 
Hence, the effective way of achieving therapeutic effectiveness would be adopting the 
strategies of either neuronal proliferation or protection or both for the neurological disorders 
[228, 229]. Inhibitor of apoptosis (IAPs) proteins has been targeted by several studies aiming 
to treat a variety of neurological disorders including cancers. Among the several IAPs studied 
with respect to brain, the role of survivin is very well documented as it was found to improve 
premature brain development [144, 230, 231]. Survivin plays an intriguing role in the 
initiation of the cell division forming the chromosome passenger complex (CPC) that consists 
of borealin, INCEPT and aurora-B-kinase. The dimerization of survivin and borealin 
translocates the CPC to the central spindle that enhances the stability of the microtubules 
thereby facilitating the proper alignment of the chromosomes on to the spindle fibres [149, 
232]. In addition, survivin complexation with the hepatitis-B-X-interacting protein (HBXIP) 
and its co-factor X-interacting protein (XIAP) prevents the apoptosis by the following 
mechanism. The survivin-HBXIP-XIAP complex attracts the procaspase-9 reducing the free 
levels of it thereby avoiding the recruitment of apoptotic protease activating factor 1 (Apaf1). 
Hence, the apoptosome formation is interfered and leads to the prevention of apoptosis [180]. 
In contrast, forceful expression of survivin significantly alters the microtubule dynamics and 
stability eventually head towards apoptosis [148]. Thus, survivin is found to have dual 
actions allowing the mitotic cell division and apoptosis regulation. Considering these 
potentials, a mutant variety of it dominant negative survivin (SurR9-C84A) have been 
synthesized that carries a polymeric arginine carrier (R9) peptide facilitating the rapid 
intracellular uptake [233]. SurR9-C84A is a mutant protein belonging to the IAPs family and 
tends to exhibit dual actions against the cancerous and the normal cells.  
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It was reported that cancer cells express higher levels of wild type survivin and treatment 
with SurR9-C84A displaces the wild type leading to an increase in the free caspase-3 levels 
and thereby initiates the cell death [22]. Contrarily, postmitotic cells like neurons lower 
endogenous survivin pool and hence treatment with SurR9-C84A tends to promote 
proliferation by organizing the CPC formation similar to the wild type. These results were 
substantiated with previously published data where SurR9-C84A showed strong apoptotic 
effects towards prostate cancer cells and induced proliferation in the retinoic acid 
differentiated SK-N-SH neurons [210, 233]. Thus, the mutant SurR9-C84A holds a novel 
therapeutic agent where its proliferative effects can be aimed against a range of neurological 
disorders while the apoptotic effects against cancers. On the other hand, oral delivery of the 
protein and peptides have serious hinderances on account of their shorter half-life, physical 
and chemical instability, enzymatic degradation in the gastrointestinal tract and poor 
permeation through the membrane barriers [234]. Hence, a novel nanoparticulate formulation 
has been developed for the SurR9-C84A delivery to rule out the hurdles seen with protein 
delivery. The biodegradable polymeric poly(lactic-co-glycolic acid) (PLGA) nanoparticles 
(NPs) were prepared for the delivery. In addition, these NPs were approved by the US Food 
and Drug Administration (FDA) for human use and are popular for their easy fabrication. 
These polymeric NPs tend to form a protective coating for the protein encapsulated and 
increase the bioavailability providing a great protein release control. Another beauty 
attributed to this nano formulation is that the NPs surface can be decorated with tissue 
specific markers enabling the more target specific action thus avoiding the non-specific drug 
accumulation and the associated toxicity [235]. Although different polymeric varieties of 
PLGA are available, the co-polymer with a 50:50 ratio of (lactide:glycolide) is employed for 
preparing the NPs and this study is the first of its kind to report the SurR9-C84A 
encapsulation in PLGA NPs.  
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The principle adopted for NPs fabrication is the modified double emulsion technique where 
the surfactant polyvinyl alcohol (PVA) concentration was fixed to 1%. For the double 
emulsion process, the organic solvent used was ethyl acetate yielding the NPs with 
homogenous size range with spherical surface morphology. To achieve enhanced 
encapsulation efficiency and the drug loading all the associated process parameters were 
optimized. Fourier transform infrared spectroscopy (FTIR) technique was used to determine 
the presence of protein while the SDS-PAGE and differential scanning calorimetry (DSC) 
techniques were used to study integrity and protein intactness inside the polymer matrix. The 
differential effects of the SurR9-C84A loaded NPs were studied on the undifferentiated     
SK-N-SH cells and the differentiated neurons.    
4.2. Material and methods 
The polymer poly (D,L-lactide-co-glycolide) RESOMER
®
 RG 503 H (PLGA 50:50, inherent 
viscosity 0.32-0.44 dL/g, Mw 24,000-38,000), poly (vinyl alcohol) (Mw 13,000-23,000,     
87-89% hydrolysed)  were purchase from Sigma Aldrich, Australia. All other solvents and 
chemicals used in the study were of analytical grade. SK-N-SH neuroblastoma cell lines were 
obtained from the American type culture collection (ATCC) and were grown as a monolayer 
in Eagle’s minimal essential medium (EMEM) supplemented with 10% of foetal bovine 
serum, 1% penicillin and streptomycin at 37°C in a saturated humid atmosphere with 5% 
CO2. 
4.2.1. Construction of survivin mutant and its purification 







4.2.2. SurR9-C84A loaded nanoparticle preparation  
The nanoparticles were prepared following the principle of modified double emulsion 
technique followed by evaporation. A 1% w/v of the polymer was dissolved in ethyl acetate 
and two equal halves of it was taken in separate tubes. A 10 mg/ml of protein was prepared in 
1% PVA and was equally mixed with the polymer solution prepared followed by sonication 
for 30 sec yielding the primary W/O emulsion. Then the final volume was made to 15 ml 
with 1% PVA in each of the tubes followed by sonication to yield the final W/O/W emulsion. 
The final emulsion was then stirred overnight at 800 RPM at 4
o
C to remove the organic 
solvent. The protein loaded nanoparticles were collected post washings with distilled water 
followed by centrifugation at 4500 RPM for 1 hr. The washings were done for three times to 
ensure the collected NPs were pure and were immediately freeze dried for 48hr and stored at 
4
o
C for further experiments. The blank NPs were prepared following the same protocol 
except the protein was replaced with milliQ water. The fluorescent labeled NPs were 
prepared using the 4% rhodamine (R6G, Sigma). The R6G was added to the 1% w/v of 











Figure 4.1. Preparation of PLGA nanoparticles using the modified double emulsion 
technique. The initial W/O emulsion is formed by mixing the PLGA dissolved in the organic 
solvent and the protein dissolved in the surfactant 1% polyvinyl alcohol (PVA) solution. 
Then it is mixed with the continuous phase consisting 1% PVA forming the W/O/W emulsion 






















4.2.3. Characterization of nanoparticles 
4.2.3.1. Particle size and surface morphology 
 The size analysis was performed by the dynamic light scattering technique using the Malvern 
Zetasizer (Malvern instruments, UK). In brief, 1 mg of the freeze dried NPs were dispersed in 
1 ml of milliQ water and measurements were read at a scattering angle of 90
o
 maintained at 
25
o
C. The nanosphere morphology was ascertained by the scanning electron microscopy 
(SEM) (SUPRA-55VP, Zeiss) where the NPs suspended in water were subjected to 
sonication and mounted on the carbon tape followed by air drying. Then the stubs were gold 
coated and left in the vacuum chamber overnight prior to SEM imaging at an accelerated 
voltage of 10 kV and a working distance of 12 and 9.9 mm. 
4.2.3.2. Encapsulation efficiency (EE) and the percentage loading  
The prepared NPs were centrifuged at 4500 RPM for 45 min at 4
o
C and the supernatant was 
collected. Protein concentration in the supernatant was determined using the Bradford’s 
protein assay kit (Thermo Scientific) and the absorbance was measured at 620 nm. The 
amount of protein present was obtained from the concentration Vs. absorbance calibration 
curves of the known standards. The EE and the percentage loading were calculated using the 
following equations: 
EE=   
 
 





Initial weight of the protein taken-amount of the protein left in the supernatants 
X 100 
 
amount of the protein taken 
weight of the protein loaded nanoparticles   X 100 
weight of the protein and the polymer used for NP preparation 
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4.2.3.3. Polymer-protein interaction 
To evaluate the possible polymer protein interactions, differential scanning calorimetric 
(DSC) study was conducted for the void and the protein loaded NPs. The corresponding DSC 
curves were obtained on the scanning calorimeter embedded with the thermal analysis data 
system. In brief, void and protein loaded NPs were measured (≥4 mg) and sealed in 
aluminium pans. A blank aluminium pan was used as a reference and the samples were 




C with a heat flow increment of 
10
o
C/min and nitrogen purging at 20 ml/min.  
4.2.3.4. Release kinetics 
The in vitro kinetics of the SurR9-C84A loaded PLGA NPs was evaluated in 10 mM PBS at 
pH 7.4 and at an acidic pH 2 mimicking the in vivo conditions that NPs might encounter.      
A predetermined amount of the freeze dried NPs were suspended in the PBS buffer and 
incubated at 37
o
C subjected to a constant rotation at 70 RPM. At regular intervals 
(0,0.25,0.5,1,2,4,6,8,12,24,48,96 hr) aliquots were collected and estimated for the protein 
concentration using a spectrophotometer at 620 nm. 
4.2.3.5. Fourier transform infrared (FTIR) spectroscopy 
A predetermined quantity of micronized IR grade KBr (400 mg) was mixed separately with 
the void and SurR9-C84A loaded NPs (1 mg dry weight) to prepare the pellets using a 
manually operated tablet press. A pressure of 5.5 metric ton for 5 min was applied and the 
pellets were scanned 16 times over mid IR region (4000 to 400 cm
-1
 wavenumber range).  
The background spectra were subtracted from the samples and the software was used for 






4.2.3.6. SDS-PAGE for protein integrity 
The integrity of the protein encapsulated within the NPs was assessed by sodium dodecyl 
sulphate–polyacrylamide gel electrophoresis (SDS–PAGE). The freeze dried NPs were stored 
at 4
o
C for 1 week and ran through the 12.5% SDS gel under reducing conditions                  
(β-mercaptoethanol) including the void NPs as control. The gel was run in Tris/Glycine/SDS 
buffer at a constant voltage of 100V for 50 min using the Bio-Rad mini-Protean 
electrophoresis system. 0.1% coomassie blue was used as the gel stain for 30 min followed 
by destaining with high destain solution (70% milliQ water, 20% methanol and 10% acetic 
acid) and later visualised using the gel-dock imaging system (Bio-RAD).  
4.2.4. In vitro nanoparticle uptake studies 
For the in vitro NP uptake study, both the differentiated and undifferentiated SK-N-SH cells 
were grown in BD Falcon™ 8-well culture slides at a density of 2x10
4
 cells/well and 
incubated with the rhodamine labeled NPs at time points of 30 min, 1, 2 and 4 hr. After the 
specified time, the media was removed and cells were washed thrice with 1XPBS to remove 
the free NPs that were neither uptaken nor adhered to the cells. Cells were immediately fixed 
with 4% paraformaldehyde for 15 min followed by washing and mounted with a coverslip 
using the Fluoroshield™ with DAPI (Sigma Aldrich). Cellular uptake was determined using 
the Leica SP5 confocal microscope (Leica systems, GmbH, Germany) and all the images 
were taken at 40X objective. The percentage internalization of NPs is expressed as mean±SD 
values obtained by counting cells in ≥ five different fields. PLGA nanoparticles were 
evaluated for their potential as an effective protein delivery system orally to the brain by 
incubating the SurR9-C84A loaded NPs with the SK-N-SH cells as a model cell line of the 





4.2.5. NP uptake mechanism 
To determine the precise NP uptake mechanism, differentiated SK-N-SH were seeded at     
10
4
 cells per well in a 96 well plate. Then they were pretreated with the following endocytic 
inhibitors: Chlorpromazine 10 µg/ml (clathrin mediated endocytosis), indomethacin 10 µg/ml 
(caveolae mediated endocytosis) Sodium azide 2 µg/ml and colchicine 5 µg/ml (pinocytosis) 
for 1 hr followed by the rhodamine labeled NPs incubations for 4 hr at 1 mg/ml 
concentrations. Post treatments, cells were washed with PBS to remove free NPs and then the 
cells were lysed with 1% Triton-X-100 in 0.2M NaOH. The resulting fluorescence was 
measured at 530 nm excitation and 630 nm emission and the corresponding weight of the 
NPs was calculated from the standard graph plotted for rhodamine labelled NPs. 
Flowcytometric analysis was also performed for the same where SK-N-SH cells were plated 
in 6 well plates and rest was the same. Post treatments, cells were washed with 1X PBS 
detached gently by pipetting and proceeded for flow cytometry analysis. 
4.2.6. Retinoic acid induced differentiation in SK-N-SH cells. 
Undifferentiated SK-N-SH cells are generated from the bone marrow metastasis and were 
subdivided into neuroblasts (N) cells, substrate adherent non-neuronal (S) cells and the  
intermediate (I) cells. N-type cells exhibit the short neuronal processes while the S-type are 
rather flat and strongly bound to the substrate. The T-type cells display intermediate 
properties of both N and S cells with or without neuronal processes and substrate adherence.  
In order to induce differentiation in neuroblastoma, 20 µM retinoic acid (Sigma Aldrich) was 







4.2.7. Wild type survivin expression in differentiated and undifferentiated SK-N-SH cells. 
In order to determine the differential expression of wild type survivin, both the differentiated 
and undifferentiated SK-N-SH cells were plated in 8-well culture slides at 2x10
4 
per well and 
proceeded towards the immunofluorescence detection. Cells were permeabilised with 0.1% 
Triton-X-100 in PBS followed by blocking with 2% rabbit serum. Then the undifferentiated 
and differentiated cells were incubated with the mouse monoclonal anti-survivin (Santa Cruz) 
1:100 dilution for 1hr followed by FITC labeled rabbit anti-mouse (1:100, Sigma Aldrich). 
Cell nucleus was stained with propidium iodide (1:500, Sigma Aldrich) for 30 min and 
mounted with mounting media. Further, imaging was carried using the Leica SP5 confocal at 
40X objective.  
4.2.8. In vitro cytotoxicity in undifferentiated SK-N-SH cells 
4.2.8.1. Live and dead cell assay 
Undifferentiated SK-N-SH cells were plated out in 96 well plate at a density of 10
4 
cells/well 
followed by the treatments with the void and SurR9-C84A loaded NPs (25, 50, 100 and 200 
µg of protein/ml concentration) for 24 hr. Untreated controls including +Ve controls (treated 
with 20%FBS) and –Ve controls (treated with 1% Triton-X-100) were included in the study 
for the calculation of percentage live and dead cells. The entire procedure was followed as 
per the manufacturer’s protocol (LIVE/DEAD® Viability/Cytotoxicity kit, Invitrogen).      
The basic principle is that the Calcein AM is a cell permeable nonfluorescent dye and emits 
fluorescence due to the intracellular esterase activity in live cells while ethidium III binds to 
the nucleic acids in the damaged cells emitting bright red fluorescence. The live/dead cell 
readings post treatments were recorded using a fluorescence microplate reader at 530 nm 





4.2.8.2. Cell proliferation study (CyQUANT) assay 
In order to evaluate the proliferative potential of SurR9-C84A on undifferentiated SK-N-SH 
cells, CyQUANT assay was performed (CyQUANT cell proliferation assay kit, Invitrogen). 
SK-N-SH cells were plated in the 96 well plate culture plate at a density of 10
4 
cells/well and 
incubated with the NP treatments corresponding to the protein concentration of 25, 50, 100 
and 200 µg/ml for 24 hr. An untreated control, void NP treated (control for protein loaded 
NPs) and 20% FBS treated (+Ve control) cells were also included in the study. The principle 
behind this assay is that CyQUANT GR dye binds to the nucleic acids and emits strong 
fluorescence reflective of the proliferating cells. Post treatments, the cells were washed and 
frozen overnight at -80
o
C overnight followed by the addition of 200 µl/well of CyQUANT 
dye reaction mixture prepared as per the manufacturers protocol. The readings were taken at 
480 nm excitation and 520 nm emission in a fluorescence microplate reader and results were 
analyzed in Microsoft excel software. 
4.2.8.3. Expression of proliferation cell nuclear antigen (PCNA) and Caspase-3 
Further to the evaluation of inhibitory effects of SurR9-C84A on undifferentiated SK-N-SH 
cells, immunofluorescence for proliferative marker PCNA and apoptotic marker caspase-3 
were studied. Cells were seeded at 2x10
4 
cells/well in BD-falcon 8 well culture slide 
following the protocol as described previously [210]. Cells were synchronized by the addition 
of nocodazole (70 ng/ml) for 12 hr, washed and then incubated for 65 min to enrich the 
anaphase and telophase population. Then the cells were subjected to NP treatments 
corresponding to the protein concentrations of 25, 50, 100 and 200 µg/ml for 24 hr. In order 
to compare the effect, cells treated with pure survivin 75 µg/ml (without nanoformulation) 
were included in the study along with the void and untreated controls. Post treatments, cells 
were washed thrice in PBS followed by fixation in 4% paraformaldehyde for 15 min.  
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Cells were permeabilised with 0.1% Triton-X-100 in PBS followed by blocking with 2% 
rabbit serum.  Then the undifferentiated cells were incubated with the mouse monoclonal 
anti-proliferating cell nuclear antigen (PCNA) (1:100, Sigma Aldrich) and rabbit anti-
caspase-3 (1:100, Cell signaling) for 1hr. FITC labeled rabbit anti-mouse (1:100, Sigma 
Aldrich) and goat anti rabbit FITC (1:100, Sigma Aldrich) were used as secondary 
antibodies. Cell nucleus was stained with propidium iodide (1:500, Sigma Aldrich) for 30 
min and mounted with mounting media. Further imaging was carried using the Leica SP5 
confocal microscope at 40X objective. 
4.2.9. In vitro proliferation in differentiated SK-N-SH cells 
4.2.9.1. Expression of proliferation cell nuclear antigen (PCNA) and Ki67 
To evaluate the proliferative potential of SurR9-C84A on differentiated SK-N-SH cells, 
immunofluorescence for the proliferative markers PCNA and Ki67 were studied. Cells were 
seeded at 2x10
4 
cells/well in BD-falcon 8 well culture slide following the protocol as 
described for the undifferentiated cells. Post treatments with SurR9-C84A, the differentiated 
cells are incubated with the mouse monoclonal anti-PCNA and mouse anti-Ki67 (1:100, 
Sigma Aldrich) for 1hr at 37
o
C. FITC labeled rabbit anti-mouse and goat anti rabbit (1:100, 
Sigma Aldrich) were used as secondary antibodies. Cell nucleus was stained with propidium 
iodide (1:500, Sigma Aldrich) for 30 min and further imaging was carried using the Leica 









4.2.9.2. BrdU labelling assay 
The proliferating potential of NP loaded SurR9-C84A was evaluated on the retinoic acid 
differentiated SK-N-SH cells. Cells were seeded at a density of 10
4
 cells/well in a 96 well 
plate and differentiation was induced for 12-14 days and confirmed with the detection of 
neurite processes. Then the cells were treated with SurR9-C84A loaded NPs corresponding to 
the protein concentrations of 50,100 and 200 µg/ml for 24 hr. Void treatment and untreated 
controls were also included. The entire protocol was followed as per the manufacturer’s 
indications BrdU Labelling and Detection Kit III (Roche). In brief, post treatments cells were 
incubated with the BrdU labelling solution for 6hr followed by fixation with precooled 
fixative (Ethanol in HCL). Then the cells were incubated with the peroxidase conjugated anti-
BrdU for 30 min and then the peroxidase substrate is introduced. The absorbance was 
measured using a microplate reader at 405 nm keeping the wavelength 490 nm as a reference. 
4.2.10. Gene expression study 
To define the dual mechanistic actions of SurR9-C84A (apoptotic on undifferentiated and 
proliferative effect on differentiated cells), qRT-PCR analysis was conducted for wild type 
survivin, caspase-9, caspase-3, caspase-8, caspase-7, Cyt-c, TRAIL, β-tubulin III, p53 and 
cyclin D1. Undifferentiated and differentiated SK-N-SH cells were grown confluent in 6 well 
plates and then treated with void and SurR9-C84A loaded NPs (corresponding to protein 
concentrations of 50,100 and 200 µg/ml). An untreated control and pure protein treated wells 
were also included in the study. Post treatments, RNA was isolated from the cells following 
the protocol and reagent supplied. (TRIzol® Reagent, Invitrogen). cDNA was prepared from 
the total RNA extracted using the SUPERSCRIPT III reverse-transcriptase, oligo-dT and 
RNase free water (Invitrogen). The prepared cDNA was used for the gene expression studies 
as described previously [210].  
97 
In brief, the 15 µl of the reaction mixture was prepared using the SYBR green PCR master 
mix (Bio-Rad) and proceeded towards the quantitative real time PCR (qRT-PCR), iCycler 
(Bio-Rad). In this study, duplicate samples were run for the said genes and a mean Ct value 
was used for the calculation. 2
−ΔΔCt
 method was adopted for the quantification while the gene
amplification was verified by melt curve analysis and visualised by the ethidium bromide 
stained 1% agarose gel. The primer sequences and annealing temperatures were given in 
material and methods table 3.1. 
4.2.11. Flow cytometry and protein expression 
4.2.11.1. Propidium Iodide (PI) staining 
The percentage dead cells post treatments with SurR9-C84A loaded NPs was evaluated by 
the flowcytometric analysis of the propidium Iodide (PI) stained cells. In brief, both the 
undifferentiated and differentiated SK-N-SH cells were plated in 6 well culture plates and 
were grown confluent followed by treatment with protein loaded NPs at a concentration of 
25, 50, 100 and 200 µg/ml concentration of the protein for 24 hr. An untreated control and 
void NP treated cells were also included in the study. Post treatment period, the cells were 
washed with ice cold PBS pH 7.4, trypsinised and centrifuged at 800 RPM for 5 min. The cell 
pellets were collected in 6 separate centrifuge tubes corresponding to the treatments and were 
added with 500 µl of 1XPBS containing 2% FBS. Cells were stained with 25 µl of 50 µg/ml 
concentration of PI and incubated at 4
o
C for 30 min and fluorescence was recorded using the
FACS cell sorter (BD Bioscience) and data was acquired using FACS software (BD 
Bioscience). 
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4.2.11.2. Annexin-V-FITC staining 
SK-N-SH cells (both undifferentiated and differentiated) grown confluent in the 6 well plates 
were treated with the SurR9-C84A loaded NPs at concentration corresponding to 50, 100 and 
200 µg/ml of the pure protein for 24 hr. An untreated control, void and native survivin        
75 µg/ml treated wells were also included in the study. After the treatment period, cells were 
washed in ice cold PBS, trypsinised and incubated separately for 10 min with the reaction 
mixture (consisting of incubation buffer, annexin fluos labelling reagent and propidium 
iodide) prepared as per the manufacturers protocol (Annexin-V-Fluos staining kit, Roche). 
Fluorescence signals were detected at excitations of 488 nm and emissions at 510±30 nm and 
600±30 nm for annexin and PI respectively using the flow cytometer (BD Bioscience) 
equipped with FACS Diva software (BD Bioscience). 
4.2.11.3. Protein expression 
Post treatments with SurR9-C84A, the undifferentiated and differentiated SK-N-SH cells 
were evaluated for the expression of apoptotic and proliferative markers respectively through 
flowcytometric analysis. Initially to begin with, undifferentiated SK-N-SH cells were studied 
for the expression of BAX, Cyt-c and caspase-3 to determine the intrinsic apoptotic cascade. 
Following this, the endogenous levels of survivin, β-tubulin, proliferating cell nuclear antigen 
and Ki67 were also estimated. Considering the proliferative potential of SurR9-C84A, 
differentiated SK-N-SH cells were mainly evaluated for cell division markers PCNA, 
β-tubulin, endogenous survivin and Ki67. Also, the apoptotic proteins as described above 
were also included for the differentiated cells. 
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4.2.11.4. SurR9-C84A and autophagy 
An in vitro analysis was performed to determine the relation between the SurR9-C84A and 
autophagy in the differentiated SK-N-SH neurons. Cells were treated with the normal dose of 
SurR9-C84A both in the native and nanoformulated forms. The other treatment groups 
included the +Ve and -Ve autophagic controls that were resveratrol and 3-methyl adenine 
respectively along with the void NPs. The induction of autophagy was determined by 





















4.3. Results  
The mutant survivin protein, SurR9-C84A competitively antagonises the dual actions of cell 
division and apoptosis exhibited by the wild type survivin overexpressed in cancers. It also 
has a significant therapeutic potential in promoting the proliferation of differentiated 
neuroblastoma cells (neuronal origin) that has no/negligible expression of survivin [210]. 
Thus, SurR9-C84A can be suitably applied to cut down the proliferation in brain cancers 
(neuroblastoma in this case) and provoke proliferation in differentiated neurons. Considering 
the limitations of protein delivery, the prime goal of this study was to formulate a novel 
polymeric nanodelivery system that would enhance its stability and thereby its half-life.          
The use of PLGA offered the safest delivery on account of its biodegradability and the 
physicochemical characterization revealed salient features of this novel nano formulation. 
The technique of modified double emulsion provided enough control on the process 















4.3.1 Protein purification particle size, surface morphology and drug encapsulation 
The protein purification was performed using the GST affinity column chromatography and 
its purity was checked against SDS-PAGE electrophoreses and later confirmed with western 
blot (Fig 4.2).  
 
  
Figure 4.2. SDS-PAGE gel and western blot for SurR9-C84A purified through the 
glutathione agarose column. A concentration of 40 µg/ml of the protein was loaded in each 
well and ran through 12.5% gel and later transferred onto a PVDF membrane. The primary 
antibody was the mouse anti survivin (1:2000) and secondary antibody was the anti-mouse 
HRP (1:1500). The presence of 16 KDa band as determined by (A) SDS-PAGE and            
(B) Western blot confirmed the purity of the protein. The images shown are a representative 




























The average particle size as determined by the dynamic light scattering was around 100-    
150 nm range ideal for the delivery of drugs through the blood brain barrier. The surface 
morphology was smooth and spherical as determined by SEM and also the nanoparticle size 




Figure 4.3. Characterization of size and surface morphology of PLGA NPs. A) Size of 
the protein and void NPs determined by dynamic light scattering; B) Scanning electron 
micrograph of void NP and C) SurR9-C84A protein loaded NPs. The figures shown are 
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In general, peptides and proteins frequently display hydrophilic behavior and entrapping them 
in the hydrophobic polymer matrix is often challenging. In this study, a reasonably high 
encapsulation of 81% was achieved employing the principle of modified double emulsion 
technique where the protein was initially solubilized in the internal aqueous phase avoiding 
the protein dispersion should the single emulsion technique be employed [238]. Also, the 
ionic interactions generated between the positively charged amino groups (NH
2+
) and the 
negatively charged carboxyl groups (COO
-
) of the acid terminated surface of PLGA polymer 
accounted for the enhanced drug entrapment [239, 240]. The average encapsulation 
efficiency and the percentage loading is shown in the following table 4.1. 
Table 4.1. The encapsulation efficiency and percentage SurR9-C84A loading  
S.No 





Wt of the 
protein in the 
supernatant 
  EE 
% 
loading 
Mean of EE 
and % 
loading 
1 50 mg 2.05 mg 0.36 mg 82.4% 3.38 80.9% ± 1.22 
and 3.2% ± 
0.14 















4.3.2. Polymer-protein interaction 
Figure 4.4 shows the DSC curve patterns for the freeze dried void and the protein loaded 
PLGA NPs. A peak was observed at 52
o
C for both the NPs (void and protein loaded) 
indicating the endothermic peak for the PLGA polymer. With reference from the DSC curve 
obtained the following inference is made. The absence of discrete melting point suggests the 
amorphous nature of the polymer and also the thermal stability of it was observed up to 
250
o
C. No significant difference was observed for the DSC curves of the void and protein 
loaded NPs indicating that the protein was encapsulated within the polymer without affecting 
its integrity. Absence of crystalline peak also infers the amorphous phase of the protein 
encapsulated inside the NPs [241, 242].   
DSC THERMOGRAM FOR VOID AND SurR9-C84A LOADED NPs 
 
Figure 4.4. DSC curve for the void and SurR9-C84A loaded PLGA NPs. A temperature 
range of 0-250
o
C was used with a heat flow increment of 10
o
C/min. An endothermic peak 
was observed at 52
o
C with no detectable changes comparatively between the void and protein 
loaded NPs inferring the amorphous nature of the protein upon encapsulation in the NPs.   















4.3.3. Release kinetics 
A biphasic protein release pattern was observed at different pH. A burst release of 63% was 
observed within 6 hr at pH 7.4 while the release rate remained sustained after 12 hr and 
reached saturation in 4 days. At pH 2, the burst release was observed to be 77% within 6 hr 
and the release pattern didn’t maintain similar consistency as found at pH 7.4. The initial high 
burst effect is due to the drug diffusion from the polymer matrix (reduced diffusion path 
length) and also because NPs in the small size range of 150 nm offer higher surface to 
volume ratio facilitating the enhanced release of protein that is near or on the NP surface 
[243]. This can also be explained as the drug release from the PLGA polymer is influenced 
by the ratio of the lactide and glycolide content. The lower ratio in PLGA (50:50) imparts 
hydrophilicity, water absorbance and faster degradation rates compared to the slower drug 
release profiles with lactide rich PLGA (85:15). In addition, the acidic conditions hasten the 
PLGA degradation which in turn enhances the autocatalysis due to the accumulation of lactic 
and glycolic acids. Hence, burst release at acidic pH was higher compared to the neutral pH 
[235, 244]. The sustained effect observed after 12 hr requires the combined effect of both 
diffusion and degradation of the polymer matrix for the protein release [243]. On the whole, 
it was evidenced that the molecular weight, co-polymeric ratio, pH and surface area of the 











Figure 4.5. Protein release from PLGA NPs at acidic and physiological pH.   
In vitro release of SurR9-C84A from the PLGA nanoparticles at pH 2 and 7.4 representing 
the acidic and neutral pH ranges that the NPs would encounter. The protein release reached 
saturation in 3 days at both pH ranges. The data shown is a representative of three 
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4.3.4 Fourier transform infrared (FTIR) spectroscopy 
FTIR spectroscopy is a valuable tool in characterising the protein binding and its integrity 
once encapsulated within the NPs. The following figure represents the FTIR spectra for the 
void and the protein loaded PLGA nanoparticles. As observed, the bands detected at 1650 
cm
-1
 and 1540 cm
-1
 confirms the protein encapsulation within the NPs and represent the 
amide I and II bands respectively. These bands arise due to the corresponding C=O and N-H 
stretch vibrations in the amide linkages of the protein. FTIR analysis also confirmed the 
intactness of the protein secondary structure during the process of nanoparticle formation and 
that the protein integrity is preserved [245]. 
 
 
Figure 4.6. FTIR spectrum for the void and SurR9-C84A loaded NPs. The peaks 
observed in the range of 1650 cm
-1
 and 1540 cm
-1
 correspond to the amide I and II bands 
respectively inferring the protein integrity and encapsulation. The data represented is as a 
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4.3.5. SDS-PAGE for protein integrity 
The Fig 4.7. shows the presence of 16KDa band characteristic for the SurR9-C84A. The 
harsh parameters involved in the nanoparticle preparation process such as the organic 
solvents, sonication and emulsification might result in the denaturation of the protein.           
As observed from the figure, the structure of the protein was intact and no additional bands 
were detected. Though there are studies reporting the degradation and protein hydrolysis 
when encapsulated in the PLGA polymer [246-248] the modified double emulsion technique 
employed in this study proved to be effective in successful encapsulation of the protein 
without denaturation.  
 
Figure 4.7. Schematic representation of SDS gel for the SurR9-C84A loaded PLGA NPs. 
A concentration of 40 µg/ml of the protein was loaded in each well and ran through 12.5% 
gel. The presence of 16 KDa band represents the SurR9-C84A and confirms the successful 
encapsulation and intact protein in the NPs. It also explains that the integrity of the protein is 
not disturbed during the nanoparticle encapsulation process. The data shown is a 
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4.3.6. In vitro nanoparticle uptake studies 
The idea behind the NP uptake study in SK-N-SH cells is that it serves as a useful model for 
evaluating the in vitro efficacy of SurR9-C84A for neurological diseases [249]. As observed 
from the figure 4.8, the number of nanoparticles interacting with the cell membrane increased 
with time so as their internalization. The significant feature of these NPs was the rapid uptake 
by the cells where 40-45% of them were internalized within 30 min of incubation. This could 
be explained because of the small size range (100-150 nm) of the NPs. As observed from the 
confocal images (Fig 4.8), the presence of rhodamine labeled NPs (red) around the nucleus 
(blue, stained by DAPI) confirms the presence of NPs in the cytoplasm and their 
internalization.     
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Figure 4.8. Rhodamine labelled SurR9-C84A NP internalization in (A and B) 
Undifferentiated and (C and D) Differentiated SK-N-SH cells. Cells were incubated with 
SurR9-C84A NPs and within 1 hr NPs accumulated around the perinuclear spaces followed 
by nuclear localisation in 2 hr. Arrowheads represent the rhodamine labelled NPs. The 
histogram is a representative of mean±SD of the NPs present inside the cells counted in 5 


































4.3.7. Retinoic acid induced differentiation in SK-N-SH cells  
Retinoic acid (20 µM) induced morphological changes starting from day 2 of its addition 
followed by distinct induction of neurite processes in the N sub-type cells. Cells were 
considered to be fully differentiated, if they developed neurite processes longer than their cell 
bodies and this was achieved post 12 days of treatment with conditioned media.   
 
 
Figure 4.9. Induction of differentiation in SK-N-SH cells. SK-N-SH cells before (A) and 
after treatment (B) with retinoic acid (RA) 20 µM respectively. Cells were considered to be 
differentiated with the development of neurite processes as indicated with arrowheads.          
The images were taken at 40X objective and are a representative of three independent 
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4.3.8. NP uptake mechanism 
Cellular uptake of NPs involves a variety of endocytic mechanisms including the clathrin, 
caveolae dependent and independent endocytosis and macropinocytosis. In order to 
determine the precise mechanism of uptake, incubation with the corresponding inhibitors 
revealed interesting results. Chlorpromazine, a clathrin endocytic inhibitor showed a 40% 
reduction in the uptake compared to the void and SurR9-C84A loaded NPs while 
indomethacin showed no difference. Slight reductions in the uptake were observed post 
sodium azide (44.2%) and colchicine (35.5%) treatments indicating that the uptake of PLGA 
NPs in differentiated SK-N-SH was through clathrin mediated endocytosis along with the 
macropinocytosis and energy involvement. Macropinocytosis is a physiological function 
utilized by the cells for extracellular fluid turnover and involvement of this process in uptake 
indicates that the few percent of NPs were internalized within the cells devoid of the cell 
surface interaction and also signifies the escape from the macrophage phagocytosis [250]. 
Flowcytometric analysis also revealed similar results, where cells pretreated with 
chlorpromazine showed only 8.1% (p<0.01) uptake compared to 24.8% of only PLGA treated 
controls. Pretreatments with indomethacin showed no change while colchicine reduced the 
uptake to 14.7% confirming the involvement of clathrin and macropinocytosis uptake 
mechanisms. To further substantiate the results, future studies require the careful evaluation 
of NP uptake using a cocktail of inhibitors which would translate the in vitro studies to 
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Figure 4.10. Flowcytometer and fluorimetry analysis for determining NP uptake 
mechanism and its quantification. (A-F) Chlorpromazine a clathrin mediated endocytic 
inhibitor showed significant (2.5 fold) reduction in the uptake compared to the controls while 
sodium azide and colchicine lowered uptake by 1.7 and 1.5 folds respectively concluding the 
involvement of energy dependent and macro pinocytosis uptake. G) Post treatments cells 
were washed with PBS to remove free NPs and then the cells were lysed with 1% Triton-X-
100 in 0.2M NaOH. The resulting fluorescence was measured at 530 nm excitation and 
630 nm emission and the corresponding weight of the NPs were calculated from the standard 
graph plotted for rhodamine labelled NPs. The data is a representative of three independent 
experiments and shown as mean±SD and considered statistically significant with **p<0.01 


























4.3.9. Wild type survivin expression in differentiated and undifferentiated SK-N-SH cells. 
As observed from the Fig 4.11A, undifferentiated SK-N-SH cells showed almost 95% of wild 
type survivin expression indicating the substantial role of survivin in proliferation while the 
differentiated cells (Fig 4.11B) showed no or negligible expression confirming lowered 
proliferative potential.   
   
Figure 4.11. Differential expression of wild type survivin in undifferentiated and 
differentiated SK-N-SH cells. A) Negligible expression of wild type survivin was observed 
in the differentiated SK-N-SH cells indicating poor proliferation rate while                              
B) Undifferentiated cells showed the maximum expression of survivin, confirming the rapid 
proliferation. All the images were taken at 40X objective and the images shown are a 
representative of wild type survivin expression in the cells counted in five independent fields. 
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4.3.10. In vitro cytotoxicity in undifferentiated SK-N-SH cells 
4.3.10.1. Live and dead cell assay 
This assay was conducted to determine the cytotoxic potential of the SurR9-C84A loaded 
NPs towards SK-N-SH cells. As observed from the figure 4.12, the protein loaded NPs were 
prominent in exerting the cytotoxic effect as 50 µg/ml of the SurR9-C84A loaded NPs were 
equally effective compared to the pure protein 75 µg/ml. This could be because of the 
enhanced stability and half-life of the protein encapsulated in the nano formulation compared 
to its free form. A dose dependent effect of the protein loaded NPs was also evident with the 
increased percent of the dead cells.    
 
 
Figure 4.12. The percentage cells alive and dead post treatments with native and  
SurR9-C84A loaded NP for 24 hr. Cells were seeded in 96 well plate and after treatment 
live and dead cell assay was performed to determine the percentage of cells alive and dead as 
per the instructions. The NP loaded SurR9-C84A (50 µg/ml) was equally effective compared 
to the 75 µg/ml concentration of native SurR9-C84A (without NPs) included in the study. 
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4.3.10.2. Cell proliferation study 
The DNA content exhibited by individual cells is constant and hence in this assay, the 
fluorescence intensity measure of DNA corresponds to the cell number and therefore gives a 
measure of the cell proliferation [251]. As observed from the figure 4.13, the SurR9-C84A 
proved to exhibit the proliferation inhibition in undifferentiated SK-N-SH (neuroblastoma) in 
a concentration dependent manner with almost half of the cells (56%) wiped out at 100 µg/ml 
concentration (p<0.05).  
 
Figure 4.13. Determination of percentage proliferation of SK-N-SH cells post treatments 
with SurR9-C84A through the CyQUANT assay. Undifferentiated SK-N-SH cells were 
treated with void and protein loaded NP for 24 hr. The SurR9-C84A treated cells showed 
dose dependant decrease in the proliferation with almost 50% reduction post treatment 
period. Untreated cells served as a control and 20% foetal bovine serum treatments were 
considered as the positive control. The data is represented as mean±SD of three independent 


























4.3.10.3. Expression of proliferation cell nuclear antigen (PCNA) and Caspase-3 
PCNA is a proliferation marker expressed at the G2/M cell cycle phase marking the 
significant influence of the wild type survivin in provoking the cell division [210].                
In this study, it was aimed to evaluate the mechanism by which the SurR9-C84A acts and 
inhibits the proliferation leading to the cell cycle arrest eventually ending up with apoptosis. 
From the following figure 4.14, it is inferred that a concentration dependant reduction in the 
expression of PCNA (A and B) and vice versa with caspase-3 (C and D) was observed.     
This indicates the antagonistic effects of SurR9-C84A after dimerization with wild type 
survivin followed by the blockade of its functioning. Thus, cells arrested in mitosis (G2/M) 
overexpressed caspase-3 eventually ending up with the cell death [252].  
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PCNA, proliferating cell nuclear antigen. 
Figure 4.14. Anti-tumor effects of SurR9-C84A loaded NPs in undifferentiated           
SK-N-SH cells. A dose dependant decreased expression of PCNA was evident with the 
treatments in undifferentiated SK-N-SH cells (A and B) while a dose dependent increased 
expression of caspase-3 was observed (C and D). PCNA and caspase-3 expression is shown 
in the FITC channel (green) indicated in arrowheads, nucleus is stained red with PI.        
Bright field (BF) and merge images were also shown. All the images were taken at 40X 
objective and the histogram is mean±SD representative of PCNA and caspase-3 expression in 
the cells counted in five independent fields. *p<0.05 is considered to be statistically 






































4.3.10.4 Propidium Iodide (PI) and Annexin-V-FITC staining 
As observed from the staining, undifferentiated SK-N-SH cells showed almost 84.8% of PI 
+Ve cells (Fig 4.15 A and B) while the viable cell percentage was reduced from 93.1% to 
68.2% post annexin V staining following treatments with SurR9-C84A treatments             
(Fig 4.15 C and D). This infers the fact that survivin mutant is significantly inducing tumor 
cell death blocking the actions of the wild type.  
 
Figure 4.15. Propidium Iodide (PI) and annexin-V-staining for the untreated controls 
and SurR9-C84A loaded NP treated cells. A) Untreated cells showing only 2.7% PI +Ve 
cells. B) SurR9-C84A treatment increase PI staining to 85%. C) Annexin-V-staining showed 
93% viable cells. D) SurR9-C84A treatment reduced the viability to 68%. Thus, it infers the 
SurR9-C84A induced cytotoxicity as evidenced through PI staining along with a drastic 
reduction in the viable cells following annexin staining. The results shown are representative 


















4.3.11. In vitro proliferation in differentiated SK-N-SH cells 
4.3.11.1. Expression of proliferation markers PCNA, Ki67 and BrdU assay 
The proliferative potential of SurR9-C84A on differentiated SK-N-SH was studied by 
confirming the expression of PCNA (Fig 4.16A and B) and Ki67 (Fig 4.16C and D). PCNA 
is expressed at the G2/M phase of the cell cycle while Ki67 is expressed at all active phases 
of the cell division except at the resting phase (G0) [253]. Thus, both these are excellent 
markers for determining the proliferation in differentiated SK-N-SH cells. Further to 
substantiate, the dividing cells were also determined utilising the BrdU assay which is an 
excellent method of monitoring the cell proliferation. BrdU is an analogue of thymidine and 
gets incorporated into the DNA of the dividing cells. Consequently, many studies have 
reported the use of BrdU labelling for determining the cell proliferation particularly the 
neurons [254]. Post treatments with SurR9-C84A, 23.2% of the differentiated SK-N-SH cells 
expressed PCNA while 16% of them were found positive for Ki67. Also, when compared 
with the controls, the BrdU labelling was found to be increased by 1.15 folds post         
SurR9-C84A treatments (Fig 4.16F). Altogether, these results confirm that the differentiated 
SK-N-SH cells which are deficit of wild type survivin, regain their proliferation when treated 
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Figure 4.16. Proliferative and neuroprotective potential of SurR9-C84A on 
differentiated SK-N-SH neurons. The percentage expression of PCNA expression was 
compared between the untreated control (A) and the SurR9-C84A treated differentiated     
SK-N-SH cells (B). Similarly, it was observed for the expression of Ki67 between the 
untreated control (C) and the SurR9-C84A treatments (D) post treatments for 24 hr. A dose 
dependant increased expression of PCNA and Ki67 was evident with the treatments in 
differentiated SK-N-SH cells. PCNA and Ki67 expression was shown in FITC channel 
(green) and nucleus is stained red with propidium iodide (PI). Bright field (BF) and merge 
images are also shown. All the images were taken at 40X objective. E) Histogram showing 
the percentage expression of PCNA and Ki67. F) BrdU assay in differentiated SK-N-SH cells 
post SurR9-C84A treatments. BrdU is an analogue of thymidine and dividing cells 
incorporate them into their DNA. Thus, cells that are BrdU +Ve indicate the proliferation and 
is concentration dependent with the treatments. The data is represented as mean±SD of three 

































4.3.11.2. Flow cytometry PI and Annexin V-FITC staining 
Apoptotic cells are typically characterised by the fragmentation of DNA followed by the 
significant loss of DNA content. PI staining is specific to the DNA and thereby provides a 
rapid estimation of percentage dead cells [255]. As observed from the figure 4.17, not much 
difference was observed for PI +Ve cells in the untreated controls and the SurR9-C84A 
treated differentiated neurons (Fig 4.17 A and B). Similarly, the annexin staining also 
revealed that the percentage viable cells were increased from 96% to 98% post treatments 
with   SurR9-C84A indicating the neuroprotective and proliferative capacity of the survivin 
mutant (Fig 4.17 C and D). 
 
Figure 4.17. Determination of dead and viable cell population in the differentiated            
SK-N-SH post SurR9-C84A treatments. In the case of PI staining (A) Untreated control 
and the (B) SurR9-C84A treatments showed not much variability in PI +Ve stained cells 
indicating that the treatments were not cytotoxic. Similarly, Annexin V fluos staining showed 
that compared to (C) Untreated control, the treatments with (D) SurR9-C84A showed a slight 
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4.3.12. Gene expression study 
To confirm the characteristic mechanism of SurR9-C84A on undifferentiated and 
differentiated SK-N-SH cells qRT-PCR was performed for the proliferative (wild type 
survivin) and the apoptotic genes (caspase-3,7,8,9, Cyt-c, p53). In the case of undifferentiated 
SK-N-SH cells the apoptotic genes caspase-3,7,8,9, Cyt-c and p53 showed 1.32, 1.54, 2.39, 
1.55, 2.84 and 1.2 fold increase respectively while the proliferative marker, endogenous 
survivin showed a 2 fold reduction confirming the anti-tumor potential of  SurR9-C84A 
(Fig 4.18A). The same apoptotic genes (caspase-8, 9 and p53) when studied in differentiated 
SK-N-SH cells showed 1.53, 1.58 and 3.33 fold reduced expression. Further, endogenous 
survivin levels showed a 1.1 fold increase in its expression provoking the proliferative 












































Gene expression in undifferentiated  
SK-N-SH cells 
Control Void Native SurR9-C84A


























Gene expression in differentiated SK-N-SH 
Control Void Native SurR9-C84A












Figure 4.18. Gene expression study in undifferentiated and differentiated SK-N-SH cells 
post SurR9-C84A treatments. SurR9-C84A showed increased expression of apoptotic 
genes in undifferentiated cells (A and C) where as a reduced expression of them was noticed 
in differentiated SK-N-SH cells (B and D). The relative expression of all the genes was 
measured and calculated relative to the house keeping gene β-actin. Data is represented as 
mean±SD of two independent experiments. Lanes 1-6 are: 1) Control 2) Void 3) Native 
SurR9-C84A 75 µg 4) SurR9-C84A 50 µg 5) SurR9-C84A 100 µg and 6) SurR9-C84A      
200 µg treatments respectively. The data is represented as mean±SD and *p<0.05; **p<0.01 
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4.3.13. Protein expression  
SurR9-C84A showed dual but distinct actions on undifferentiated and differentiated          
SK-N-SH cells that represent the tumorous and neuronal characteristics. Apoptotic markers 
like p53, BAX, Cyt-c and caspase-3 were upregulated by 77.4, 90.9, 4.5 and 14% 
respectively indicating the anti-tumor effects of SurR9-C84A. Also, the proliferative markers 
β-tubulin, survivin, PCNA and Ki67 were downregulated by 34.5, 79, 25.88 and 15% 
respectively (Fig 4.19). These results were complying with our earlier results  of the anti-







Figure 4.19. Flowcytometry analysis for protein expression in undifferentiated           
SK-N-SH post treatments with SurR9-C84A NPs. Compared with the untreated control the 
proteins involved in cell cycle progression like survivin, PCNA, Ki67 and β-tubulin were 
downregulated and the apoptotic markers BAX, Cyt-c, caspase-3 and p53 were upregulated 
post SurR9-C84A treatments. This confirms the anti-tumor potential of SurR9-C84A against 
the undifferentiated SK-N-SH cells.  
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Owing to the proliferative potential of SurR9-C84A in neurons with low endogenous pool of 
survivin, differentiated SK-N-SH cells exhibited upregulation of cell division markers. 
Endogenous survivin levels increased up to 46.3% while PCNA and Ki67 showed a 5.1 and 
24.9% increment respectively. Substantiating this, the apoptotic markers Cyt-c, caspase-3 and 
p53 showed a respective reduction by 65.6, 54.5 and 74.5%. Also, β-tubulin III, the specific 
neuronal differentiating marker also showed a 3.7% downregulation indicating the change of 
differentiation phase to proliferation (Fig 4.20). Considering these dual actions, SurR9-C84A 








Figure 4.20. Flowcytometry analysis for protein expression in the differentiated         
SK-N-SH cells post SurR9-C84A NP treatments. SurR9-C84A increased the expression of 
cell proliferation markers like β-tubulin, survivin, PCNA and Ki67 in differentiated SK-N-SH 
cells while the indicators of apoptosis caspase-3, Cyt-c and p53 showed reduced expression 
compared to the controls. Also, the differentiating marker β-tubulin III showed slight 
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Table 4.2. Comparison of protein expression in undifferentiated and differentiated  
SK-N-SH cells post SurR9-C84A treatments 
S.NO Stained for Undifferentiated Remarks Differentiated Remarks 
1 Annexin-V-fluos 30.8% +Ve Apoptosis 98% -Ve 
Reduced 
apoptosis 
2 PI 84.8 +Ve Apoptosis 69.5% -Ve 
Reduced 
apoptosis 





















6 Caspase-3 14%↑ Apoptosis 54.5%↓ 
Reduced 
apoptosis 







8 BAX 90.9 %↑ Apoptosis ------------- 








10 p53 77.4%↑ Apoptosis 74.5%↓ 
Reduced 
apoptosis 








4.3.14. SurR9-C84A and autophagy 
As observed from the figure 4.21, the expression of autophagic markers LC3-II and BEC1 
were found to be downregulated post treatments with SurR9-C84A. As compared to the 
untreated control, the expression of LC3-II and BEC1 were reduced by 2.3 and 3 folds post 
SurR9-C84A treatments. However, the negative autophagic control (3-methyl adenine) 
significantly reduced the expression of LC3-II by -1.92 folds with no change in BEC1 
expression. Resveratrol, the +Ve autophagy control induced LC3-II and BEC1 expression 
that showed a significant 2.5 and 54 folds respectively. With respect to the nanoformulated 
SurR9-C84A, a slight increment was observed for LC3-II and BEC1 attributed as 1.2 and 1.4 
folds while the void NPs alone showed 1.4 and 4.9 folds respectively. Autophagy is one of 
the critical processes regulating programmed cell death and its induction is confirmed by the 
conversion of cytoplasmic LC3-I form to membrane bound LC3-II [256]. Another important 
inducer of autophagy is the protein BEC1 that belongs to the Class III phosphatidylinositol-3-
kinase (PI3KCIII) family. It plays a central role in recruiting the autophagy related substrates 
and executes the autophagic process [257]. Thus, it is inferred from the above results that 
SurR9-C84A is acting against the autophagy induction as observed with downregulation of 
LC3-II and BEC1 expression. However, the same is not holding true in case of nano 
encapsulated form of SurR9-C84A as there is a slightly increased expression of autophagic 
markers. This is explained as: void NPs by themselves are showing an increment in LC3-II 
and BEC1 expression and thus the NPs are attributing this property to the encapsulated 
SurR9-C84A protein. The same was also observed with the western blot analysis (Fig 4.21C) 
where SurR9-C84A showed strong inhibition of LC3-II compared to the untreated control 























































Figure 4.21. Anti-autophagic actions of SurR9-C84A in differentiated SK-N-SH cells.  
A) SurR9-C84A exhibited strong anti-autophagic actions by inhibiting the expression of the 
specific autophagic markers such as the membrane bound LC3-II and BEC-1. Flowcytometry 
analysis has revealed the anti-autophagic actions where both the native and nanoformulated 
SurR9-C84A reduced the expression of autophagic specific BEC-1 and membrane bound 
LC3-II markers. Treatments with 3-methyl adenine and resveratrol served as the -Ve and +Ve 
controls respectively. B) Histogram showing the autophagic marker expression (LC3-II and 
BEC1) for various treatments. C) Western blot analysis for autophagic marker post       
SurR9-C84A treatments. 1) Control; 2) 3-Methyl adenine; 3) Native SurR9-C84A only;         
4) SurR9-C84A NP; 5) Void NP; 6) Resveratrol. The data is represented as mean±SD of two 
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4.3.15. Immunofluorescence for LC3-II expression 
In order to further confirm the autophagy, the expression of the membrane bound LC3-II 
marker was determined using the immunofluorescence. As seen from the figure 4.22, the 
expression of LC3-II expression was evident with the +Ve control resveratrol which showed 
a 4.5 fold increment compared to the untreated control while the –Ve control 3-MA showed   
-2.02 fold reduction. While the native protein, nanoparticle loaded protein and void NPs 
showed a negligible 1.4, 1.4 and 2 folds increased expression. To further substantiate the 
autophagic induction, a polyclonal antibody that can detect both the nuclear (LC3) and 
membrane bound (LC3-II) was used. Interestingly, the untreated and 3-MA treated control 
showed nuclear expression indicating the absence of autophagy and in contrast the +Ve 
control resveratrol showed membrane expression of LC3-II confirming the autophagic 
induction. Surprisingly, both the native and the nanoparticle loaded protein including the void 
NP showed  negligible expression of the membrane bound LC3-II thus confirming the 
absence of autophagy. 
AUTOPHAGIC INFLUENCE OF SurR9-C84A ON THE DIFFERENTIATED SK-N-SH CELLS 
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Figure 4.22. Determination of non-specific and specific autophagic marker expression in 
SK-N-SH neurons. The +Ve marker for autophagy LC3-II expression was profound with 
resveratrol treatment which showed a strong membrane bound protein expression. In contrast, 
the untreated and 3-MA treated controls showed nuclear expression of the protein thus 
confirming the absence of autophagy. Similarly, negligible membrane expression was 
observed with the native and nanoparticle loaded SurR9-C84A including the void NPs thus 
confirming the absence of autophagy. All the images were taken at 40X objective and the 
histogram is mean±SD representative of LC3-II expression in the cells counted in five 























SurR9-C84A effect on autophagy 





In the recent times, a rapid improvement has been made on the understanding of various 
neurological disorders ranging from brain tumors to neurodegeneration. Despite the 
pathological differences in these diseases, the ultimate result is the irreversible degeneration 
or death of the neurons [5]. Hence, there is an absolute need for an ideal therapeutic that is 
differentially toxic to brain tumor cells while protective towards the degenerating neurons.    
In this study, comparative effects of SurR9-C84A on the tumorous undifferentiated SK-N-SH 
and the differentiated neurons were studied for the first time. Considering the wild type 
survivin it mainly interacts with the microtubules stabilising them and organises the CPC 
initiating the cell division [258]. On account of the differences in wild type pool, tumor cells 
proliferate indefinitely while the neurons (differentiated SK-N-SH in this case) suffer from 
reduced or no proliferation which is a reflective of high and low expression levels of survivin 
respectively [161, 210]. Survivin is an attractive target with respect to cancer therapeutics 
because of its specific expression in the tumor compared to the normal cells which is highly 
unlikely for the other IAPs studied so far. Survivin is over expressed and found to regulate 
cell division and apoptotic mechanisms in tumor cells. Several studies have confirmed that 
small molecules inhibitors, antagonists, anti-sense agents acting against survivin interfere 
with survivin expression or function and regress the tumor progression [183, 233, 259, 260].         
In addition, reports were also published where survivin overexpression was found to be 
correlating with resistance developed in the advanced tumors [230, 261]. Thus, survivin 
targeting has gained attention in cancer therapeutics and several strategies have been 
considered for an effective therapeutic outcome. Preliminarily, vaccination was tried to 




However, this attempt was failed because of the strong host antibody responses developed 
against the survivin peptides but this study was of diagnostic significance for screening the 
antibodies in the patients. The next level of targeting included the molecular antagonists of 
survivin such as the antisense agents, dominant-negative mutants and siRNA that showed 
strong tumor suppression upon interfering the wild type survivin [183, 260, 262]. Finally, 
pharmacological inhibition was tried as the third approach where survivin phosphorylation 
was blocked at Thr34 position by the mitotic kinase p34cdc2 [185]. The above results 
indicate that interfering wild type survivin functions yield a strong anti tumor activity and 
hence SurR9-C84A loaded NPs were tested against the neuroblastoma cells. Owing to the 
hurdles in delivering the protein drugs biodegradable polymeric PLGA NPs were used to 
enhance their physicochemical stability, bioavailability and half-life of SurR9-C84A.        
The synthetic polymeric PLGA NPs have a better control drug release in addition to offering 
improvised ways of surface decoration for targeted delivery [234]. Moreover, the prepared 
NPs are biodegradable and biocompatible yielding lactic and glycolic acids that are 
metabolised to non-toxic carbon dioxide and water. The NPs showed an initial burst followed 
by sustained release of the protein and this feature is attributed due to the equal co-polymeric 
ratio of PLA and PGA used in this study [263-265]. The prepared NPs were small and 
homogenous and were able to accumulate in the perinuclear spaces along with the nucleus 
within 30 min of incubation. As compared with previous results [183, 259, 260, 262],   
SurR9-C84A also showed reduced proliferation in the undifferentiated SK-N-SH cells in a 
concentration dependent manner. These results were further confirmed by the in vitro 
CyQUANT, Live and Dead assay followed by evaluation of the lowered expression of wild 
type survivin and proliferation markers PCNA and Ki67. Subsequently, there was also an 
enhanced expression of apoptotic genes caspase-3 caspase-8 and caspase-9 along with a 
remarkable downregulation of wild type survivin (Fig 4.18A).  
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The mechanistic role of survivin in initiating the apoptosis was unveiled by studying the 
expression of Cyt-c, caspase-3 and caspase-9 and was found to comply with the 
mitochondrial mediated intrinsic pathway as published earlier [266]. SurR9-C84A was able 
to show an enhanced expression of caspase-3 and caspase-9 and showed the following 
mechanism for inducing apoptosis in undifferentiated cells. SurR9-C84A is forcefully 
expressed upon treatment dimerises and displaces the over expressed wild type survivin pool 
leading to disturbed microtubule dynamics. Survivin-Smac/DIABLO complex formation is 
even inhibited thereby relieving its inhibitory effect and thus sets the caspase-3 free for action 
[267]. Also, on account of the absence of wild type survivin hepatitis B-X-interacting protein 
on its own cannot block the procaspase-9activation and thus initiates the mitochondrial 
mediated apoptosis that eventually culminate in cell death. Owing to the cancerous nature, 
undifferentiated neuroblastoma cells show cyclin D1 overexpression but surprisingly it is 
found to initiate the programmed cell death. A number of reports have identified that 
postmitotic cells including the neuroblastoma cell lines overexpress cyclin D1 preceding 
apoptosis [210, 268]. This is explained as, cells exhibit a specific selection strategy where 
optimum expression of it leads to overgrowth while higher expression levels induces 
apoptotic cell death [269]. On the similar lines, the overexpression of cyclin D1 in 
undifferentiated SK-N-SH cells post SurR9-C84A was observed to cause apoptosis and vice 
versa with differentiated cells. To conclude, SurR9-C84A displaces the wild type survivin 
upon forceful expression from the microtubular assembly causing serious microtubular 







4.4.1. Proliferative effects 
As discussed various neurological diseases are characterised by the significant neuronal loss 
and the prime strategy to counteract it is to develop anti-apoptotic therapeutics to rescue the 
neurons and their damage. Amongst the various anti-apoptotic molecules, survivin   
belonging to the IAPs family will find tremendous application for treating these diseases as it 
has the dual action regulating cell cycle and apoptosis. Previously, it has been reported that 
survivin has an essential role in the premature brain development where its deficiency lead to 
abnormal brain hypoplasty and immature foetal deaths [144, 270] and it also protected the 
astrocytes post brain injury by complexing active caspase-3 [137]. Besides playing a vital 
role in spindle fibre formation, cell cycle progression, CPC organization survivin also was 
found to contribute premature brain development [144]. Hence, the strategy of 
neurogeneration or neuroprotection has been employed to answer the issue of degeneration. 
Preclinical studies have already shown the effectiveness of anti-apoptotic molecules such as 
Bcl-2 and members of IAPs family for their protective activity [133, 196]. Thus, survivin an 
IAPs family protein bearing anti-apoptotic and proliferative activity has been targeted for 
treating the neurological ailments. Adopting this principle, a study has reported the neural 
progenitor cell proliferation in the brain where the modulation of survivin expression or the 
Wnt signalling was responsible for this cause [271]. On the similar lines, targeting survivin 
has shown neuroprotector activity in an in vitro multiple sclerosis model where BeAn strain 
of TMEV was employed for insulting the mouse brain astrocytes. In another study, the  
apoptotic events were nullified following the elevated survivin expression where it 
complexed the caspase-3 activity  displaying protective activity [195]. In addition,              
the dominant negative mutant survivinM34 also was found to have cytoprotective actions 
against the DNA damaging agents [185, 262].  
142 
 
Several mutant versions of survivin have been explored considering their cytoprotective 
potential and in this study SurR9-C84A mutant has been employed. The unique feature of 
this mutant is that it is indistinguishable from the wild type survivin in stabilising the 
microtubule assembly and organising the CPC. In addition, it mimics the wild type survivin 
as it neither has the interference with chromosomal separation nor the cell division [161]. 
Previous data also exists explaining the extensive protective and proliferative potential of 
SurR9-C84A in the differentiated neurons against oxidative stress and T-cell mediated 
toxicity [21, 138, 197, 210].  Thus, targeting survivin as a therapeutic is a significant option 
for neuronal proliferation and neuroprotection. In order to confirm the proliferative effects, 
differentiated SK-N-SH neurons were treated with SurR9-C84A loaded NPs and 
interestingly, they showed enhanced BrdU incorporation that is cell proliferation specific. 
They also showed an increased expression of wild type survivin and proliferation markers 
such as PCNA and Ki67 confirming the cell cycle progression as determined by 
immunofluorescence and flow cytometry. Endogenously, differentiated SK-N-SH neurons 
showed reduced or no expression of survivin due to their limited inability to divide but post 
SurR9-C84A treatment they showed enhanced survivin expression indicating initiation of 
proliferation. The mechanism is explained as SurR9-C84A interaction with the microtubular 
assembly was evident thereby initiating the spindle formation and this action is 
indistinguishable to that of wild type survivin [22, 161]. This study is the first of its kinds 
comparing the differential actions of nanoformualted SurR9-C84A on the undifferentiated 
(tumorous neuroblastoma) and differentiated SK-N-SH neurons. In the undifferentiated cells, 
cytotoxic effect was evident due to high wild type survivin expression due to the dominant 
negative actions of SurR9-C84A confirmed through the upregulation of caspase-3, Cyt-c, 
cyclin D1, annexin and PI +Ve cells.  
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In contrast, owing to the low endogenous survivin in differentiated cells levels proliferative 
effect was reported for SurR9-C84A with enhanced wild type survivin, PCNA and Ki67 
levels. In conclusion, the dual actions of SurR9-C84A were observed due to the differential 
endogenous survivin expression levels. Finally, as observed from the results SurR9-C84A 
showed strong anti-autophagic actions as compared to the +Ve controls further substantiating 





Figure 4.23. SurR9-C84A mechanism of action on undifferentiated and differentiated 
SK-N-SH cells. In the case of undifferentiated cells, soon after the release of SurR9-C84A 
from the NPs it dimerises with wild type survivin and antagonises its function leading to the 
cell cycle arrest. It interferes with the formation of Survivin-Smac/DIABLO complex and 
thereby relieves its inhibitory effect on Caspase-9 activity. Also, due to the unavailability of 
wild type survivin hepatitis B-X-interacting protein cannot alone inhibit the activation of 
procaspase-9. The levels of BAX, Cyt-c and Caspase-9 are also increased followed by the 
activation of caspase-3 thus propagating the mitochondrial mediated apoptosis. In the 
differentiated SK-N-SH cells where there was a low endogenous pool of wild type survivin, 
SurR9-C84A was able to interact with the microtubular assembly and initiate the 
chromosome passenger complex formation and thus initiate the neuronal division. This was 
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In this study, the dual actions of SurR9-C84A have been demonstrated where it showed 
cytotoxic actions in undifferentiated and proliferative effects in differentiated SK-N-SH cells. 
This may drive a potential future application of SurR9-C84A for treating a variety of 
neurological disorders. The beauty of this therapeutic would be selective killing of brain 
tumor cells owing to the nature of high endogenous survivin expression sparing the 
differentiated neurons. Also, initiation of neuronal proliferation would be a tremendous 
















SURVIVIN MUTANT PROTEIN (SurR9-C84A) NEUROPROTECTIVE ACTIONS 
AGAINST IN VITRO ALZHEIMER’S ASSOCIATED TOXICITY AND 
INFLAMMATION 
Abstract 
Alzheimer’s disease (AD) is a chronic untreatable neurodegenerative disease characterised by 
the hallmark pathology of amyloid plaque deposition and inflammation. The major limitation 
in treating this disease is because of the deficit understanding of the cellular processes leading 
to neuronal death and the escape mechanisms from these toxic insults. In this phase of the 
study, neuroprotective effects of SurR9-C84A were evaluated against the β-amyloid toxicity. 
Surprisingly, the mutant protein showed a reduced Cyt-c and caspase-3 expression and an 
enhanced expression of neuronal integrity markers following the neuroprotective 
ERK/MAPK signalling. Further, it also showed enhanced neuronal protection against the 
neuroglia induced inflammatory insults and NMDA mediated excitotoxicity suggesting 









Inflammation is one of the characteristic features of several neurological disorders and 
despite the acute and chronic disease stage of the disease the neurons being postmitotic in 
nature are particularly susceptible to its damage. In a majority of the central nervous system 
disorders such as the brain infections, ischemia, trauma and neurodegeneration etc., 
inflammation seem to be the primary culprit for the activation of the supporting astrocytes 
and/or microglial cells [272]. Alzheimer’s disease (AD) is a progressive neurodegenerative 
disease typically characterised by the formation of β-amyloid (Aβ) plaques and 
neurofibrillary tangles. The senile plaques are a result of accumulation of Aβ monomers 
which are formed because of the abnormal enzymatic cleavage of the amyloid precursor 
protein (APP) following which the polymerisation of monomers takes place yielding the 
Aβ-peptides. Neurofibrillary tangles the other pathological hallmark of AD occur as a result 
of abnormal phosphorylation of tau, a microtubule associated protein [37]. Pathologically, the 
lesions seen in AD are principally found to arise because of the presence of several mediators 
that are also common to the inflammation generation as observed in several studies [273-
275]. Thus, inflammation can be foreseen as a key forerunner or a later consequence of AD. 
In particular, of all the glial cells microglial activation is seen as a close proximity in all the 
neurodegenerative diseases and is responsible for the inflammatory insult. Astrocytes, the 
other principal class of neuroglial cells though regulate the physiological processes of 
synaptic transmission, ionic balance and the neuronal activity become reactive and 
phagocytic in the event neurodegeneration [276]. Thus, the disease states is further worsened 
due to the microglia and astrocyte co-operation creating a severe inflammatory milieu and 
culminate secreting cytokines, chemokines and other effector molecules [277]. 
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It has also been published where the classical microglial activation was found to induce 
inflammation mediated neurotoxicity.  For instance, the serum levels of TNF-α were reported 
to be elevated in AD [278] while other study reported the inherent Aβ peptide mediated 
secretion of inflammatory components, TNF-α and IL-6 [279]. Microglia were found 
responding to Aβ plaques and were involved in the secretion of prime inflammatory 
components such as nitric oxide [278, 280] along with the neurotoxic pro-inflammatory 
cytokines such as IL-1β. These cytokines secreted by the reactive microglia are in turn 
endowed with the potential of astrocyte stimulation, initiation of the inflammatory cascade 
and culminating in neurodegeneration [281-283]. The Aβ peptides in AD are not only 
responsible for the local inflammatory assault but also worsen the disease severity by 
attracting the blood borne monocytes. On account of the dynamic interplay that exists 
between the endogenous and exogenous brain immunity, the secreted cytokines and 
chemokines from the microglia attract the monocytes granting easy access into the blood 
brain barrier [283]. In addition, the neuritic plaques in AD are surrounded by activated 
microglial cells representing an activated phenotype that responds to the β-amyloid fibrils 
secreting of cytokines, chemokines and other neurotoxic mediators. Thus, to closely mimic 
the AD associated inflammation, THP-1 cell line a commonly used human microglial model 
is used for the complete study [282, 284].   Supporting the role of microglial inflammation in 
neurodegeneration, several studies reported the potential sites of inflammation in the brains 
of AD patients are the neuritic plaques surrounded by the reactive microglia [285, 286].            
This hypothesis was also proved as observed with available epidemiologic and clinical trial 
data where the incidence and AD progression was significantly lowered post administration 
of anti-inflammatory agents [287-289].  
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The basic idea behind this study was generated after understanding the AD pathology and the 
significance of inflammation in worsening the disease condition. Thus, the inflammatory 
condition in vitro was simulated and the therapeutic potential of SurR9-C84A was evaluated 
for rescuing the neurons. In conclusion, neurotoxicity is unavoidable due to the Aβ plaque 
generation and its association with the inflammatory mediators secreted by the reactive glia. 
Several approaches have been developed to study the neuron and microglia interactions        
in vitro. In this study, the neuroprotective activity of SurR9-C84A was tested against AD and 
its associated inflammation. For this, SurR9-C84A treated differentiated SK-N-SH neurons 
were incubated with Aβ fragments for evaluating the protective effect. For the AD associated 
inflammation, neurons were incubated with the cytokine rich supernatants collected from 
insulted glia along with the co-culture of activated microglia and the neurons. 
5.2. Material and methods 
The endotoxin lipopolysaccharides (LPS) from Escherichia coli 055:B5, Phorbol-12-
myristate-13-acetate (PMA), amyloid β protein fragment 1-40, retinoic acid, D-Galactose and 
melatonin were all obtained from Sigma Aldrich. The void and SurR9-C84A loaded 
nanoparticles used in the study were prepared according to the protocol described in the 
fourth chapter. Cell lines used in the study SK-N-SH, CCF-STTG1 and THP-1 were obtained 
from American type culture collection (ATCC). SK-N-SH cells were grown in Eagle’s 
minimum essential medium (MEM) and CCFs in Dulbecco’s modified eagles medium 
(DMEM) supplemented with 10% foetal bovine serum and 1% penicillin/streptomycin while 
THP-1 cells were maintained in Rosewell park memorial institute (RPMI) 1640 medium 




5.2.1. Stimulation of microglial and neuroglial cells for cytokine secretion 
Microglial cells: THP-1 cells were plated in the 12 well plates and grown confluent. They 
were differentiated to macrophage like cells post treatment with 100 ng/ml of Phorbol-         
12-myristate-13-acetate (PMA) for 3 days with successive replacement of the conditioned 
media. Activation of the THP-1 cells for the secretion of various cytokines was achieved 
following the incubation with 10 µg/ml of LPS for 24 hr. Post activation for 6 hr with LPS, 
the cells were centrifuged at 1500 RPM and the supernatants were collected for TNF-α as it is 
secreted earlier and rest of the cytokines were collected after 24 hours of incubation. 
Similarly post differentiation with PMA THP-1 cells were activated with 100 µM of             
β-amyloid for the cytokine secretion. The collected supernatants were also evaluated for the 
cytokine expression using the cytokine array kit (R&D biosciences) following manufacturers 
protocol. 
5.2.2. Neuroglial cells: Astrocytes were grown in 6 well plates and grown confluent. 
Stimulation of the CCF cells for the secretion of various cytokines was achieved following 
the incubation with 100 µM of β-amyloid for 24 hr following which the cytokine rich media 
was collected and used for further experiments. The collected supernatants were also 
evaluated for the cytokine expression using the cytokine array kit (R&D biosciences) 
following manufacturers protocol. 
5.2.3. SurR9-C84A and nitric oxide inhibition 
In order to evaluate the anti-inflammatory potential of SurR9-C84A, preliminarily we 
evaluated its effect on nitric oxide production ability of activated THP-1 cells using Griess 
reagent kit (Invitrogen). THP-1 cells were plated in 96 well plates at 10
4 
cells/well. Then the 
cells were pre-treated with SurR9-C84A loaded PLGA NPs at 200 µg/ml concentration.  
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An untreated LPS only activated control and inactivated controls were also included in the 
study. Following the treatment period supernatants were collected and then evaluated for the 
nitrite levels as per the manufacturer’s protocol. In brief, 20 µl of Griess reagent was mixed 
with 150 µl of the supernatant sample and made up to 300 µl with milliQ water. Readings 
were taken at 530 nm in a microplate reader and all the experiment was performed in 
triplicates.   
5.2.4. In vitro neuroprotective effect against inflammation 
5.2.4.1. SurR9-C84A against the LPS and β-amyloid stimulated THP-1 secretions 
The neuroprotective potential of SurR9-C84A was evaluated using a simple in vitro model of 
neuro-inflammation. SK-N-SH cells were plated in 96 well plate at a density of 10
4 
cells/well 
and were differentiated following the protocol as described earlier [210]. Post differentiation 
they were pre-treated with SurR9-C84A loaded PLGA NPs at 200 µg/ml concentration. After 
pre-treatment, the supernatants collected from LPS and β-amyloid stimulated THP-1 cells 
were introduced (10% of total media added) and incubated for 24 hr. The latter stimulation 
was included to mimic the β-amyloid activation of microglial cells in vivo pathologic 
condition. After the said time, the percentage cytotoxicity was evaluated using the LDH assay 
(Roche). Other treatments included in the study are indomethacin, insulin like growth factor 
(IGF-1) and nerve growth factor (NGF) as +Ve controls and 1% Triton-X-100 as -Ve control. 
Also, to evaluate the cytotoxic potential of the cytokines secreted, differentiated SK-N-SH 
cells were introduced with stimulated and unstimulated THP supernatants without prior pre-
treatments. The entire study was run in triplicates and readings were taken at 490 nm keeping 




5.2.4.2. SurR9-C84A against the LPS stimulated THP-1 secretions 
SurR9-C84A was initially evaluated for the protective effect in neurons post LPS stimulated 
THP-1 cytokine rich supernatant incubation. In prior, the neurons were treated with       
SurR9-C84A followed by the THP supernatants for 24 hr.  An untreated control was also 
included along with the IGF-1 as +Ve controls. Following the insult, the neuroprotective 
potential was evaluated by assessing the neuronal integrity markers myelin basic protein 
(MBP) and neurofilament 200. MBP expression was assessed by immunofluorescence, 
flowcytometry and immunocytochemistry while NF 200 was assessed by ICC alone. In brief, 
cells were washed with PBS, fixed with 4% PF and blocked with 2% rabbit serum. Then the 
neurons were stained with the mouse monoclonal anti-MBP (Santa Cruz) 1:100 dilution for   
1 hr followed by FITC labeled rabbit anti-mouse (1:100, Sigma Aldrich). Fluorescence was 
recorded using the FACS cell sorter (BD Bioscience) and data was acquired using BD FACS 
canto software (BD Bioscience). For immunofluorescence, cell nucleus was stained with 
propidium iodide (1:500, Sigma Aldrich) for 30 min and mounted with mounting media. 
Further imaging was carried using the Leica SP5 confocal microscope at 40X objective.      
For immunocytochemistry (ICC), the antibodies were the same and DAB-stain was 
performed as per the manufacturer’s protocol (Vector Labs) and counterstained with methyl 







5.2.4.3. SurR9-C84A against the β-amyloid stimulated astrocyte secretions 
Similar to the above study, astrocytes were activated with 100 µM of β-amyloid for 24 hr and 
the secretions were added to the SK-N-SH neurons pre-treated with SurR9-C84A loaded 
PLGA NPs at 200 µg/ml concentration. +Ve and –Ve controls used were the IGF-1 and 1% 
Triton-X-100 and the % cytotoxicity was measured using the LDH assay. Further to this, 
flowcytometric analysis was also carried out to determine the anti-inflammatory properties of 
SurR9-C84A. In brief, astrocytes were treated with β-amyloid for 24 hr and analysed for the 
expression of GFAP, TNF-α and IL-1β. GFAP is expressed in reactive astrocytes while   
TNF-α and IL-1β are the well-known pro-inflammatory cytokines. 
5.2.4.4. SurR9-C84A against the β-amyloid toxicity: In vitro AD toxicity model 
The neuroprotective potential of SurR9-C84A was further confirmed against the direct         
β-amyloid induced toxicity in differentiated SK-N-SH cells. Differentiated cells were plated 
in 96 well plate at a density of 10
4 
cells/well and were pre-treated incubated with various 
concentrations of SurR9-C84A loaded PLGA NPs (50,100 and 200 µg/ml). After                 
pre-treatments, 100 µM of β-amyloid fragment was introduced into the wells and incubated 
for 24 hr. An untreated control was also included along with the IGF-1 and NGF as +Ve 
controls. Following 24 hr, the percentage cytotoxicity was evaluated using the LDH assay as 
per the manufacturers protocol (Roche). The entire study was ran in triplicates and readings 
were taken at 490 nm keeping the reference as 600 nm. After cytotoxic measurement, the 
nitrite lowering capacity of SurR9-C84A was also evaluated with the left over supernatants 




5.2.4.5. Real time PCR and DNA fragmentation 
To determine neuroprotective actions of SurR9-C84A, qRT-PCR analysis was conducted for 
wild type survivin, proinflammatory genes: TNF-α, IL-1β, inducible nitric oxide synthase 
(iNOS); apoptotic genes: p53, Cyt-c and caspase-3; neuronal integrity markers: neurofilament 
(NF) 68, NF 160, NF 200, neuron specific enolase; Alzheimer’s related genes: apolipoprotein 
E (ApoE) and glycogen synthase kinase-3-beta (GSK-3β) and finally ERK/MAPK genes 
were studied. Differentiated SK-N-SH cells were grown confluent in 6 well plates and then 
pre-treated with void and SurR9-C84A loaded NPs for 24 hr. Following pre-treatments, cells 
were washed thoroughly with 1X PBS and then introduced with β-amyloid fragments and 
incubated for 24 hr. Post treatments, TRIzol® reagent (Invitrogen) was used to isolate the 
RNA from the cells following the supplier’s protocol and mRNA was immediately converted 
to cDNA. SUPERSCRIPT III reverse-transcriptase, oligo-dT and RNase free water 
(Invitrogen) were used for this conversion. Gene expression study was performed using the 
prepared cDNA and the previously described method [210].  In brief, 15 µl of the reaction 
mixture was prepared composing of the SYBR green PCR master mix (Bio-Rad), cDNA and 
RNAse free water. In this study, the quantitative real time PCR (qRT-PCR), iCycler (Bio-
Rad) was used and the 2
−ΔΔCt
 method was employed for studying the gene quantification.    
All the said genes were run in duplicate samples following which a mean Ct value was used 
for quantifying and finally visualised by the ethidium bromide staining. The list of primers 






5.2.4.6. DNA fragmentation 
Following the isolation of RNA, DNA was precipitated from the interphase and organic 
phase with 100% ethanol and the pellet was obtained by centrifugation. Then the pellet was 
washed twice in 0.1M sodium citrate in 10% ethanol, air dried and redissolved in 8 mM 
NaOH at pH 9. The integrity of DNA in all the samples was analysed by staining with 
ethidium bromide on 1% agarose gel. 
5.2.4.7. Propidium Iodide (PI) staining 
The percentage cytotoxicity of the β-amyloid fragments and the counter effect of           
SurR9-C84A was evaluated by the PI stained flowcytometric analysis. In brief, SK-N-SH 
cells were grown confluent and differentiated in 6 well culture plates followed by               
pre-treatment with SurR9-C84A loaded NPs at a concentration of 25, 50, 100 and 200 µg/ml 
for 24 hr. Then neuronal insult was achieved following the incubation with 100 µM              
β-amyloid for 24 hr. A β-amyloid only treated control and void NP treated cells were also 
included in the study. After the treatment period, the cells were carefully washed with ice 
cold PBS pH 7.4, trypsinised and then stained with PI. Fluorescence was recorded using the 








5.2.4.8. Protein expression though flowcytometry and Western blotting 
Post pre-treatments with SurR9-C84A, differentiated SK-N-SH cells were subjected to the 
neuronal insult following the incubation with β-amyloid for 24 hr. After the desired time 
expression of Cyt-c, NF 68, NF 160, NF 200, NSE and ERK were evaluated. In brief, 
following treatments cells were carefully rinsed with 1X PBS, fixed with fresh 4% 
paraformaldehyde for 15 min followed by permeabilisation with 0.1% Triton-X-100. Every 
step was followed by PBS washings and then the cells were blocked with 3% bovine serum 
albumin (BSA) for 25 min at 37
o
C. This was followed by incubation with primary sheep 
monoclonal anti-Cyt-c (1:100), mouse monoclonal anti-NF 68, NF 160, NF 200 (1:100 
Sigma Aldrich), rabbit monoclonal anti NSE (1:100, Epitomics) and anti-ERK (1:100, Santa 
Cruz) antibody for 1 hr at 37
o
C. The corresponding secondary antibodies used were rabbit 
anti-goat IgG (whole molecule)–FITC (1:100), rabbit anti-mouse IgG (whole molecule)–
FITC (1:100) and goat anti- rabbit IgG (whole molecule)–FITC (1:100, Sigma Aldrich). 
Fluorescence was recorded using the FACS cell sorter (BD Bioscience) and data was 
acquired using BD FACS canto software (BD Bioscience). For western blot analysis, 100 µM 
of β-amyloid only treated and SurR9-C84A/β-amyloid treated differentiated cell lysates 
protein was used and radio immuno precipitation assay (RIPA) buffer was used for preparing 
the cell lysates. The protein concentration was determined using the Bradford assay.          
The primary antibodies used were mouse anti-survivin (D8) (1:500, Santa Cruz), mouse anti-       
NF 68, NF 160, NF 200 (1:300),  mouse monoclonal anti-proliferating cell nuclear antigen 
(PCNA) (1:500), mouse anti-β-tubulin III (1:500, Sigma Aldrich), rabbit anti NSE (1:500, 





Corresponding secondary antibodies used were peroxidase conjugate anti-mouse (1:100,000, 
Sigma Aldrich) and peroxidase conjugate anti-rabbit (1:2000, Cell Signalling) with an 
incubation time of 90 min at RT. ECL system (Amersham Biosciences, Arlington Heights, 
IL, USA) was employed for developing and detecting the blots. 
5.2.4.9. SurR9-C84A against the N-methyl D-aspartate (NMDA) induced toxicity 
The neuroprotective potential of SurR9-C84A was further evaluated against the NMDA 
induced excitotoxicity that plays a substantial role in neurodegenerative diseases. For this, 
differentiated SK-N-SH cells were plated in 96 well plate at a density of 10
4 
cells/well and
rest of the protocol was same as employed for β-amyloid toxicity except that NMDA 100 µM 
was used in this case. Following 24 hr, the percentage cytotoxicity was evaluated using the 
LDH assay (Roche). The entire study was run in triplicates and readings were taken at 
490 nm keeping the reference as 600 nm. 
5.2.4.10. CyQUANT assay post NMDA/SurR9-C84A treatments 
Post NMDA toxicity study, cells were frozen at -80
o
C overnight and proceeded towards
CyQUANT assay as per the manufacturers protocol (Invitrogen). The readings were taken at 
480 nm excitation and 520 nm emission in a fluorescence microplate reader and results were 
analyzed in Microsoft excel software. 
5.2.4.11. Propidium Iodide (PI) staining 
The percentage cytotoxicity of NMDA and the counter effect of SurR9-C84A was evaluated 
by the PI stained flowcytometric analysis as described for β-amyloid toxicity. Fluorescence 
was recorded using the FACS cell sorter (BD Bioscience) and data was acquired using BD 
FACS canto software (BD Bioscience). 
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5.2.4.12. Mitochondrial staining 
Post NMDA insult and NMDA/SurR9-C84A treatments cells were subjected to staining 
using the mitochondrial staining kit (Sigma Aldrich) and the protocol was followed as per the 
manufacturer’s protocol. In brief, the kit comprises of cationic JC-1 dye that binds to the 
mitochondria and differentiates the cell status based on the fluorescence that it emits.       
Post staining with JC-1 dye, cells were imaged using Leica SP5 confocal microscope at 40X 
objective. 
5.2.5. Neuronal and microglial cell co-culture 
In order to mimic the natural environment of microglial and neuronal interaction, a co-culture 
model has been developed with differentiated SK-N-SH neurons and the β-amyloid 
stimulated THP-1 cells. 
5.2.5.1. Percentage cytotoxicity and nitrite measurement 
SK-N-SH cells were differentiated in 12 well plates for 2 weeks and then acclimatized with 
the RPMI medium used for THP-1 cells so as to nullify the effects of media induced 
difference. Then, the medium was replaced with the conditioned medium containing 1x10
5
THP cells with or without β-amyloid and PMA for differentiating neurotoxic and control 
experiments respectively. Co-cultures were grown for 5 days and then cell death was 
determined using the LDH assay as described earlier. Protective effects of SurR9-C84A were 
evaluated comparing against the +Ve controls IGF-1, NGF included in the study. THP-1 cells 
showed several significant morphological changes after differentiating with PMA and 
activation with β-amyloid and showed characteristic formation of large cell clusters, substrate 
adhesion, increased cell size and diameter. 
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5.2.5.2. Flowcytometry for NF 200 expression post co-culture 
In order to determine the neuroprotective effect of SurR9-C84A and its ability to maintain the 
neuronal integrity flowcytometry was performed for the expression of NF 200. CD163,            
a specific marker expressed on the activated macrophages was also analysed in this study. 
Following the co-culture for 5 days, cells were carefully washed with 1x PBS and proceeded 
towards flow cytometry analysis and all the steps were same as described earlier.               
The primary antibodies used were the mouse anti-NF 200 (1:100, Sigma Aldrich) and mouse   
anti-CD163 (1:100, Santa Cruz) specific to neurons and macrophages respectively.             
The corresponding secondary antibody used was rabbit anti mouse FITC (1:100, Sigma 
Aldrich).  
5.2.5.3. Confocal microscopy for NF 200 expression 
In order to further validate the neuroprotective effect of SurR9-C84A, NF 200 expression was 





per well and then pre-treated with various concentrations (50, 100 and 200 µg/ml) of 
SurR9-C84A loaded NPs for 24 hr. Later the wells were introduced with the conditioned 
medium containing β-amyloid stimulated THP-1 cells and further incubated for 5 days.     
After the co-culture period, cells were washed with PBS, fixed with 4% PF and then 
permeabilised with 0.1% Triton-X-100 in PBS followed by blocking with 2% rabbit serum. 
Then the neurons were stained with the mouse monoclonal anti-NF 200 (1:100, Sigma 
Aldrich) dilution for 1 hr followed by FITC labeled rabbit anti-mouse (1:100, Sigma 
Aldrich). Cell nucleus was stained with propidium iodide (1:500, Sigma Aldrich) for 30 min 
and mounted with mounting media. Further imaging was carried using the Leica SP5 




5.3.1. Stimulation of microglial and neuroglial cells for cytokine secretion and NO inhibition 
THP-1 cells showed several significant morphological changes after differentiating with 
PMA and showed characteristic formation of large cell clusters with increased diameters and 
enhanced substrate adhesion as shown in the Fig 5.1A and B.  
  
Figure 5.1. Differentiation of THP-1 monocytes to macrophages post PMA treatment. 
The images shown are the schematic representation of (A) normal THP-1 cells and (B) the 
differentiated THP cells/ macrophages. For inducing the differentiation THP-1 cells were 
treated daily with PMA for three days at 100 ng/ml concentration. Post treatments changes 
observed were the enlarged cell membranes, formation of aggregates and cell adherence to 
the tissue culture plates. The arrowheads in the figure indicating the formation of aggregates 
post induction of differentiation. The images shown above are a representative of three 
independent experiments and were taken at 40X objective. 
 A 





After differentiation, the macrophages were activated with LPS for the secretion of various 
cytokines and as observed from the Fig 5.2A-C. All the cytokines including the 
proinflammatory IL-1β and TNF-α were elevated and comparatively the intensity and the 
number of cytokines secreted by the THPs following β-amyloid activation was higher. The 
unstimulated THP control was also included in the study to give a clear picture of the 
cytokines that were secreted post activation. As observed, activation with LPS and β-amyloid 
significantly increased the cytokine secretion. 
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Figure 5.2. Evaluation of inflammatory secretions from the inactive THP control and 
PMA differentiated/activated macrophages.  Cytokine array was performed for the 
supernatants collected from the control and LPS/β-amyloid stimulated THP-1 macrophages. 
A) Cytokine secretion from unstimulated THP-1 cells; B) Cytokine secretion from LPS 
stimulated THP-1 macrophages; C) Cytokine secretion from β-amyloid stimulated THP-1 
macrophages. Macrophages stimulated with LPS and β-amyloid insults showed secretion of a 
variety of cytokines such as the pro-inflammatory (IL-β, TNF-α, IL-6), inflammatory (IL-1ra, 
IL-6, IL-8, IP-10) cytokines and chemokines such as (GROa, I-309, IL-8, IP-10, I-TAC, 
MCP-1, MIP-1α, MIP-1β, RANTES). However, β-amyloid induced much intense secretion 
of these inflammatory mediators compared to the bacterial LPS. The results shown are a 
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Table 5.1.  The percentage inflammatory secretions post LPS and β-amyloid insults in 
THP-1 cells 
S.No 
Type of inflammatory 
secretion 
LPS stimulation  
(% compared to 
control) 
β-amyloid stimulation  
(% compared to 
control) 
1 Pro-inflammatory 
IL-1β 100↑ >100↑ 
TNF-α 100↑ >100↑ 
IL-6 100↑ >100↑ 
IL-1ra 76↓ 40.3↓ 
G-CSF ---- 100↑ 
2 Chemokines 
GROa 36↑ 34↑ 
I-309 100↑ 100↑ 
IL-8 81.6↓ 76.2↓ 
IP-10 100↑ >100↑ 
I-TAC ----- 100 
MCP-1 100↑ >100↑ 
MIF 21↓ 5↓ 
MIP- α 32↑ 47↑ 
MIP-1β 100 >100 
RANTES 4↑ 33↑ 
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Following this, preliminarily the potential of SurR9-C84A in inhibiting the secretion of pro-
inflammatory nitric oxide by the THP-1 cells was evaluated. Interestingly, it was found that 
pre-treatment with SurR9-C84A 200 µg prior to stimulation with LPS reduced the NO levels 
to 15.4%. This was considered to be significant, as the SurR9-C84A treatments reduced the 
NO production way less than the control inactive/unstimulated THPs that showed 90% NO 
production. This study initially gave us a clue about the anti-inflammatory potential of 
SurR9-C84A. 
Figure 5.3. SurR9-C84A attenuate nitrite levels in LPS stimulated THP-1 cells. THP-1 
cells were activated with PMA for 3 days. Then they were pre-treated with SurR9-C84A 
loaded NPs for 24 hr followed by stimulation with LPS for 24 hr. Post incubation the 
supernatants were evaluated for the nitrite levels using the Griess reagent. SurR9-C84A was 
observed to lower the nitrite production at 200 µg/ml concentration. Data is represented as 
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5.3.2. In vitro neuroprotective effect against inflammation 
5.3.2.1. SurR9-C84A against the LPS and β-amyloid stimulated THP-1 secretions 
The initial neuroprotector activity of SurR9-C84A was evaluated in differentiated SK-N-SH 
neurons post inflammatory insult induced by both the LPS and β-amyloid stimulated THP 
secretions. As observed from the Fig 5.4, LPS stimulated THP secretions induced 16.3% cell 
death while the unstimulated inactive THP secretions were negligibly effective in inducing 
the neuronal death and accounted to only 1% confirming the successful microglial activation. 
Triton-X-100 included in the study served as a negative control and considered inducing 
100% cell death and the corresponding cytotoxicity was calculated compared to it.          
The treatment controls pre-treated with indomethacin, IGF-1, NGF and the SurR9-C84A 
were found to be effective in inhibiting the neuronal death with a percentage reduction to 
1.1,-0.52, -0.5 and -1.8% respectively. Interestingly, the % neuronal toxicity increased to 
46.8% with the β-amyloid stimulated THP secretions compared to 16.3% with LPS 
stimulation while the inactive/unstimulated THP secretions were able to induce 12.7 % cell 
death. However, following pre-treatments with indomethacin, IGF-1, NGF and the 
SurR9-C84A cytotoxicity was reduced to 10.3, 15.1,-4.9 and 8.3% respectively. Thus, 





Figure 5.4. Determination of cytotoxicity post incubations with β-amyloid and LPS 
stimulated THP-1 macrophage secretions. SK-N-SH neurons were pre-treated with        
200 µg/ml of SurR9-C84A along with +Ve controls IGF-1, NGF and indomethacin for 24 hr 
followed by treatment with β-amyloid and LPS stimulated macrophage secretions for 24 hr. 
Pre-treatment with SurR9-C84A proved to be more effective in lowering the cytotoxicity 
compared to the +Ve controls except NGF. The % cytotoxicity was determined using the 
LDH assay and the data is a representative of three independent experiments and expressed as 























5.3.2.2. SurR9-C84A against the LPS stimulated THP-1 secretions 
Further to the above results, SurR9-C84A also showed enhanced neuronal protective activity 
against LPS stimulated THP-1 cytokine rich secretions. As observed from the Fig 5.5A and 
5B, post T-cell insults alone NF 200 and MBP showed a reduction of 3 and 3.7 fold 
respectively while SurR9-C84A pre-treatments showed an enhanced expression of the same 
by 2.6 and 2.7 folds. The neuroprotective effects of SurR9-C84A were comparable to the 
+Ve control employed (IGF-1) which showed 2.9 fold increments for both NF 200 and MBP 
following  T-cell insults. In addition, the protective effect of SurR9-C84A was also tested 
against T-cell insults by determining the expression of MBP using the immunofluorescence 
and flowcytometry analysis. As observed from the Fig 5.6, SurR9-C84A showed 3.5 folds 
(***p<0.001) increased expression of MBP while flowcytometry analysis (Fig 5.7) showed 
its increment was 4 folds (*p<0.05) higher compared to T-cell insults. 
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1MBP, myelin basic protein; 
2
NF 200, neurofilament 200.









MBP, myelin basic protein; 
3
NF 200, neurofilament 200.
Figure 5.5. Determination of neuronal integrity markers NF 200 and MBP post SurR9-
C84A/T-cell insults. SK-N-SH neurons were pre-treated with 200 µg/ml of SurR9-C84A 
along with +Ve controls IGF-1 for 24 hr followed by treatment with LPS stimulated THP 
secretions for 24 hr. A) Phase contrast images showing control and post T-cell insults.          
B) Immunocytochemistry performed for NF 200 expression was observed to have restored
post SurR9-C84A/T-cell insults. C) Similarly, it restored the MBP expression in the SK-N-
SH neurons. Pre-treatment with SurR9-C84A proved to be equally effective in restoring the 
neuronal integrity markers compared to the +Ve control IGF-1. D) Histogram showing the 
MBP and NF 200 expression. All the images were taken at 40X objective and the histogram 
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Figure 5.6. Determination of myelin basic protein expression post SurR9-C84A/T-cell 
insults. SurR9-C84A restored the expression of neuronal integrity marker MBP post LPS 
stimulated T-cell insults. SK-N-SH neurons were pre-treated with 200 µg/ml of SurR9-C84A 
along with +Ve controls IGF-1 for 24 hr followed by treatment with cytokine rich secretions 
for 24 hr. Pre-treatment with SurR9-C84A restored the neuronal integrity compared to the 
+Ve control IGF-1. All the images were taken at 40X objective and the histogram is 
mean±SD representative of MBP expression in the cells counted in five independent fields. 


























Figure 5.7. Flowcytometry analysis for the determination of myelin basic protein 
expression post SurR9-C84A/T-cell insults.  SurR9-C84A restored the expression of 
neuronal integrity marker MBP post LPS stimulated T-cell insults. SK-N-SH neurons were 
pre-treated with 200 µg/ml of SurR9-C84A along with +Ve controls IGF-1 for 24 hr followed 
by treatment with cytokine rich secretions for 24 hr. Pre-treatment with SurR9-C84A restored 
the neuronal integrity compared to the +Ve control IGF-1. The data is represented as 
mean±SD of three independent experiments with *p<0.01 is considered statistically 
significant (students t-test). 
MBP-control T-cell insult

























5.3.2.3. SurR9-C84A against the β-amyloid stimulated astrocyte secretions 
Similar to the above study, astrocytes stimulated with β-amyloid showed a massive 92% cell 
death while the unstimulated secretions were negligible in inducing the cell death.        
As observed from the Fig 5.8A, flowcytometry analysis confirmed the anti-inflammatory 
properties of SurR9-C84A where it significantly reduced the expression of GFAP, TNF-α and 
IL-1β by 11, 4.7 and 7 folds respectively. Further, cytotoxicity revealed that indomethacin 
was ineffective in reversing the cell death (82%) while SurR9-C84A seemed to lower the 
cytotoxicity to 54%. IGF-1 and NGF treatments lowered the cytotoxicity to 37 and 32% 
respectively (Fig 5.8B). 
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 Figure 5.8. SurR9-C84A attenuate β-amyloid stimulated astrocyte secretions and its 
cytotoxic effects on SK-N-SH cells. A) Flowcytometry for the expression of GFAP, TNF-α 
and IL-1β in β-amyloid stimulated astrocytes. β-amyloid induced the enhanced expression of 
reactive astrocytes marker GFAP and the pro-inflammatory TNF-α and IL-1β and the same 
were downregulated post SurR9-C84A treatments. B) SurR9-C84A attenuate β-amyloid 
stimulated astrocyte cytotoxicity in the differentiated SK-N-SH neurons. SK-N-SH cells were 
pre-treated with 200 µg/ml of SurR9-C84A along with +Ve controls IGF-1, NGF and 
indomethacin for 24 hr followed by treatment with β-amyloid stimulated astrocyte secretions 
for 24 hr. Pre-treatment with SurR9-C84A proved to be effective in lowering the cytotoxicity 
as compared to the astrocyte supernatant only treatment. The % cytotoxicity was determined 
using LDH assay and the data is a representative of at least three independent experiments 



























5.3.2.4. SurR9-C84A against the β-amyloid toxicity 
In order to determine the neuroprotector potential of SurR9-C84A, the neurons were directly 
subjected to the β-amyloid insult with or without pre-treatments with SurR9-C84A, IGF-1, 
NGF and indomethacin. 1% Triton-X-100 was calculated to be 100% and the β-amyloid only 
treated control showed 79% cell death while the pre-treatments with SurR9-C84A, IGF-1, 
NGF and indomethacin reduced the neuronal death to 13.2, -2.4, -4.5% and 18.6% 
respectively. Thus, SurR9-C84A treatment showed a 6 fold increased protection towards the 
neurons compared to the β-amyloid only treated group. 
Figure 5.9. Protective actions of SurR9-C84A against the β-amyloid induced toxicity. 
SK-N-SH neurons were pre-treated with 200 µg/ml of SurR9-C84A along with +Ve controls 
IGF-1, NGF and indomethacin for 24 hr followed by treatment with β-amyloid for 24 hr. 
Pre-treatment with SurR9-C84A proved to be effective in lowering the cytotoxicity. 
The % cytotoxicity was determined using LDH assay and the data is a representative of at 
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5.3.2.5. Real time PCR 
qRT-PCR studies were performed to elucidate the characteristic neuroprotector mechanism of 
SurR9-C84A and its ability to surmount the β-amyloid induced cytotoxicity. qRT-PCR was 
performed sequentially for the inflammatory, apoptotic, neuronal integrity markers, 
Alzheimer’s related genes and ERK/MAPK genes. In the case of inflammatory genes, pro-
inflammatory IL-β and TNF-α showed 1.9 and 7.8 fold reduced expression respectively. 
Apoptotic markers Cyt-c, p53 and caspase-3 were reduced by 2.8, 1.7 and 1.9 folds while the 
neuronal integrity markers endogenous survivin, NF 68, 160, 200 and β-tubulin III showed a 
corresponding increment of 3.1, 16.7, 1.7, 3.7 and 1.3 folds respectively. The Alzheimer’s 
related genes ApoE and APP was respectively reduced by 2.4 and 2 folds while the ERK 
showed a massive increase of 345 folds suggesting its role in the neuroprotection mechanism 









































Figure 5.10. Gene expression study post SurR9-C84A/β-amyloid insult in the neurons. 
A) SurR9-C84A showed reduced expression of inflammatory (TNF-α and IL-1β), apoptotic 
(Cyt-c, p53 and caspase-3) genes with an increase in the survival and integrity markers 
(survivin, NF 68, NF 160, NF 200 and NSE). Alzheimer related genes ApoE and APP were 
considerably reduced and the gene responsible for neuroprotective signalling ERK was 
significantly increased. The relative expression of all the genes was calculated relative to     
β-actin that served as an internal control. Data is represented as mean±SD and *p<0.05 is 
statistically significant (students t-test). B) Lanes 1-3 are β-amyloid only treatment, untreated 



















5.3.2.6. Propidium Iodide (PI) staining 
The β-amyloid induced toxicity and the counteracting effect of SurR9-C84A was further 
confirmed with the PI staining using flow cytometry analysis. Apoptotic cells tend to loose 
significant amount of the DNA content on account of the fragmentation and PI staining being 
specific to the DNA gives  a clear picture of the percentage dead cells by quantifying the PI 
+Ve cells [290]. As observed from the Fig 5.11., a significant amount of dead cells (71% PI 
+Ve cells) were observed upon incubation with β-amyloid while the SurR9-C84A             
pre-treatment reverted the cytotoxic effects displaying an enhanced neuroprotector activity. 
The % PI +Ve cells were reduced to 17 while the PI –Ve cells were increased to 76% 
confirming the neuron protector ability. This positive effect of SurR9-C84A was compared 
against the positive control IGF-1 which showed 91% of PI –Ve cells. 
 
Figure 5.11 Determination of percentage dead cell population post SurR9-C84A/           
β-amyloid insults.  PI staining analysis was performed for pre-treatments with SurR9-C84A 
following β-amyloid insult. SurR9-C84A showed a considerable decrease in the percentage 
PI +Ve cells (17%) compared to the untreated β-amyloid only treated control (71%) 
confirming its potential in restoring the health of the neurons. The results represented are 
from two independent set of experiments. 
82% 18% 29% 71% 76% 17% 91% 7%
Control β-amyloid 100µM SurR9-C84A 200µg IGF 50ng
181 
 
5.3.2.7. Protein expression though flow cytometry  
In order to confirm the neuroprotector activity of SurR9-C84A against the β-amyloid insult, 
flow cytometry was performed for the expression of Cyt-c, caspase-3, Bcl-2 and thereby 
determining the anti-apoptotic activity. The results showed a significant reduction of Cyt-c 
and caspase-3 to 1.3 and 58% respectively, while the Bcl-2 expression increased to 95%.  The 
analysis for neuronal integrity marker expression (NF 68, NF 160, NF 200 and neuron 
specific enolase (NSE) confirmed the ability of SurR9-C84A to maintain the neuronal 
integrity with a drastic increase to 63, 55, 99 and 99% respectively. Further to this, 
ERK/MAPK analysis showed a 96% (*p<0.05) increase compared to 43% of β-amyloid only 
treatment comprising of 2.2 fold increase. Thus, this significant increment in ERK expression 
revealed the strategic mechanism of SurR9-C84A involving the ERK pathway in protecting 
the neurons from the β-amyloid toxicity. Table 5.2. gives a clear picture of SurR9-C84A 
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100 µM only 
treatment in 
% 
SurR9-C84A    
200 µg/β-amyloid 
(100 µM) in % 
Fold 
change 
1 Cyt-c 0.8 71 16.7 4.2↓ 
2 Caspase-3 0.75 66.4 47 1.4↓ 
3 Bcl-2 67.5 48.5 88 1.8↑ 
4 NF 68 31.4 13 54 4.1↑ 
5 NF 160 53 8.2 29 3.5↑ 
6 NF 200 63 48 70 1.4↑ 
7 NSE 67 44 85 1.9↑ 




NSE, neuron specific enolase 
Figure 5.12. Determination of various protein expressions in the SK-N-SH neurons  
Protein expression in the neurons subjected to SurR9-C84A/β-amyloid insult by 
flowcytometric analysis confirmed the reduced expression of apoptotic markers (Cyt-c, p53 
and caspase-3) along with an increased expression of neuro-integrity markers (NF 68, 160, 
200, NSE). The neuroprotective signalling molecule ERK was also elevated post          
SurR9-C84A treatments confirming the neuroprotective potential of SurR9-C84A. The data 





5.3.2.8. Cytokine and apoptotic array analysis 
In addition, to confirm the enhanced neuroprotective effect of SurR9-C84A cytokine and 
apoptotic array analysis was carried post SurR9-C84A treatment. Surprisingly, it exhibited 
reduced level of all the cytokine secretions post stimulation with β-amyloid in mono and     
co-cultures along with the apoptotic markers. Untreated controls were also included to 
compare the neuroprotective effect exhibited by SurR9-C84A. As observed from the 
following figures, it was evident that pre-treatment with SurR9-C84A not only reduced the 
inflammatory cytokines (Fig 5.13A-C) but also rescued the neurons from the toxic effects of 
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Figure 5.13. Effect of SurR9-C84A on the cytokine secretion post β-amyloid stimulation. 
Cytokine expression in the THP-1 cells post β-amyloid induced insults was reduced after 
treatments with SurR9-C84A. A) Cytokine array for β-amyloid THP secretion alone;         
B) SK-N-SH neurons treated with SurR9-C84A followed by β-amyloid stimulated THP
secretion; C) SurR9-C84A treatments in SK-N-SH and β-amyloid stimulated THP co-culture. 
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Figure 5.14. Apoptotic array for SK-N-SH neurons treated with SurR9-C84A/ 
β-amyloid. The β-amyloid stimulated THP and the SK-N-SH neuronal co-culture resembled 
the in vivo situation of neuronal and microglial cells where activated THP-1 cells secreted the 
neuro toxic cytokines. However, pre-treatments with SurR9-C84A rescued the neurons as 
compared to the untreated controls. This was confirmed by the reduced expression of 
apoptotic markers compared with: A) β-amyloid stimulated THP secretion incubation; 
B) Arrowheads showing reduced apoptotic and increased survival protein expression post
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Table 5.3. SurR9-C84A induced changes in the expression of apoptotic and survival 
molecules post β-amyloid insults in SK-N-SH neurons. 
S.No Type of molecule 













5.3.2.9 DNA fragmentation 
In support of the neuroprotective effect exhibited by SurR9-C84A, the DNA fragmentation a 
classical hallmark of apoptosis was analysed and compared between the β-amyloid only 
treated control and SurR9-C84A/β-amyloid treated groups. Substantiating the results 
obtained earlier the β-amyloid only treated group showed complete DNA fragmentation 
indicating the severe toxicity and even the void NP treated group showed the same result. 
Interestingly, SurR9-C84A devoid of the nano formulation also didn’t show any protective 
effect on the DNA and this is explained because of its shorter half-life and reduced 
bioavailability in the native form. Supporting this hypothesis, the nanoformulated         
SurR9-C84A showed an enhanced protective effect on account of its improved availability 
and half-life. 
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Figure 5.15. Determination of DNA integrity following SurR9-C84A/β-amyloid induced 
insults. As observed from the figure, DNA fragmentation was evident with the β-amyloid 
induced insult while treatments with SurR9-C84A (starting from 50 µg – 200 µg only in 
nanoformulated form) served to maintain the integrity of the DNA post Aβ induced insult. 
Even the native form of the protein was unable to show an intact DNA and this could be 
because of the shorter half-life of the protein. In contrast, the nano encapsulated SurR9-C84A 
protected and enhanced the protein bioavailability and thus it was able to restore the DNA 
integrity. 
24hr, β-amyloid induced DNA fragmentation 
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5.3.2.10 Western blotting 
Finally, western blot performed for β-tubulin III, NF 68, NF 160, NF 200, NSE, proliferating 
cell nuclear antigen (PCNA) and ERK showed an enhanced expression in the SurR9-C84A/ 
β-amyloid treatment group compared to the β-amyloid only treated control. Thus, it confirms 
the neuroprotective actions of SurR9-C84A against the β-amyloid induced insult and the 
possible mechanism through which SurR9-C84A exhibits its actions involve the ERK 
signalling pathway as described in Fig 5.16. All the above protein expression was compared 
against β-actin and tubulin as the internal standards.  
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Figure 5.16. Determination of protein expression following SurR9-C84A/β-amyloid. 
Western blot analysis was performed for the β-amyloid only treated and SurR9-C84A pre-
treated SK-N-SH neurons to determine the severity of insults. This study confirmed the 
expression of survival (survivin), proliferative (PCNA) and neuronal integrity markers 
(NF 68, NF 160, NF 200, β-tub III) post SurR9-C84A treatment compared to the β-amyloid 
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5.3.2.11. SurR9-C84A against the N-methyl D-aspartate (NMDA) induced toxicity 
Further, to evaluate the extended neuroprotective activity, SurR9-C84A was tested against 
the NMDA excitotoxicity. The % cytotoxicity measurement study revealed 13% cell death 
with NDMA alone while the pre-treatment with SurR9-C84A and other positive 
neuroprotector controls (IGF-1 and NGF) showed a drastic reduction in the neuronal death. 
SurR9-C84A, IGF-1 and NGF reduced the cell death by 48, 35 and 62% respectively further 
substantiating the neuroprotector activity of SurR9-C84A.  In addition, post cytotoxicity 
estimation cells were preserved and proceeded for the determining the cell proliferation post 
NMDA and     pre-treatments/NMDA insult. 
Figure 5.17. Determination of neuroprotective activity of SurR9-C84A against NMDA 
induced toxicity. SK-N-SH neurons were pre-treated with 200 µg/ml of SurR9-C84A along 
with +Ve controls IGF-1 and NGF for 24 hr followed by treatment with NMDA for 24 hr. 
Pre-treatment with SurR9-C84A proved to be effective in lowering the cytotoxicity and the 
same is determined using the LDH assay. Data is the representative of three independent set 
of experiments and shown as mean±SD with *p<0.05; **p<0.01 considered statistically 




























CyQUANT assay was performed for the left over cells post NMDA induced toxicity to 
determine whether SurR9-C84A has restored the viability post treatments. As observed from 
the Fig 5.18, cell proliferation was limited to only 58% with NMDA alone while 
pre-treatments with SurR9-C84A, IGF-1 and NGF showed an enhanced proliferative 
potential corresponding to 158, 171 and 184% respectively. This again confirms the extended 
protective actions of SurR9-C84A in not only bypassing the neurons from cell death, but also 
preserving their proliferative potential. 
Figure 5.18. Determination of proliferative potential of SurR9-C84A following NMDA 
induced toxicity. CyQUANT assay was performed post SurR9-C84A/NMDA insult where 
SurR9-C84A treatments restored the proliferative potential in the neurons compared to the 
NMDA only treated controls. Data is representative of at least three independent experiments 













Control NDMA 100µM SurR9-C84A
200µg



















Further, the percentage cell death with NMDA was also confirmed with PI staining using the 
flow cytometry analysis. The results confirmed that the PI +Ve (dead) cells with NMDA 
alone were 84% while the pretreatment with SurR9-C84A 200 µg and the positive control 
IGF-1 reduced the dead cell population to 12% and 9% respectively indicating the extended 
neuroprotective potential. 
Figure 5.19. Determination of percentage cell death with NMDA insults and 
counteracting effects of SurR9-C84A against it. PI staining post NMDA/SurR9-C84A 
insult showed that SurR9-C84A significantly protected the neurons as indicated from the 
reduced PI +Ve cells compared to the NMDA only treated controls. The neuroprotector 
activity of the protein was similar to the +Ve control IGF used in this study. 
77% 22% 16% 84%
85% 12% 89% 9%
Control NMDA 100µM
SurR9-C84A 200µg IGF 50ng
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5.3.2.12. Mitochondrial staining 
Post NMDA and pre-treatments/NMDA insult, neurons were subjected to mitochondrial 
staining. Mitochondria represent the power houses of all the eukaryotic cells comprising of 
inner and outer membranes and the voltage gradient across these membranes are –Ve and 
+Ve respectively. Any changes in the membrane potential alarms the early apoptotic event 
and thus measuring the voltage gradient will effectively differentiate the healthy and 
apoptotic cells. In this study, mitochondrial membrane potential dissipation is observed by 
the uptake of cationic JC-1 dye into the mitochondrial matrix where healthy cells accumulate 
the dye in the matrix forming bright red fluorescent aggregates. In case of the apoptotic cells, 
voltage gradient dissipates and hence prevents the JC-1 dye accumulation in the matrix 
dispersing it into the cytoplasm. In this instance, fluorescence is seen shifting from red to 
green due to the formation of JC-1 monomers in the apoptotic cells. As observed from the 
Fig 5.19, NMDA treatment alone showed 100% of mitochondrial depolarization similar to 
that of valinomycin (an internal standard included in the study) indicating the apoptotic 
events. Pretreatment with SurR9-C84A 200 µg showed a drastic reduction in the % 
depolarized cells accounting to only 15% indicating the extensive neuroprotective capability 




Figure 5.20. Determination of depolarised and non-depolarised mitochondria following 
NMDA insults and SurR9-C84A counteracting effects. SK-N-SH neurons were observed 
for the mitochondrial membrane depolarisation where insult with NMDA showed maximum 
depolarisation indicating the membrane potential change and apoptotic follow through. 
However, SurR9-C84A treatments drastically reduced the depolarisation indicating the 
neuroprotective potential against NMDA mediated excitotoxicity. Depolarised mitochondrial 
expression is shown in FITC channel (green), non-depolarised expression in TRITC channel 











5.3.3. Neuronal and microglial cell co-culture  
A co-culture model of activated THP and differentiated SK-N-SH neurons was established to 
closely mimic the in vivo neuro-inflammation condition prevailing in AD. Here, the activated 
THPs resemble the microglia and the differentiated SK-N-SH cells replace the neuronal cells 
in vivo. 
5.3.3.1. Percentage cytotoxicity  
As observed from the Fig 5.20A, post co-culturing for 5 days, β-amyloid stimulated THP 
cells showed high degree cytotoxicity accounting to 89% and while the inactive/unstimulated 
THP cells showed only 20% cell death. A β-amyloid only treated group was also included in 
the study showing 49% cell death confirming the fact that THP cells turned aggressive after 
activating with β-amyloid in inducing the neuronal death. Considering the neuroprotective 
activity of SurR9-C84A, the % cell death was significantly reduced to 21% while the other 
treatments IGF-1 and NGF showed only 8 and 11% cytotoxicity. On the whole, the 
neuroprotective actions of SurR9-C84A were in agreement with the previous results and were 
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Figure 5.21. Neuroprotective actions of SurR9-C84A against β-amyloid stimulated 
THPs and SK-N-SH co-culture. A) Microscopic images of co-cultured neurons and active 
THPs revealed significant morphological changes in the untreated β-amyloid stimulated 
THPs and neurons compared to the neuroprotector treatments. SurR9-C84A significantly 
retained the intact neurite processes for the entire co-culture duration compared to the 
untreated active THP+SK-N-SH culture; B) Histogram representing the neurite processes 
post co-culture; C) Co-cultured neurons and active THPs were pre-treated with 200 µg/ml of 
SurR9-C84A along with +Ve control IGF-1 for 24 hr followed by activation with β-amyloid 
for 24 hr. Pre-treatment with SurR9-C84A proved to be effective in lowering the cytotoxicity 
throughout the co-culture period and was determined using LDH assay. ***p<0.001 is 






















5.3.3.2. Flow cytometry and confocal microscopy for NF 200 expression post co-culture 
Finally, to authenticate the neuroprotective actions of SurR9-C84A, the co-cultured cells 
were studied for the expression of neuron specific marker NF 200 and THP cells were studied 
for the expression of CD163, a macrophage specific marker. As observed from the flow 
cytometric analysis Fig 5.22A, untreated SK-N-SH only cells expressed 58.5% of NF 200 
while the co-cultured inactive/unstimulated THP and SK-N-SH showed negligible reduction 
to 46%. A substantial reduction to 6% was noticed in Aβ stimulated THP and SK-N-SH 
group while the pre-treatment with SurR9-C84A and IGF-1 showed a concrete increase in the 
NF 200 expression corresponding to 64 and 79% respectively. The same was also confirmed 
with the confocal microscopy (Fig 5.23A) for the NF 200 expression where SurR9-C84A   
pre-treatment retained 61% of it while the untreated activated THP and SK-N-SH showed 
only 7% expression. Thus, the results validate SurR9-C84A as a potential candidate both for 
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Figure 5.22. Flowcytometry analysis for the expression of CD163 and NF 200 in 
activated THPs and neurons respectively. A) CD163 expression was significantly observed 
in the active THPs confirming their activation phase. The inactive/unstimulated THP/ 
SK-N-SH control showed negligible lowering of NF 200 expression while the stimulated 
THP/ SK-N-SH co-culture showed massive reduction in the integrity marker NF 200 which 
corresponded to only 6%. However, NF 200 expression was restored in the co-culture post 
SurR9-C84A treatments which increased to 64% substantiating the previous results. Thus, 
SurR9-C84A was able to restore the NF 200 expression in the activated microglia-neuronal 
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NF 200, neurofilament 200. 
Figure 5.23. Determination of neuroprotective activity of SurR9-C84A post activated 
THP/neuronal co-culture. A) Neurons were observed for the expression of NF 200 post 
co-culture to evaluate the potential neuroprotector activity of SurR9-C84A. Surprisingly, 
SurR9-C84A retained 64% of NF 200 expression explaining its potential as a neuroprotector 
compound compared to only 6% expression in untreated THP+SK-N-SH neurons. NF 200 
expression is shown in FITC channel (green), nucleus is stained red with PI. B) Histogram 
for NF 200 expression post co-culture. All the images were taken at 40X objective and the 
histogram is representative of mean±SD with ***p<0.001 is considered statistically 






















5.3.3.3. Protective actions of SurR9-C84A against D-Galactose toxicity 
Further to its enhanced neuroprotective activity, SurR9-C84A was able rescue the neurons 
from the D-Gal induced toxicity. As observed from the Fig 5.23A, D-Gal induced a 
significant 13.8 fold increment in the β-amyloid protein expression while pre-treatment with 
the SurR9-C84A prior to D-Gal insult lowered the expression by 4.5 folds (p<0.05). The 
same was compared against the +Ve control melatonin which was capable of lowering the 
β-amyloid expression by 3.7 folds. It was further substantiated by the western blot analysis 
where SurR9-C84A showed lowered expression of β-amyloid protein (Fig 5.24D).
In addition to this, D-Gal insults reduced the expression of β-tubulin III by 2.7 folds 
compared to the control while SurR9-C84A and melatonin increased its expression by 1.4 
and 1.5 folds respectively post D-Gal insults. 
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Figure 5.24. Protective actions of SurR9-C84A against D-Galactose induced insults.        
A) Flowcytometry for β-amyloid expression post D-Gal insults. B) Flowcytometry for
β-tubulin III expression post D-Gal insults. C) Histogram showing the flowcytometry for 
β-amyloid and β-tubulin III expression. D) Western blot showing the expression of β-amyloid 
post D-Gal insults. 1) Control; 2) D-Gal; 3) SurR9-C84A; 4) Melatonin. The data is 
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Micro and macroglia represent the supporting neuroglial cell population and are implicated in 
mediating the inflammation and brain circuit development respectively. Microglia are the 
resident macrophages within the CNS while the oligodendrocytes and astrocytes together 
constitute macroglia. The maintenance of the intrinsic brain physiological processes are 
majoritily looked after by astrocytes but the neuronal insults turn them aberrant and therefore 
start secreting inflammatory cytokines and chemokines. TNF-α and IL-1β the                     
pro-inflammatory cytokines are secreted predominantly by them explaining the pathologic 
importance of astrocytes in initiating the neuronal inflammation and degeneration [293-295]. 
It is rather interesting to observe that neuropathological damage is often localised and brain 
region specific, evident by the pathological events and neuronal loss. This condition is aptly 
explained due to the presence of provoking pro-inflammatory stimuli such as LPS and the 
presence of microglia is attributed to the region specific damage [296]. This condition is 
often worsened due to the astrocyte-microglia interactions that synergise the initiation and 
execution of innate immune responses resulting in the devastating neuronal inflammation. 
This condition signifies the exact AD pathological process involving the neuronal and 
neuroglial cell crosstalk leading to the abnormal autocrine-paracrine interactions thereby 
amplifying the neuronal inflammation [297-299]. Finally, the end result is the severe tissue 
degeneration and the neuronal death. Considering the vital role of neuroglia in initiating the 
neuro-inflammation in AD, the same is mimicked in this study where microglial cells and 
astrocytes were activated with the bacterial endotoxin LPS and β-amyloid fragments.          
The neuro-protective potential of SurR9-C84A was evaluated against this inflammatory insult 
where neurons were incubated with the cytokine rich supernatants along with the neuronal 
and microglial co-culture.  
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With respect to the microglia mediated toxicity to mimic the in vivo insults, THP-1 cells were 
stimulated using bacterial LPS and β-amyloid fragment and cytokine secretions were 
assessed using the cytokine array kits. Interestingly, THP-1 cells showed increased 
expression of cytokines with β-amyloid activation compared to LPS. However, irrespective 
of activation SurR9-C84A was found to rescue the neurons from cytokine toxicity as 
observed from Fig 5.3. In addition, SurR9-C84A also showed the intact expression of 
neuronal integrity markers NF 200 and MBP further confirming its neuron protective ability 
against microglial inflammatory insults (Fig 5.5A, B and 5.6). To demonstrate the macroglia 
induced inflammation, astrocytes were activated with Aβ fragment and the efficacy of      
SurR9-C84A was evaluated post neuronal incubation with cytokine rich secretions.              
As observed for microglia insults, SurR9-C84A was even effective in nullifying the astrocyte 
insults. In addition it also lowered the expression of GFAP, pro-inflammatory TNF-α and      
IL-1β corresponding to 11, 4.7 and 7 folds respectively (Fig 5.8) in the astrocytes. GFAP is a 
sensitive marker expressed in the instance of inflammatory or toxic insults and reflects the 
phenomenon of reactive astrogliosis both in vitro and in vivo [300]. Thus, these observations 
confirm the extended SurR9-C84A neuro-protective actions against inflammatory insults 
posed by the activated neuroglia (microglial and astrocytes). Next, the in vitro AD model was 
mimicked by incubating the neurons with β-amyloid fragment and SurR9-C84A was assessed 
for its neuroprotective activity. Initially, pre-treatment with SurR9-C84A lowered the 
percentage cytotoxicity as compared to the untreated β-amyloid only control. This 
corresponded to a significant 6 fold increase in the protection reflecting the neuroprotective 
potential. Further to this qRT-PCR studies also substantiated the protective actions of      
SurR9-C84A where it showed the downregulation of inflammatory, apoptotic and 
Alzheimer’s related genes (Fig 5.10) along with a subsequent increase of neuronal integrity 
markers compared to β-amyloid only treated controls.  
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These initial results gave a clue about the extended protective capacity of the mutant protein 
and further evidences were obtained post protein study analysis using flowcytometry and 
western blot. PI staining results revealed that 70.5% of cells were stained PI +Ve with Aβ 
treatment alone while it was reduced drastically to 17.3% post SurR9-C84A treatments. 
Further, PCR analysis also showed an enhanced expression of Cyt-c and caspase-3 with Aβ 
treatment while SurR9-C84A enhanced the survival and neuronal integrity marker expression 
of Bcl-2, NF 68, NF 160, NF 200 and NSE. Finally, the same was also confirmed at the 
protein level by western blot analysis where SurR9-C84A treatment showed enhanced 
expression of wild type survivin, β-tubulin III, NF 68, NF 160, NF 200, NSE, PCNA and 
ERK/MAPK compared to the β-amyloid only treated control. In conclusion, the mechanism 
behind the enhanced SurR9-C84A neuroprotection was found to be executed following the 
ERK/MAPK signalling pathway. Mitogen-activated protein kinases (MAPKs) are 
serine/threonine-specific protein kinase signal transducers and were found to have a pivotal 
role in regulating the cellular events of death and survival [301, 302]. Amongst the three 
MAPKs, the extracellular ERK/MAPK signalling is commonly associated with cell survival 
[303]. Although, it was previously reported to involve in aggressive proliferation and 
inhibition of apoptosis in cancer cells [304] some of the recent studies inferred that of 
ERK/MAPK signalling is also involved to exhibit the neuroprotective effects [305-308]. 
When the results were analysed, ERK/MAPK levels were elevated both at the gene and 
protein levels post SurR9-C84A treatments (Fig 5.10, 5.12, 5.16). In addition to ERK, Bcl-2 
the downstream effector molecule associated with anti-apoptosis [309-311] showed an 
increment of 1.2 folds post mutant protein treatments. The increased Bcl-2 levels negatively 
regulated the Cyt-c release [312] reducing it to 50 folds thereby inhibiting the caspase-3 
activation that showed a 58% reduction following SurR9-C84A pre-treatments.  
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In addition to this,  SurR9-C84A also enhanced the wild type survivin expression which is a 
critical anti-apoptotic factor  and is in compliance with earlier results [313]. There was also a 
noticeable increased expression of proliferative marker, PCNA along with the neuronal 
integrity markers NF68, 160, 200 and NSE post SurR9-C84A treatments as compared to the 
amyloid insult alone. These results were in agreement that the neuronal integrity marker 
expression reflects the neuronal health as indicated previously [314-316]. Thus, the 
neuroprotective potential of SurR9-C84A was confirmed with these results where it helped in 
maintain the neuronal integrity and regaining their proliferative potential post Aβ insult. 
SurR9-C84A also showed some intriguing results, where activated microglia showed a 
reduction in the secretion of TNF-α, IL-1β, IL-6 and IL-8 at mRNA level. This could also be 
speculated for the extended neuroprotective actions exhibited by SurR9-C84A against the 
microglial cytokine rich secretions. In summary, pre-treatment with SurR9-C84A against the 
LPS and β-amyloid stimulated microglial cytokine secretions reduced the % cytotoxicity to 8 
and 5.6 folds respectively. While, the cytotoxicity against the β-amyloid stimulated astrocyte 
secretions was reduced by 1.72 folds along with the respective reduction of GFAP, TNF-α 
and IL-1β by 11, 4.7 and 7 folds. A co-culture model of neurons and activated microglia has 
also been developed to closely simulate the neuro-inflammatory milieu prevailing in the AD 
brain.  In this instant too, SurR9-C84A surmounted the toxic effects substantiating the earlier 
results where neuronal death was reduced to 4.2 folds along with 61% preservation of the 
neuronal integrity marker NF 200. In addition, excitotoxicity insult associated with AD was 
induced using NMDA [317] and the protective actions of SurR9-C84A were evaluated 
against it. A 3.6 fold increased protection was attributed to SurR9-C84A pre-treatment and 
was further confirmed with the mitochondrial membrane staining where 6.6 fold reduction in 
the % depolarised cells was observed.  
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Last but not least, SurR9-C84A was also effective in reversing the aging associated 
neurodegeneration where it showed a significant reduction in the expression of β-amyloid 
expression by 4.5 folds (Fig 5.24) post D-Gal insults. This is the first report on the 
neuroprotective potential of SurR9-C84A against all the possible insults associated with AD 
and inflammation involving reactive neuroglia. 
Conclusions 
Neuroglial cells have a vital role to play in regulating the host defence in various neurological 
disorders involving inflammation and other insults. In response to these insults, neuroglia 
turn reactive secreting a plethora of inflammatory cytokines and chemokines. The same was 
observed with LPS and β-amyloid in this case. Considering their potential in progressing and 
worsening the AD, an ideal therapeutic has to be developed to alleviate the toxicity.              
In this instance, SurR9-C84A displayed remarkable neuroprotector activity against the Aβ 
toxicity and the associated inflammatory component. In addition, it also lowered the cytokine 
secretions in the activated microglia. Therefore, SurR9-C84A claims to be a novel therapeutic 









LACTOFERRIN INDUCED DIFFERENTIATION IN THE UNDIFFERENTIATED 
SK-N-SH CELLS 
Abstract 
In this study, the differentiating actions of milk protein based bovine lactoferrin (bLf) and the 
iron saturated bovine lactoferrin (Fe-bLf) were investigated against the cancerous SK-N-SH 
neuroblastoma cells.  The differentiating effects of these proteins were evident when treated 
at a concentration lower than the threshold dose required for anti-cancer activity with the 
increased expression of neuron specific differentiating markers. However, slight differences 
were noted for these proteins in inducing the differentiation where bLf showed its effects by 
involving the PI3K signalling pathway and therefore were more capable of inducing the early 
differentiating markers. Fe-bLf treatments showed predominant ERK signalling mechanism 
evidenced by the elevated expression of mature differentiation markers. However, with 
respect to differentiation induction both the proteins showed a common feature of lowering 
the endogenous survivin expression that is highly essential for the proliferation. This is 
explained as due to the lowered endogenous expression of survivin in the SK-N-SH cells 
their proliferation was halted and preparative changes required for differentiation were 
induced. Thus, Lf on account of its differentiating effects entitles a novel therapeutic for 




Lactoferrin (Lf) is an iron binding single chain glycoprotein molecule consisting of 690 
aminoacid sequences with an average size of 70-80 KDa. Innately, it possesses strong natural 
host defence mechanisms evident by its presence in majority of the body secretions.  
Structural analysis of Lf revealed that the homologous N and C-terminal lobes are internally 
folded and the iron binding sites were enclosed within the independent domains. In the 
unmodified pure Lf, the approximate iron saturation is observed to be only 15% indicating 
that the internal lobes of it are not completely saturated. The protein ligands in its structure 
present the desired negative charge enabling a high iron binding capacity. Thus, a strong Fe
3+ 
binding is seen with Lf and the same affinity poses hostile conditions for iron release. 
Therefore, the iron release is possible only by the specific receptors or at the lower pH levels 
capable of destabilising the protein. The Lf is not only endowed to Fe
3+
 binding but also 




. In contrast, Lf can also be 
made metal free and referred as the Apo-Lf [198]. Compared to other transferrin family 
members, Lf shows iron binding specificity at a lower pH (~3) and a pH above 5.5 tends to 
release Fe
3+
ions. On the basis of this observation, Lf function primarily was presumed to be 
iron absorption but later it was confirmed to possess multifunctional activities such as 
intestinal cell proliferation, anti-microbial activity, immune response regulation and 
myelopoiesis [199-201]. In addition, protective actions of Lf were confirmed it showed 
elevated levels in neurodegeneration [202], inflammatory diseases such as asthma, arthritis 
[203] and intestinal bowel diseases [204]. In all of these pathologic conditions, Lf levels were 
observed to be elevated suggesting that it has a strong protective role. Supporting its 
protective role, several studies reported anti-inflammatory actions of Lf against airway 
obstruction, hyper-responsiveness collagen-induced arthritis
 
and allergen induced 
inflammation [205].  
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In addition to this, bovine Lf (bLf) and iron saturated bovine Lf (Fe-bLf) were found to show 
strong anti-cancer potential in the chemical carcinogen challenged tumor mice model along 
with tumor metastasis inhibition [201, 206]. Several modifications were also made with the 
introduction of recombinant human lactoferrin (talactoferrin) where oral administration of it 
was found to effectively regress the human squamous carcinoma model developed in the 
immune compromised nude mice [207]. Iron is an essential co-factor for the basic 
biochemical needs of the cells regulating the activities such as the oxygen transport, energy 
metabolism and DNA synthesis. This is attributed to the unique co-ordination and redox 
reactivity of iron that allows it to bind with oxygen, mediate electron transfer and catalysis 
[318]. The major proportion of body iron is present in the haemoglobin of red blood cells 
facilitating the oxygen transport. In the case of neurons, iron is majorly transported via the 
transferrin receptor endocytosis and divalent metal transporter (DMT-1) protein from the 
blood stream and has no scope for storing the excess iron. This is confirmed by the lack of 
ferritin protein expression and explains the fact that the iron uptake is immediately followed 
by its use and any excess is transported rather than being stored [319]. Ferroportin and 
hephaestin are the two recently identified proteins where the former is involved in membrane 
bound iron transport while the latter oxidises the ferrous to ferric iron for transferrin binding 
[320]. The specific reason behind no iron storage is explained as higher iron accumulation is 
reported in majority of the age related neurodegenerative diseases. In addition, under aerobic 
conditions, iron catalyses the reactive oxygen species propagation causing the oxidative 
damage to the brain tissue [321-323]. In this study, both the proteins used bLf and Fe-bLf has 
iron content and therefore their influence on the iron metabolism was studied. 
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The human neuroblastoma SK-N-SH cell derived from the neuroblastoma tissue is a 
continuous cancer cell and is one of the vital neuronal cell lines available for studying the 
brain tumors [324], mechanisms of neuronal protection and neurodegenerative diseases such 
as the Alzheimer’s disease (AD) [325] and Parkinson’s disease (PD) [138]. Though bLf and 
its variant iron saturated Lf are endowed with potent anti-cancer activities, [206, 326-328] 
their exact physiological and biological functions in the neurons are yet to be revealed. In this 
study, the detailed effect of natural bLf and its iron-saturated form (Fe-bLf) were studied in 
the tumorous SK-N-SH neuroblastoma cell lines. A relative low cumulative doses much 
lower than the anti-cancer threshold were used in the entire study and  this is the first of its 
kind to assess the low dose Lf therapy on the cancer cell line. 
6.2. Material and methods 
Ferric [Fe(III)] nonahydrate, anti-actin, anti-tubulin III, anti-neurofilament (NF) 68, anti-   
NF 160, anti-NF 200 anti-mouse IgG FITC and anti-mouse horseradish peroxidase (HRP) 
antibodies were procured from Sigma Aldrich (Australia). All the miRNA related products 
(miRNA isolation kit, cDNA synthesis reaction mix, primers) were also obtained from Sigma 
Aldrich (Australia). SK-N-SH neuroblastoma cell lines were purchased from the American 
type culture collection (ATCC) and were grown as a monolayer in standard Eagle’s minimum 
essential medium (EMEM) supplemented with 10% of foetal bovine serum. To prevent 
microbial infections 1% penicillin and streptomycin was added to the media and cells were 
maintained at 37°C in a saturated humid atmosphere with 5% CO2. Polyvinylidene fluoride 
(PVDF) membranes for immunoblotting were purchased from Amersham biosciences and 
rest of the chemicals used in this study were of analytical grade. 
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6.2.1. Preparation, iron estimation and purity of iron saturated bovine lactoferrin (Fe-bLf) 
The preparation of Fe-bLf was followed as per our previously published data [201, 206].         
In brief, fresh bLf was dialyzed against the mild citric acid solution (pH 2.6) for 2 days and 
this process removes any of the bound metal ions form the bLf. Then the free bLf was 
saturated with ferric [Fe(III)] nonahydrate to form the bLf- Fe3+co-ordinate complexes 
yielding the iron saturated bLf that was confirmed by the deep red colour development. 
The level of iron saturation was determined spectrophotometrically as described previously 
[201, 329] and iron saturation ≥ 93% only was used in the entire study. The purity of bLf and 
prepared Fe-bLf was tested against the SDS-PAGE electrophoresis and confirmed with 
western blot analysis. The primary antibody for bLf detection was the goat-anti bovine 
lactoferrin (Bethyl laboratories, Inc) and the corresponding secondary antibody was the rabbit 
anti-goat HRP (Sigma Aldrich). 
6.2.2. bLf internalization 
SK-N-SH cells were grown as a monolayer in BD Falcon™ 8-well culture slides at 2x10
4
cells/well density and then incubated with bLf at a 30 µg/ml concentration for 2 hr at 37
o
C.
After the incubation time, cells were washed thrice with 1X PBS to remove the free and 
unutilized bLf left over in the media. Then the cells were fixed with 4% paraformaldehyde 
immediately for 15 min followed by permeabilisation with 0.1% Triton-X-100 and washing. 
Then the primary antibody, goat anti bovine lactoferrin was introduced and incubated for 1 hr 
followed by the FITC labeled rabbit anti goat IgG antibody. Fluoroshield
™
 with PI (Sigma
Aldrich) was used for nucleus staining. bLf internalization was determined using the Leica 
SP5 confocal microscope (Leica systems, GmbH, Germany) and all the images were taken at 
40X objective. The percentage internalization is expressed as mean±SD values obtained by 
counting cells in ≥ five different fields. 
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6.2.3. Morphology changes 
Preliminarily, to determine the low dose differentiating effect of bLf and Fe-bLf, SK-N-SH 
cells were plated in the BD Falcon™ 8-well culture slide and treated at various log 
concentrations ranging from 1, 3, 10, 30, 100, 300 and 1000 µg/ml concentration’s daily. 
Treatments were added cumulatively on a daily basis following which changes in the 
morphology were observed with an inverted lab microscope.  
6.2.4. CyQUANT assay 
The proliferative potential and in turn cytotoxic actions of both bLf and Fe-bLf on SK-N-SH 
cells was analyzed by the CyQUANT (Invitrogen) assay. For this, SK-N-SH cells were plated 
at 10
4 
cells/well density in 96 well plate and incubated with the various concentrations 1, 3, 
10, 30, 100, 300 and 1000 µg/ml of bLf and Fe-bLf for 24 hr. An untreated control, 20% FBS 
treated (+Ve control) and retinoic acid (RA) treated cells (RA induces differentiation in       
SK-N-SH cells) were also included in the study. Post treatment period cells were washed and 
frozen at -80
o
C overnight and proceeded for CyQUANT dye reaction mixture measurement 
as per the manufacturer’s protocol. The excitation and emission was at 480 nm and 520 nm 
respectively and the readings were recorded using a fluorescence microplate reader.  
6.2.5. Expression of differentiating markers 
Further to the morphological changes observed, the expression of differentiating markers was 
observed using the immunofluorescence studies. Cells were seeded at 2x10
4 
cells/well in   
BD-falcon 8 well culture slide and treated with the cumulative doses of bLf and Fe-bLf        
30 µg/ml each for 5 days. An untreated control and +Ve control of RA induced differentiated 
cells were also included in this study. Following treatments, cells were washed 3X in PBS, 
fixed with 4% PF for 15 min and permeabilised in 0.1% Triton-X-100.  
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Cells were blocked with 3% bovine serum albumin followed by incubations with primary 
anti-tubulin III, anti-neurofilament (NF) 68, anti-NF 160, anti-NF 200 antibodies (Sigma 
Aldrich). Then the secondary anti mouse FITC was introduced (Sigma Aldrich) followed by 
nucleus staining with PI (Sigma Aldrich). Then fluorescence imaging was carried using the 
Leica SP5 confocal microscope at 40X objective. 
6.2.6. Gene expression study 
In order to reveal the mechanism of bLf induced differentiation in SK-N-SH cells, gene 
expression analysis was performed for the differentiating markers and signalling pathways. 
Real time qRT-PCR analysis was conducted for the expression of β-tubulin III, NF 68, 
NF 160, NF 200, neuron specific enolase (differentiating markers), lactoferrin related 
receptor protein (LRP)1, LRP2, transferrin, PI3K and ERK (mechanistic markers). 
Post treatments with bLf and Fe-bLf, RNA was isolated following the manufacturer’s 
protocol and reagents (TRIzol® reagent, Invitrogen) as discussed in section 3.7.1 . 
qRT-PCR was performed according to the protocol described in section 3.7.2 and 3.7.3.
The list of primer sequences and annealing temperatures are described in Table 3.1. 
6.2.7. Flow cytometry and protein expression 
Post treatments with Lf, SK-N-SH cells were evaluated for the expression of differentiating 
markers at the protein level through flowcytometric analysis. In brief, following treatments 
the cells were gently detached from the culture plates with a rubber policeman and fixed 
immediately in 4% PF. Following this, they were permeabilised, blocked with 3% BSA and 
then incubated with primary antibodies for differentiating markers as discussed in 
immunofluorescence experiments.  The protein expression was studied using the flow 
cytometer (BD Bioscience) equipped with FACS Diva software (BD Bioscience). 
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6.2.8. Western blot for differentiating markers 
Post treatments with bLf, lysates were collected and expression of differentiating markers 
primarily NF 68, NF 160 and NF 200 were evaluated keeping GAPDH as the internal control. 
The primary antibodies used were mouse anti-GAPDH (1:300, Santa Cruz) NF 68, NF 160 
and NF 200 (1:300, Sigma Aldrich) with overnight incubation followed by incubations with 
rabbit anti-mouse HRP (1:100000, Sigma Aldrich). The blots were developed using the ECL 
developing system (GE health care).  
6.2.9. Wild type survivin expression  
SK-N-SH cells were evaluated for the expression of proliferating marker, survivin post 
treatments with bLf, Fe-bLf and the +Ve control RA. In brief, following treatments cells were 
gently detached from the culture plates, fixed immediately in 4% PF, permeabilised and were 
blocked with 3% BSA. Mouse anti-survivin (1:100, Santa Cruz) was used as the primary 
antibody and then incubated with rabbit-anti mouse TRITC for detection of wild type 
survivin expression. The protein expression was studied with FACS Diva software using the 
flow cytometer (BD Bioscience). 
6.2.10. miRNA expression and iron metabolism 
The SK-N-SH cells were seeded in 6 well plates and treated with 30 µg bLf and Fe-bLf for 5 
days. Post treatments, miRNA was isolated and cDNA was prepared as per the protocol 
described in section 3.8. Then the miRNA amplification was performed using the qRT-PCR 
following the 40 reaction cycle described in section 3.8.2. The list of miRNA primers used in 







Table 6.1. List of miRNA primers used for amplification study  
S.NO miRNA Mature sequence Catalogue No 
1 HSA-miR-122-3p AACGCCAUUAUCACACUAAAUA MIRAP00133 
2 HSA-miR-320a AAAAGCUGGGUUGAGAGGGCGA MIRAP00304 
3 HSA-miR-196a CGGCAACAAGAAACUGCCUGAG MIRAP00239 
4 HSA-miR-584-5p UUAUGGUUUGCCUGGGACUGAG MIRAP00569 
5 HSA-miR-485-3p GUCAUACACGGCUCUCCUCUCU MIRAP00419 
6 HSA-miR-214-3p ACAGCAGGCACAGACAGGCAGU MIRAP00265 
7 HSA-miR-200b-3p UAAUACUGCCUGGUAAUGAUGA MIRAP00249 



















6.3.1. Preparation, iron estimation and purity of iron saturated bovine lactoferrin (Fe-bLf) 
As observed from the Fig 6.1A and B, presence of 80 KDa bands confirmed the purity of  
both the proteins bLf and the iron saturated bLf. The percentage iron saturation in Fe-bLf  























Figure 6.1. Determination of protein purity in bLf and Fe-bLf samples. A) SDS-PAGE 
was performed for bLf and iron saturated bLf. Samples were loaded at a concentration 
corresponding to 50 µg/ml and were ran on a 10% SDS gel. Presence of 80 KDa bands 
confirmed the presence of bLf. B) The purity of the proteins was confirmed by the western 
blot. C) The % iron saturation in Fe-bLf was determined by 280/465 ratio method. The data 



























6.3.2. bLf internalization 
Post incubations with bLf treatments for 4 hr, all the cells seemed to uptake and internalize 
the bLf corresponding to 84 %. Few of the cells showed the periplasmic bLf evident from the 
green fluorescence indicating the initial interaction of protein with the cell surface. The bLf 
interaction with the DNA was also confirmed with its nuclear localization following 4 hr 












Figure 6.2. Determination of bLf internalization in the undifferentiated SK-N-SH cells. 
SK-N-SH cells were incubated with bLf and evaluated for the bLf internalization using 
immunofluorescence. bLf was successfully internalized as indicated by the arrowheads where 
bLf was localised around the periplasmic spaces and the nucleus within 4 hr of incubation. 
All the images were taken at 40X objective and the histogram is mean±SD representative of 
bLf expression in the cells counted in five independent fields. ***p<0.001 is considered 
statistically significant (students t-test).  




















6.3.3. Morphology changes 
Bovine Lf and Fe-bLf were treated in a cumulative fashion at lower dose starting from 1 µg  
to a max of 1 mg and morphological changes were observed on a daily basis. 1 and 3 µg 
haven’t showed any significant effect and were not included in the results. However, 
concentrations starting from 10 µg have started to show differentiation evident from the cell 
shape and elongation of the neurite processes from the 2 day corresponding to 15.4 and 17% 
for bLf and Fe-bLf. 30 µg had the maximum differentiating effect post 5 day treatments 
compared to rest of the doses used and this conclusion was made from the observation based 
on the number of alive cells showing neurite processes. The % differentiation of bLF and    
Fe-bLf at 30 µg dose was observed to be 46.8 and 43.2% respectively and was the maximum 
with all the doses compared. bLf at 100, 300 and 1000 µg showed 24.8, 18.2 and 17.6% of 
differentiation while Fe-bLf showed 25.6, 18.8 and 19.6% respectively.  Though doses above 
30 µg showed signs of differentiation, the relative ratio of live cells to cells with neurite 
processes reduced implicating the 30 µg as the optimal dose of differentiation and hence used 
for rest of the study (Fig 6.3B). The differentiating effects of bLf were compared against the 
standard retinoic acid induced differentiation.     
 







































Figure 6.3. Retinoic acid induced differentiation and morphological changes induced by 
bLf and Fe-bLf treatments. A) Retinoic acid treatments at a concentration of 20 µM 
induced differentiation in SK-N-SH cells with continuous treatments for 10-12 days. Around 
81% cells were found to be differentiated as observed with the neurite process development. 
B) SK-N-SH cells were treated with bLf and Fe-bLf cumulatively for 5 days with varying 
concentrations ranging from 1-1000 µg. Morphology changes were observed from day 1 and 
treatments with 30 µg/ml of both bLf and Fe-bLf were optimum in inducing differentiation. 
Doses above this range showed apoptotic effects and hence not included in the rest of the 
study. Retinoic acid induced differentiation served as the positive control. Data is represented 
as mean±SD with cells counted in at least 5 different fields and the images were taken at 40X 
































6.3.4. CyQUANT assay 
CyQUANT GR dye binds and emits strong fluorescence upon binding to the nucleic acids 
which is a reflective of the proliferating cells. As observed from the Fig 6.4, the % 
proliferation of SK-N-SH cells reduced with increased doses and lower dose seemed to 
unalter the growth kinetics. No drastic changes were observed with 10 and 30 µg 
concentrations of both bLf and Fe-bLf. However, 100 µg of bLf showed initial reduction in 
the proliferation which was 94% while 300 and 1000 µg were corresponding to 60 and 69% 
respectively. Similarly, Fe-bLf at 100 µg dose reduced proliferation to 79% while 300 and 




Figure 6.4. Determination of bLf and Fe-bLf actions on the proliferative potential of 
SK-N-SH cells. CyQUANT assay was performed for determining the percentage 
proliferation. bLf and Fe-bLf showed no changes in the proliferative status up to 30 µg 
however a reduced cell growth was evident from 100 µg and above doses. Data is represented 























6.3.5. Expression of differentiating markers 
As observed from the figure 6.5, both the doses of bLf and Fe-bLf were observed to have a 
profound differentiating effect of the SK-N-SH neuroblastoma cells. This was evident with 
the expression of neurofilaments (NF) which are the markers for neuronal differentiation and 
integrity [330, 331]. In this study, post treatments with bLf and Fe-bLf all the neurofilament  
markers were evaluated keeping RA induced differentiated cells as the +Ve control. To our 
surprise, all the NF markers were expressed with both the treatments. Bovine Lf 
corresponded to 22.1, 46.8 and 62.6% expression of NF 68, NF 160 and NF 200 respectively 
while it was 19.5, 43.2 and 60% with Fe-bLf. Arrowheads indicating the corresponding NF’s 
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Figure 6.5. Determination of neurofilament expression in the SK-N-SH cells post bLf 
and Fe-bLf treatments. SK-N-SH cells were treated with bLf and Fe-bLf and then the 
neurofilament expression was detected through immunofluorescence study. Differentiation of 
SK-N-SH cells was evident with the expression of NF 68, NF 160 and NF 200 indicated in 
the FITC (green) channel from top to bottom. Nucleus is shown in the PI (red) channel.         
All the images were taken at 40X objective and the histogram is mean±SD representative of 
neurofilament expression in the cells counted in five independent fields. ***p<0.001, 
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6.3.6 Gene expression study 
To confirm the mechanistic differentiation of both the proteins, gene analysis was carried out 
post treatments. A variety of differentiating marker genes were elevated along with the iron 
family receptor genes for both proteins but slight differences were noted for signalling 
molecules. In the case of bLf, the differentiating genes β-tubulin III, NF 68, NF 160, NF 200 
and NSE were found to increase by 2.5, 2.5, 3.4, 64.7 and 43 folds respectively while the 
receptor genes Lf, LRP1 and LRP2 showed 3.3, 2.2 and 1.5 fold increments. The signalling 
genes PI3K and ERK showed 149 and 1.2 fold upregulation. However, the differentiating 
genes were found to be upregulated slightly higher with Fe-bLf compared to bLf.                 
β-tubulin III, NF 68, NF 160, NF 200 and NSE showed 1.5, 2.8, 8.6, 147.7 and 142 fold 
increments while the receptor genes namely Lf, LRP1 and LRP2 showed an increase of 3.2, 
3.2 and 3.4 folds respectively. Finally, the signalling genes PI3K and ERK were found to be 
upregulated by 83 and 3.9 folds respectively. Comparatively after analysing the gene 
expression, bLf induced differentiation, following the PI3K pathway and got internalized 
predominantly through the LRP1 receptors. In contrast, Fe-bLf showed differentiation 
following both PI3K/ERK pathways and its internalization was through all the receptor genes 











































Figure 6.6. Gene expression study post bLf and Fe-bLf treatments. Both forms of 
lactoferrin treatments showed increased expression of differentiating marker genes such as 
the neurofilaments, β-tubulin III and NSE. The relative expression of all the genes was 
measured and calculated relative to the house keeping gene β-actin. Data is represented as 
























































6.3.7. Flowcytometry and protein expression 
Owing to the tumorigenic potential of SK-N-SH cells, treatments with bLf and Fe-bLf at low 
dose induced upregulation of neuronal differentiation markers. The endogenous expression of 
neurofilaments and β-tubulin III was significantly lower in the control groups but post Lf 
treatments, a remarkable increase in differentiation was observed. bLf induced an increase in 
the expression of β-tub III(45.7), NF68(65.2), NF160(50.2), NF200(40.6), NSE(88), 
PI3K(46.2) and ERK(14.9) while Fe-bLf showed an increase of β-tubulin III (45), 
NF68(43.06), NF160(40.7), NF200(21.6), NSE(58.47), ERK(31.2), PI3K(22.5). The 
percentage increase is shown in the brackets assuming the differentiation induced by +Ve 
control retinoic acid as 100%. This confirms the differentiating potential of both forms of Lf 
proteins in SK-N-SH neuroblastoma cell line both at the gene and protein level. Considering 
this unique differentiating potential of Lf, it can be employed as a promising therapeutic for 
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Figure 6.7. Effect of bLf and Fe-bLf on the expression of various proteins in the         
SK-N-SH cells. Both forms of Lf increased the expression of neuronal differentiation 
markers like β-tubulin III, NF 68, NF 160, NF 200 and NSE. However, the expression levels 
of the signalling molecules were different for bLf and Fe-bLf where the former showed an 
enhanced expression of PI3K while the latter showed an elevation of both PI3K and ERK 
protein signalling. The data represented is as a mean±SD with *p<0.01 is considered 
statistically significant (students t-test). 
PI3K Control PI3K bLf PI3K Fe-bLf 
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6.3.8. Western blot for differentiating markers 
Finally, western blot performed for the expression of differentiating markers NF 68, NF 160 
and NF 200 was confirmed post treatments with Lf. As shown in the figure 6.8, 
differentiating marker expression was evident in the treatment group compared to the 
untreated control. Thus, it confirms the neuro differentiating actions of both bLf and Fe-bLf 
following the signalling mechanisms of PI3K and ERK pathways. All the above protein 
expression was compared against GAPDH as the internal standard control.  
 
 
Figure 6.8. Confirmation of differentiation markers in the SK-N-SH cells following 
treatments with bLf and Fe-bLf. Western blot analysis confirmed the expression of 
neuronal differentiating markers NF 68, NF 160 and NF200 post bLf and Fe-bLf treatment 
compared to the +Ve control retinoic acid. The untreated control showed negligible 












6.3.9. Wild type survivin expression 
Next the expression of wild type survivin was addressed, that is ubiquitously and selectively 
expressed in all the tumor cells playing a major role in the proliferation. To our surprise, 
endogenous expression of survivin reduced post treatments with bLf and Fe-bLf 
corresponding to 29.5 and 15.5 folds respectively as compared to the +Ve control RA 
(p<0.05). This can be explained as that both forms of Lf induced differentiation evident from 
the downregulation of endogenous survivin expression. This is exactly in agreement with the 
fact that differentiated postmitotic cells like neurons constitute very negligible or no 
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Figure 6.9. Effect of bLf and Fe-bLf on the expression of wild type survivin relating to 
the proliferation. SK-N-SH cells show overexpression of survivin reflecting their aggressive 
proliferation. Post treatments with Lf survivin expression drastically lowered with lowered 
proliferation. Thus, it is indicating that the treatments initiated the preparatory changes for the 
induction of differentiation evidenced by the reduced expression of wild type survivin as the 
early event. It is evident from the fact that cells undergoing the differentiation show reduced 
proliferation.  The data is represented as mean±SD of three independent experiments with 
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6.3.10. miRNA expression and iron metabolism 
Micro RNAs represent the special class of small noncoding RNAs with a major function of 
regulating the posttranscriptional level of gene expression [333]. In this study, a variety of 
miRNAs potentially involving in the iron metabolism were evaluated post treatments with 
bLf and Fe-bLf. Interesting results were observed post treatments and are discussed as 
follows. miRNA 122-3p is reduced by 1.28 and 1.44 folds respectively by bLf and Fe-bLf 
indicating that the cholesterol levels and fatty acid synthesis are negatively affected. Though 
miRNA is liver specific, trace amounts of it is also observed in the brain.  Interestingly, 
miRNA 320a expression showed 1.36 folds reduction with bLf and 1.3 folds increase with 
Fe-bLf. This could be explained as miRNA 320 is associated majorly with reduced iron 
uptake by repressing the transferrin receptor (TFR) translation [334]. Also, bLf has reduced 
iron content than Fe-bLf comparatively and therefore, has lesser chances of saturating the 
endogenous TFR. Hence, Fe-bLf might have shown increased miRNA 320a expression to 
surmount the iron uptake via TFR. Neurons also lack the iron storage mechanism to avoid the 
associated insults and therefore have shown the reduced expression of miRNA 196 and 
miRNA-let-7d. Functionally, both the miRNAs derepress the ferritin expression that is 
negatively regulated by Bach1 and enhance iron storage [335, 336]. In this study, it was 
observed that bLf reduced the miRNA 196a by 2 folds while no change was observed for        
Fe-bLf, whereas miRNA let-7d was reduced by 1.38 and 1.26 folds respectively by bLf and 
Fe-bLf. miRNA 584 essentially regulates the posttranscriptional expression of lactoferrin 
receptor and hence, bLf and Fe-bLf showed 1.26 and 1.12 folds reduction respectively. This 
was further confirmed with the gene expression (Fig 6.6) where bLf and Fe-bLf showed 3.3 
and 3.2 folds increased expression of LFR. miRNA 485-3p is found to be positively affecting 
the cellular iron content targeting the ferroportin (FPN) transporter [337].  
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Considering the treatments, contrast results were obtained where bLf showed a 5 folds 
reduction while Fe-bLf showed 2.7 folds increment. miRNA 214-3p is found to directly bind 
and affect the lactoferrin RNA thereby regulating its expression [338]. In this study, 
compared to the untreated control, bLf showed 1.23 folds and Fe-bLf contributed to 1.8 folds 
increment in its expression. The results are quiet interesting, as it was reported earlier that the 
miRNA 214 was positively affecting the differentiation [333]. Hence, Fe-bLf and bLf are 
considered to induce differentiation possibly involving the upregulation of miRNA 214. 
Lastly, miRNA 200b-3p that is reported to involve in the cellular iron storage, showed an 
















Figure 6.10. bLf and Fe-bLf induced effect on the miRNA expression. A) Pure miRNA 
isolated from the SK-N-SH cells post treatments with bLf and Fe-bLf. B) Amplified miRNA 
following qRT-PCR. A decreased expression of miRNA 122-3p, miRNA 584-5p and miRNA 
let-7d-5p and an increased expression of miRNA 214-3p and miRNA 200b-3p was evident 
post treatments. Variable expression was observed for miRNA 320a and miRNA 485-3p. 
Interestingly, miRNA 214-3p expression was increased that is reported to be positively 
affecting the neuronal differentiation confirming the involvement of bLf and Fe-bLf.           
C) Relative fold change expression of amplified miRNA compared to the positive control 
primer. The data is represented as mean±SD of two independent experiments with *p<0.05, 
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The differentiating effect of bLf and Fe-bLf were investigated on the human neuroblastoma 
cell lines in the present study which involved the PI3K/ERK signalling in inducing this 
effect. Lf specific receptors are common and are expressed in several mammalian cells such 
as hepatocytes, blood cells, intestinal cells etc., but however differ in internalising the protein 
[342]. Lf internalization is reported via a number of receptors that include the lactoferrin 
[343], transferrin [344], LRP1 and LRP2 [345]. Some studies have shown the merits of brain 
specific therapeutic delivery by conjugating with Lf based on the abundant availability of 
human Lf receptors (hLf-R) in the CNS [346-348]. There are close similarities between hLf 
and bLf and the aminoacids responsible for iron binding are highly conserved in these species 
[349]. In this study, bLf treatments showed 3.3, 2.2, 1.5 and 1.4 folds increased expression of 
Lf, LRP1, LRP2 and transferrin receptors respectively. However, Fe-bLf showed increased 
expression of Lf, LRP1, LRP2 and transferrin receptors by 3.2, 3.2, 3.2 and 1.6 folds 
respectively. These results suggest that the uptake of bLf was mostly through the Lf and 
LRP1 receptors while Fe-bLf was more specifically uptaken by Lf, LRP1 and LRP2 
receptors. The reason behind this variable uptake mechanism is explained as each cell has its 
own internalization mechanism involving different receptors and also because of the iron 
saturation in Fe-bLf compared to bLf might have favoured its excessive uptake by LRP1 and 
LRP2 receptors. It was observed that following bLf and Fe-bLf treatments the neuronal 
differentiating marker expression of β-tubulin III and the neurofilaments was elevated 
significantly.  Class III β-tubulin is one of the tubulin family isotype proteins and is widely 
regarded as a selective neuronal marker in developmental neurobiology research [350].       
To confirm the neuronal differentiating marker expression, gene and protein level 




Interestingly, both bLf and Fe-bLf showed an enhanced expression of it corresponding to 2.5 
and 6.7 fold increments respectively at the gene and protein level with bLf while Fe-bLf 
showed 1.5 and 6.7 fold increment. This also suggested that bLf induced early differentiation 
in the SK-N-SH cells predominantly compared to Fe-bLf as β-tubulin III is identified as a 
precursor of early differentiation [351, 352]. The basic requirements essential for the onset of 
differentiation includes the exit from cell cycle, prolonged neurite process generation and 
expression of differentiation inducing genes. Neurofilaments (NFs), a very important neuron 
specific markers belong to this group and their expression represents the induction of 
differentiation in  the neurons [353]. They constitute the intermediate filaments and are 
categorised as NF 68, 160 and 200 on the basis of their molecular weight [354].                 
The expression of NFs was elevated with both the treatments and more specifically Fe-bLf 
enhanced the NF 200 gene expression. This phenomenon represents the matured neuronal 
differentiation [355] and that Fe-bLf was found to have more of this action compared to bLf. 
However, the same doesn’t hold true for NF 200 expression post Fe-bLf treatments at the 
protein level. The other differentiating marker studied was the neuron specific enolase (NSE) 
and both the protein treatments showed enhanced expression confirming the neuronal 
differentiation [356]. In this study, bLf induced differentiation was evidenced by the 
neurofilament upregulation involving the PI3K signalling mechanism predominantly.                
It is proven and well-studied that PI3K signalling has a significant role to play mediating the 
various aspects of neuronal growth, survival and differentiation [357, 358]. However, the 
other protein Fe-bLf was found to involve both the PI3K and ERK signalling pathways to 
induce the differentiation. This is in compliance with the previous studies showing the prime 




Interestingly, PI3K and ERK pathways are related in that ERK activation is reported to 
involve primarily regulating neuronal survival and death. PI3K has the ability to turn on and 
off the ERK signalling and this activity purely relies on the substrate identity and the 
extracellular stimuli [363]. When implied in this study, the prominent PI3K mediated 
differentiating effect of bLf observed to inhibit the activation of ERK but in the case of           
Fe-bLf, a slightly reduced expression of PI3K elevated the ERK pathway. However both the 
pathways were involved in differentiation. This phenomenon also explains the reason behind 
the mature neuronal marker expression (NF 200 in this case) post Fe-bLf treatments that 
involved ERK signalling [364]. Thus to conclude, the relation between PI3K and ERK was 
inverse to each other and that ERK was solely responsible for the mature neuronal marker 
expression. Also, the IAP family protein survivin that is more related to dividing cells was 
downregulated after the protein treatments. This confirms a fact that differentiation induced 
by Lf is witnessed by the downregulation of survivin and the lowered proliferation potential. 
This phenomenon complies with the principle that the high endogenous survivin corresponds 
to rapidly dividing cells [233] while the initiation of differentiation lowers the proliferative 
ability in the cells showing lower levels of growth factors [365, 366]. In addition, bLf and     
Fe-bLf negatively affected the cholesterol, fatty acid synthesis and iron storage confirmed 
with the reduced expression of miR122-3p, miRNA 320a and miRNA let-7d-5p. However, 
the induction of differentiation and the expression of LFR were positively affected with the 









Altogether, both forms of Lf tested in the study, showed the differentiating effects on the 
neuroblastoma cells at a suboptimal dose much lower than their threshold anti-cancer 
activity.  This observation endows potential future bLf applications in treating brain tumors 
on account of its differentiating ability. Alongside, a variety of neurodegenerative diseases 
can also be treated using bLf as it helps in maintaining the integrity of neuronal markers that 
are a reflective of the neuronal health. As brain environment has abundant Lf receptors future 
applications include the development of conjugated Lf-aptamer/LNA delivery systems for 




















CONCLUSION AND FUTURE DIRECTIONS 
7.1. Concluding remarks 
Neurological diseases are the most devastating disorders particularly in the aging population 
especially in Australia, dragging more research attention. As discussed earlier, each 
individual disorder has unique pathology associated but the ultimate outcome of these 
diseases is the death of the neurons [1, 5]. The brain neoplasms show aggressive proliferation 
invading the surrounding normal brain tissue and eventually cause serious damage elevating 
the intracranial pressure. This leads to the irreparable CNS damage and the patient life is 
seriously hazarded [86]. In addition, in a vast majority of cancers, survivin expression has 
been found to be increased in brain neoplasms. This is associated with tumor resistance to 
various apoptotic insults mediated through caspase dependent and independent mechanisms, 
aggressive proliferative index and tumor recurrence [367]. Hence, targeting survivin that is 
specific to proliferating tumor cells has gained immense research interest and several 
mutants, small molecule inhibitors of it are under evaluation.  Results have been published, 
where antagonizing survivin in tumor cells showed apoptosis in vitro and in vivo preclinical 
models without non-specific toxicity [22, 368, 369]. In contrast, neuronal degeneration 
involves the expression of cell cycle markers in the differentiated neurons with a 
characteristic feature of cell cycle exit. Thus, all the kinases, signalling molecules, 
transcription factors and cell cycle regulators that seem to be active in other cells are in fact 
dormant in the neurons further complicating the recovery from degeneration. It has been 
found that in AD and PD, neurons failed to complete the cell cycle exit showing and 
increased expression of cyclin-D1 [370, 371].   
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In addition, postmitotic neurons entry into the cell cycle leads to the devastating event of 
caspase 3 activation that culminates in apoptosis execution [27, 28]. Although, several IAPs 
were tried against repairing the damaged neurons the inadequate recovery of them suggests 
the need of developing effective therapeutics that not only enhance the proliferation, but also 
preserve the integrity [128-131]. This would certainly answer the burning problem of 
neurodegeneration and benefit the aging population. Survivin belongs to the family of IAPs 
and bears dual actions that include the mitotic process regulation and apoptosis inhibition.  
On the basis its tumor specific expression compared to the normal cells, survivin is an 
attractive target with respect to cancer therapeutics and is highly unlikely for other IAPs so 
far studied [183, 372]. Several reports have confirmed that tumor progression can be 
successfully abrogated using survivin antagonists, small molecules inhibitors and anti-sense 
agents [166, 168, 172, 183]. A sound strategy that gained attention was the dominant-
negative survivin mutants that showed strong potential in suppressing the tumor cell 
populations. In this study, SurR9-C84A was tested against the aggressive neuroblastoma cells 
(undifferentiated SK-N-SH cells) that showed high component of wild type survivin 
expression. The dominant negative protein was found to induce tumor cell death as it 
disturbed the microtubular dynamics upon forceful expression displacing the wild type.      
On the contrary, it also showed proliferative and protective effects in the differentiated      
SK-N-SH neurons that behaved as the postmitotic cells with cell cycle marker 
overexpression. In addition, SK-N-SH neurons showed reduced or no expression of survivin 
while treatment with SurR9-C84A restored proliferation. This is because of its interaction 
with the microtubular assembly following which the spindle formation was initiated that was 
indistinguishable to the actions of endogenous survivin [21, 138, 197]. The protective actions 
of it were also evaluated and the detailed findings will be discussed as: 
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 Differential actions of SurR9-C84A in undifferentiated (tumorigenic) and 
differentiated (neuronal) SK-N-SH cells and its cellular mechanism 
 Neuroprotective functions of SurR9-C84A against β-amyloid toxicity  
 Extensive protective potential of SurR9-C84A against T-cell mediated inflammation 
 Differentiating potential of milk protein bLf and the iron saturated Lf 
7.2. Differential actions of SurR9-C84A 
Survivin, a unique member of the IAP family has a dual role in the execution of cell 
proliferation and inhibition of apoptosis. To demonstrate the entirely contrast differential 
functions of apoptosis initiation and proliferation, the mutant dominant negative survivin       
(SurR9-C84A) was employed. The R9 peptide facilitates the rapid permeation of the mutant 
through the cellular barriers with superior uptake and is highly beneficial over the 
conventional carriers [373].  In the current study, undifferentiated SK-N-SH cells represented 
the tumor cells with aggressive proliferation and their high endogenous survivin expression 
was determined both at the gene and protein levels. Similar to the previously published data 
[138, 197, 210], the retinoic acid induced differentiated cells resembled neurons with 
extensive neurite processes and a low endogenous survivin pool was detected in them. 
Furthermore, the differentiation caused the cell cycle arrest in G0/G1 phase creating the 
perfect in vitro model of postmitotic neurons. Preliminarily, both the undifferentiated and 
differentiated cells showed the internalization of SurR9-C84A loaded NPs within 30 min 
followed by its release in the cytoplasm and nucleus accumulation. Interestingly, the 
tumorous undifferentiated SK-N-SH cells showed lowered proliferation upon SurR9-C84A 
treatment confirmed by the cell proliferation assays such as the CyQUANT and Live and 
Dead assay.  
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These results were further confirmed by the reduced endogenous survivin expression and 
proliferation markers such as PCNA and Ki67 along with an increased Caspase-9 and 
caspase-3 expression. Similar results were reported, where hindering the wild type survivin 
actions using dominant-negative survivin mutants and antisense oligonucleotides lead to 
tumor cell death [172, 183]. The mechanism hypothesised for anti-tumor actions of       
SurR9-C84A is that post dimerization with wild type survivin, microtubule dynamics was 
disturbed leading to the devastating effects. Due to the unavailability of wild type survivin, 
the Survivin-Smac/DIABLO complex formation was interrupted leading to caspase-3 
activity. Further, in the absence of wild type survivin, HBXIP lost its capacity to inhibit the 
procaspase-9 activation and this in turn propagated mitochondrial mediated apoptosis. On the 
other hand, several studies have reported the essential role of survivin in premature brain 
development along with protective activity against brain hypoplasty and foetal deaths [144, 
270]. As discussed, wild type survivin has a prominent role in cell cycle progression where it 
initiates the chromosome passenger complex formation and regulates the molecular 
dynamics. Hence, to address the neurodegenerative diseases, the strategy of either 
neurogeneration or neuroprotection will be fruitful and agents acting against apoptosis such 
as IAPs are thus considered. In this study, surprisingly differentiated SK-N-SH neurons upon 
treatment with SurR9-C84A loaded NPs showed signs of increased proliferation confirmed 
by BrdU incorporation and elevated expression of  proliferation markers such as survivin, 
PCNA and Ki67. Owing to the low endogenous survivin pool in differentiated neurons, 
SurR9-C84A was able to stabilise the microtubular assembly initiating the spindle formation 
indistinguishable to wild type survivin. These dual effects observed with SurR9-C84A were 
due to the differential expression of endogenous survivin levels. A cytotoxic effect was 
evident in high wild type survivin expressing undifferentiated cells due to the displacement of 
the endogenous survivin by SurR9-C84A and disturbed microtubular dynamics (Fig 7.1A).  
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In contrast, a proliferative effect was reported for the differentiated cells owing to their low 
endogenous survivin levels where SurR9-C84A effects were indistinguishable from wild 
type. The differential actions observed with SurR9-C84A were explained on the basis of 
differential endogenous survivin expression levels. Likewise, SurR9-C84A treatment caused 
forceful expression and disturbed microtubular dynamics in undifferentiated cells that already 
had high wild type pool survivin expression.  In contrast, owing to their low endogenous 
survivin pool SurR9-C84A replaced the actions of it in the differentiated neurons.              
This unique ability of SurR9-C84A finds a potential application in the treatment of a range of 
neurological disorders. For instance, brain tumor selective killing owing to the high 
endogenous survivin expression and vice versa in degenerative neurons. 
7.3. Neuroprotective functions of SurR9-C84A against β-amyloid toxicity  
Alzheimer’s disease is a chronic neurodegenerative disease with the pathological 
accumulation of amyloid-beta peptide (Aβ) and hyper phosphorylated microtubule-Tau 
protein. As per the amyloid hypothesis, Aβ deposition occurs due to the abnormal cleavage of 
the amyloid precursor protein (APP) resulting in the Aβ40 and Aβ42 fragments in the brain.      
In the event of pathologic conditions, genetic, age-related and environmental factors the 
metabolic shift drives the formation of Aβ oligomers posing severe neurotoxicity. These 
plaques result in the activation of pro-inflammatory cascades, oxidative stress, mitochondrial 
dysfunction and terminate post massive neuronal apoptosis [95, 96, 98]. In this study,              
the β-amyloid peptide induced insult was created in vitro by incubating the differentiated 
neurons with Aβ for a specific period of time. The cytotoxicity in the neurons was observed 
post increased expression of Cyt-c and caspase-3. In addition to this, there was also a 
significant downregulation of the neuronal integrity markers such as NF68, NF 160, NF 200 
and neuron specific enolase (NSE).  
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In contrast, post treatments with SurR9-C84A loaded NPs, the apoptotic marker expression 
was significantly lowered while the neuronal integrity markers were observed to be intact 
post β-amyloid insults. In addition, the protective actions were evident with the observation 
of increased anti-apoptotic proteins such Bcl-2 and wild type survivin. The reduced levels of 
Cyt-c observed could be because of the increase in Bcl-2 protein levels. To further support 
this hypothesis, DNA fragmentation a classical hallmark of apoptosis was analysed and 
compared between the β-amyloid only treated control and SurR9-C84A/β-amyloid treated 
groups. DNA fragmentation was evident in the β-amyloid only treated group indicating 
severe toxicity while SurR9-C84A rescued the DNA fragmentation in neurons. Interestingly, 
SurR9-C84A without the nano formulation was also incapable of showing a protective effect 
and this could be because of the reduced half-life and bioavailability in the native form. 
Hence, the nanoformulated SurR9-C84A showed an extensive protective effect because of its 
improved availability and half-life. This confirmed the enhanced neuroprotective actions of            
SurR9-C84A against β-amyloid toxicity. Further to this, the strategic mechanism of       
SurR9-C84A in protecting the neurons was explored where an enhanced expression of 
ERK/MAPK pathway signalling was observed in the protein treated groups compared to the 
untreated controls. The serine/threonine-specific protein kinase signal transducers such as the 
mitogen-activated protein kinases (MAPKs) were reported to have a vital role in regulating 
both the processes of cellular death and survival [301, 302]. Of the three MAPKs, commonly 
implied signalling in the cell survival is the extracellular regulated kinase (ERK/MAPK) 
despite findings of it in enhancing the cancer cell proliferation and apoptosis inhibition [303]. 
Thus, the neuroprotective actions of SurR9-C84A were confirmed against the β-amyloid 
induced toxicity and the possible mechanism through which it exhibited these actions 
involved the ERK signalling pathway (Fig 7.1B). 
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7.4. Extensive protective potential of SurR9-C84A against T-cell mediated 
inflammation. 
In the case of AD, Aβ and NFTs provide a fertile environment for the generation of 
inflammatory cascade. In this milieu, the reactive microglia, activated astrocytes and the 
abnormal neurites of the degenerating neurons surround these highly intractable structures 
and initiate the secretion of neurotoxic cytokines [103]. Though immune privileged, at times 
of neurotoxic insults (for instance abnormal plaque deposition) brain is often infiltrated by 
the T-cells. They are also accompanied by the astrocytes amplifying the immune response 
and induce the generation of nitric oxide (NO), reactive oxygen species (ROS), powerful pro-
inflammatory cytokines such as IL-1β, TNF-α etc., thus leading to acute and chronic 
inflammatory reactions [104]. All the participants and stressful events of the inflammatory 
cascade stimulate the APP processing thereby producing abundant Aβ-42 plaques and 
abrogate all possible neuroprotective events including soluble APP formation which 
otherwise shall support the neurons. The T-cell initiated inflammation and Aβ plaque 
formation are cyclic events which will positively influence each other and are highly 
detrimental to the neurons whether generated alone or in concert [105]. In order to mimic the 
AD associated inflammation, THP-1 cells, the most widely used T-cell line representing 
microglia were used in this study. The inflammatory insult to the neurons was induced by 
activating them with various stimuli such as the β-amyloid fragment and bacterial LPS. These 
cells showed an enhanced expression of cytokines that were found to be cytotoxic to         
SK-N-SH neurons determined by LDH release assay and the apoptotic microarray. However, 
the protein loaded NP treatment rescued the neurons against the inflammatory toxicity where 
the percentage expression of survival molecules such as wild type survivin, Bcl-2, HSP-70 
etc., were increased along with a drastic reduction in apoptotic Cyt-c and caspase-3 levels. 
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 Interestingly, SurR9-C84A also found to reduce the cytokine secretions in activated THP-1 
cells compared to the untreated groups. These results confirmed the potent neuroprotective 
activities of SurR9-C84A not only against the Aβ toxicity but also against the associated 
inflammation. As discussed earlier, neurons exhibit the characteristic features of cell division 
absence and continued cell cycle arrest and failure to exhibit these typical features causes the 
neurons to undergo  neurodegeneration [374]. For instance, due to various apoptotic stimuli 
cyclin-D1 expression is highly elevated in dying neurons and is associated with the maximum 
apoptosis but antagonising or down regulating cyclin-D1 was found to cause neuronal rescue 
[21]. Few of the results showed that SurR9-C84A showed a lowered cyclin-D1 expression 
which was essential for reduced transition of the neurons from G0/G1 to the S phase.            
As observed in neurodegeneration, where apoptosis of the neurons is mainly because of the 
cell cycle exit, SurR9-C84A arrested this activity and thus rescued the neurons. In addition, 
the co-culture studies of activated THP-1 cells and SK-N-SH neurons were conducted to 
closely mimic the AD associated inflammation in vitro. Pre-treatment with SurR9-C84A was 
found to be highly resistant in showing the cell death as compared to the untreated groups. 
The extensive anti-apoptotic effect of SurR9-C84A was explained on the basis of its ability to 
subside the mitochondrial depolarisation. The strong neuroprotective actions of SurR9-C84A 
were explained post observation of neuronal integrity markers such as the myelin basic 
protein and NF 200. The T-cell supernatants drastically reduced the expression of these 
markers in untreated control group.  On the whole, SurR9-C84A was found to play a role of 
potent neuroprotector where it rescued the neurons against the toxic inflammatory cytokines 






Figure 7.1. Dual actions of SurR9-C84A against the tumor cells and differentiated 
neurons subjected to Alzheimer’s disease insult. A) SurR9-C84A showed a strong 
cytotoxic activity against the undifferentiated SK-N-SH tumor cells owing to their high 
endogenous expression. SurR9-C84A competitively inhibited the actions of wild type protein 
by binding to it and making it unavailable following which there is a loss of microtubule 
dynamics and cell death. B)  In contrast, the negligible levels of endogenous survivin in the 
postmitotic differentiated neurons the mutant behaved indistinguishable to the wild type and 
hence showed proliferative and protective actions. SurR9-C84A rescued the neurons against 
the β-amyloid toxicity and activated neuroglial cytokine secretions. Further, the 
nanoformulation also added to the increased bioavailability of the mutant protein and 


















7.5. Differentiating potential of milk protein bLf and the iron saturated Lf 
Lactoferrin (Lf) is a single chain iron binding glycoprotein molecule consisting of 690 
aminoacid sequences in its structure with an approximate size of 70-80 KDa. As a line of 
natural defence, it exists in almost all of the body secretions. It has a high iron affinity 
showing an approximate iron saturation of 15% but the lobes of it are not completely 
saturated offering the negative charge for strong Fe
3+ 
binding.  On account of the remarkable 
physicochemical feature of its ability and affinity to bind iron, it was presumed that the 
biological activity of Lf was essential for iron absorption but later it was recognised to have 
multiple functions [198]. In addition to this, Lf levels were found to be elevated in 
neurodegeneration and inflammatory conditions alerting the concepts of defensive actions 
exhibited by Lf [202]. It was also reported that bLf along with its variant, iron saturated Lf 
have strong anti-cancer and anti-inflammatory activity. In the present study, the effect of 
natural bLf and iron-saturated bLf (Fe-bLf) were observed in the undifferentiated SK-N-SH 
cells post administration in cumulative doses much lower than the optimum 
chemotherapeutic dose used. This study is the first of its kind to determine the effect of low 
dose cumulative bLf therapy on the undifferentiated cancer cell line. Previously, it was 
published that Lf holds some differentiation induction in osteoblasts [345] and based on this 
capacity its activity was tested on undifferentiated SK-N-SH cells. Surprisingly, studying the 
cumulative dose effects of bLf and Fe-bLf for 5 days on undifferentiated SK-N-SH cells 
revealed remarkable changes. First of them, was the change in morphology of the cells 





In addition, all the differentiating markers specific to neurons such as NF 68, NF 160,         
NF 200, NSE and β-tubulin III were found to be drastically elevated and the same was 
confirmed by comparing these effects using retinoic acid induced differentiation [208] both at 
the gene and protein level. Based on previous results, it was identified that β-tubulin III is an 
early differentiating marker [21] and the NF 200 is considered to be expressed at a mature 
stage of the neuronal life cycle [364]. As observed from the results, bLf was found to induce 
predominant expression of β-tubulin III suggesting its early differentiating actions.               
In contrast, Fe-bLf though induced the expression of all the differentiation markers it 
majoritily enhanced the expression of the mature differentiation marker NF 200. This gave a 
clue that both the proteins induced differentiation where bLf and Fe-bLf responsible for 
predominant expression of early and mature neuronal markers respectively. The next move 
was to identify the mechanism following which these proteins were able to induce 
differentiation. Previously, it has been shown that PI3K signalling is a vital signalling 
mechanism involved in the growth of the neurons, their survival and differentiation [357, 
358]. In addition to this, ERK signalling was found to be equally important for regulating the 
vital functions of the neurons such as their survival, differentiation and death [359, 361, 362]. 
However, PI3K signalling regulates the ERK and this can be either activation or deactivation. 
The final output of regulation is solely dependent on the PI3K substrate specificity which can 
turn on or turn off the ERK signalling [363]. When the signalling pathways are analysed for 
bLf and Fe-bLf, it was found that PI3K signalling was predominant for bLf induced 
differentiation evidenced neurofilament and β-tubulin III upregulation. However, for Fe-bLf, 
ERK signalling showed maximum activation where NF 200 marker expression was 
predominant though a slight increase in PI3K was observed. Thus to conclude, PI3K 
signalling was responsible for bLf actions and for Fe-bLf PI3K and ERK were related 
inversely where dominant differentiation was induced by ERK.  
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Furthermore, bLf and Fe-bLf influenced positively the expression of lactoferrin receptor and 
differentiation as observed with the miRNA 584-5p and miRNA 214-3p expression.              
In summary, the cell permeable recombinant SurR9-C84A mutant protein showed rapid 
internalization in the differentiated and undifferentiated SK-N-SH cells. It exhibited 
differential actions in the tumor cells and differentiated neurons where apoptotic and 
protective actions were predominant respectively. The apoptotic actions were evident by its 
dimerization with the wild type survivin and making it unavailable for complexing the 
caspases and thereby setting them free. In addition, forceful expression of survivin by treating 
with SurR9-C84A disturbed microtubule dynamics, destabilized XIAP and initiated the 
apoptosome formation following which mitochondrial mediated cell death was observed.       
In the case of retinoic acid differentiated neurons with a low endogenous survivin pool, 
SurR9-C84A enhanced proliferation and protection by stabilising the microtubule dynamics 
and XIAP protein indistinguishable from the wild type. Further, to this the neuroprotective 
actions of SurR9-C84A tested against the β-amyloid plaques were prominent rescuing the 
neurons from toxicity. In addition, the β-amyloid associated inflammatory insults were also 
nullified by its extensive protective actions where ERK pathway was involved. Also, the milk 
protein bLf and its variant showed significant differentiation in cumulative doses following 
the PI3K and PI3K/ERK signalling mechanisms respectively. Thus, SurR9-C84A, bLf and 
Fe-bLf finds tremendous application for treating a variety of neurological disorders ranging 






7.6. Preparation and characterization of nanoparticles 
7.6.1. Polymeric nanoparticles 
They fall in a size range of 10-1000 nm and endowed with special features of carrying high 
drug loads in addition to protecting the encapsulated drug against degradation. They are quiet 
stable and exhibit unique surface properties that can be easily modified to disguise the 
macrophages of reticulo endothelial system [375]. There are several ways of preparing 
polymeric NPs and the list is described as follows.  
7.6.1.1. Solvent evaporation 
This is the most commonly adopted technique for the polymeric NPs preparation which 
further includes the strategies of preparing either single-emulsions (e.g. oil-in-water, O/W) or 
the double-emulsions (e.g. W/O/W).  In brief, this technique involves the polymer dissolution 
in the organic solvents like dichloromethane, ethyl acetate, acetone etc. The emulsion is 
formed when the aqueous phase with the surfactant is added to the polymer solution 
following which sonication or homogenization induces the formation of nanosized polymeric 
droplets. Then, the organic solvent is evaporated on a magnetic stirrer and the NPs are 
collected by centrifugation [376].  
7.6.1.2. Salting out 
Salting out process was first introduced by Bindschaedler et al 1990., who described a 
modified version of the emulsion process that lacks the use of toxic surfactants and 
chlorinated solvents. In this technique, the polymer solvent is completely miscible with water                 
(e.g. acetone) and the emulsion formation is achieved by dissolving high concentration of salt 







In this technique, drug and polymer are solubilised in the organic phase and added to aqueous 
surfactant phase. Then under reduced pressure, the organic phase is evaporated leading to the 
precipitation of NPs [378]. 
7.6.1.4. Dialysis 
This technique often resembles the nanoprecipitation method and offers a simple yet effective 
method for the small and homogenous NP fabrication. In brief, the desired polymer is 
dissolved in an organic solvent and introduced into a dialysis tube and dialysed against an 
immiscible solvent. The gradual displacement of the solvent leads to the progressive 
aggregation and formation of homogenous NPs suspension [376]. 
7.6.1.5. Supercritical fluid technology 
In order to outweigh the potential toxicity associated with the use of organic solvents, 
supercritical fluid technology has been introduced as a much safer alternative to the 
conventional methods of NP preparation. This technique involves the rapid expansion of 
supercritical solution, where the solute is dissolved in a supercritical fluid forming a solution. 
Then, the solution is rapidly evaporated forcing it through an orifice or a capillary nozzle 
where the rapid pressure reduction results in homogenous NPs formation [379]. Apart from 
these techniques, there is interesting literature available on the polymerisation of monomer 
technology for the fabrication of polymeric NPs [376]. In addition, this technique has three 






i. Conventional emulsion polymerisation: It involves the use of water, a low water 
soluble monomer as a solubilising initiator and a surfactant. Poly(alkyl cyanoacrylate) 
nanoparticles are majorly prepared by this technique. 
ii. Surfactant-free emulsion polymerization: It is similar to the above technique described 
except the inclusion of surfactants for polymerisation (e.g. polyacrylate NPs). 
iii. Mini-emulsion polymerization: This technique is different from the above as it 
employs the use of a low molecular mass co-stabilizer and a high-shear device 
(ultrasound) for the polymerisation to occur. 
7.6.2. Preparation of metallic nanoparticles 
The metal NPs have significantly garnered the researcher’s attention on account of their 
potential application in the fields of biomedical sciences and engineering. They are indeed the 
focus of interest, as they can be synthesized with the inclusions of several structural and 
surface modifications. This has opened new avenues for their application in the fields of 
targeted drug and gene delivery, magnetic separation, target analyte concentration and most 
importantly the diagnostic imaging.  The various imaging techniques such as MRI, PET, CT, 
SERS and ultrasound are invaluable in detailing the existing disease condition, but they 
require a contrast agent for effective functioning. Thus, it paved the way for the invention of 







7.6.2.1. Iron oxide NPs 
Iron mainly exists in three oxide forms which are the FeO, (Fe2O3) and Fe3O4.  Fe2O3 is an 
inorganic, reddish brown compound and exhibits paramagnetic nature while Fe3O4 is 
superparamagnetic compound naturally occurs as the mineral magnetite. The 
superparamagnetic iron oxide nanoparticles (SPION) have an ultrafine size, brilliant 
magnetic properties with enhanced biocompatibility. These unique features entitle them as 
promising candidates for various biomedical applications and in addition they serve as 
excellent MRI contrast agents with improved in vivo stability [381]. Chemical                     
co-precipitation of iron salts is the most commonly employed technique adopted for the 
synthesis of magnetite nanoparticles. This technique favours the bulk synthesis of the NPs but 
however lacks the control on size distribution and therefore results in the formation of 
ultrasmall particles of iron oxide (USPIO) (10–40 nm) and small particles of iron oxide 
(SPIO) (60–150 nm). USPIOs can sometimes be monocrystalline and called as 
monocrystalline iron oxide nanoparticles (MIONs) [382]. 
7.6.2.2. Gold NPs 
Colloidal gold, also termed as gold NPs is a colloidal suspension of nanosized fine gold 
particulates and the history of their usage dates back to the Roman times where it was used to 
stain the glass [383]. However, the modern science has discovered that the colloidal gold NPs 
have different physicochemical properties when compared to the bulk gold and hence find 
potential application in the biomedical field. Gold NPs are generally prepared by the 
reduction of hydrogen tetrachloroaurate (HAuCl4) gold salts using citric acid that give rise to 
the NPs of 10-20 nm [384]. However, several other modifications have been introduced to 
synthesize gold NPs of variable sizes and shapes.  
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7.6.2.3. Silver NPs 
Silver NPs though called as the particles of silver, they are often composed of huge 
proportions of silver oxide and range in the size of 1 to 100 nm. Similar to the gold NPs, the 
use of silver dates back to the history finding its initial use as a decorative item.  Typically, 
silver NPs are synthesized by the reduction reactions where silver salts are reduced in the 
presence of a colloidal stabiliser yielding fine nanosized particulates. The recent 
advancements include the use of a reducing sugar (β-d-glucose) and starch as the stabiliser in 
the fabrication process [385]. 
7.6.3. Characterization techniques 
In order to have an understanding of the nanoparticle synthesis and their applications, it is 
highly essential to characterize the same. Ever since, the introduction of nanotechnology 
tremendous efforts have been made in framing the characterization techniques with regards to 
their size, shape, morphology and etc. Microscopy techniques are most popular for assessing 
the particle size and morphology characterization. Among these, scanning electron 
microscopy (SEM) and transmission electron microscopy (TEM) are vital in determining the 
particle size and atomic absorption spectrophotometry (AAS) is used to find the metallic NPs 
concentration.  
7.6.3.1. Scanning electron microscopy 
SEM is an advanced and sophisticated microscopic technique employed for studying the 
morphology, size, shape and conductivity of the sample. This technique also allows 
visualisation of the samples at the nanoscale range. It is easy to analyse the SEM images 
although it has a much lower resolution of 15 nm compared to TEM.  
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The general principle involved is that an electron beam is made to hit the surface of the 
sample and the emitted waves were collected by the detectors allowing them to be visualised 
digitally [386]. 
7.6.3.2. Transmission electron microscopy 
TEM is another highly sensitive method of visualizing the morphology of the NPs and added 
to this it also facilitates imaging of the particles that are of few angstroms (10
-10
 m) and sub-
atomic size. The principle behind this technique is that the thin specimen is penetrated by a 
monochromatic electron beam. A part of the beam will be transmitted through the objective 
lens following which it is projected onto a visual screen generating the image. Further 
advancement was made with the introduction of high-resolution transmission electron 
microscopy (HRTEM) that is capable of imaging the specimen’s crystallographic structure at 
an atomic scale. Thus, the high resolution imaging made possible by TEM is indeed a 
valuable tool to interpret ultrasmall features of crystalline material [386]. 
7.6.3.3. Dynamic light scattering 
Dynamic light scattering is a technique related to physics and used for studying the particle 
size and their distribution profile in a solution. The principle involved is that light scatters in 
all directions when it hits a smaller particle and the scattered light undergoes interference 
within these fluctuations. DLS is commonly employed as a preliminary technique for 






7.6.3.4. Differential scanning calorimetry 
Differential scanning calorimetry (DSC) is a thermo analytical technique employed for 
detecting the thermal stability and possible polymer protein interactions. The heat changes 
are analysed comparing the sample with the standard as a function of temperature.              
The principle behind it is that when a sample undergoes phase transition, it either allows the 
inflow or outflow of heat that is considered as the endotherms or exotherms and is 
characteristic to specific material. Absence of crystalline peak also infers the amorphous 
phase of the protein encapsulated inside the NPs [241, 242].   
7.6.3.5. Fourier transform infrared resonance 
FTIR spectroscopy is a valuable tool in characterizing the protein binding and its integrity 
once encapsulated within the NPs and generally measures absorption spectrum. The principle 
here is that when a single light beam or multiples of it are allowed to pass through the desired 
sample, it records the absorbance corresponding to the wavelength that the sample emits. 
Later, the graph plotted is analysed and the characteristics of the sample is determined. This 
technique allows detecting the presence of drug loading on to the nanoparticle as it gives as 





 confirms the protein encapsulation within the NPs and represent the 
amide I and II bands respectively. These bands arise due to the corresponding C=O and N-H 






7.6.3.6. X-ray diffraction 
X-Ray diffraction (XRD) is a conventional technique for determining the structure, phase 
transitions and average size of the metallic NPs. The basic principle adopted is that the        
X-rays are allowed to strike the powdered specimen and measuring the X-ray diffraction 
angle details the structure and the lattice parameters of the NPs powder. The size of the NPs 
measured through XRD seems to be bigger as determined through TEM studies due to the 
widening of the X-ray diffraction lines [388]. 
7.6.3.7. X-ray absorption spectroscopy 
X-ray absorption spectroscopy (XAS) is a valuable technology available for determining the 
geometric and/or electronic structure of the desired sample. Synchrotron radiation sources are 
utilised for this study that can generate intense X-rays that are fine tuned for exciting the core 
electrons (0.1-100keV photon energy). The application of this technique provides a detailed 
knowledge related to the bond angles, bond lengths and presence of conjugates around the 
specimen employed in addition to its local structure [386]. 
7.6.3.8. Small angle neutron scattering 
This technique is used to determine the structure of various specimens that fall in a range of 
1-1000 nm where it utilises elastic neutron scattering at a smaller scattering angles. In brief,   
a beam of neutrons is passed through a sample where they are scattered either because of the 
nuclear interactions or due to the magnetic interactions of the unpaired electrons. This is 
perhaps a very useful technique for studying the magnetic NPs detailing the features of 
surface area, shape of the scattered particles, magnetic structure and the effect of external 
magnetic field on them [389]. 
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Table 7.1. Various parameters and characterization of nanoparticles. 
S.No Parameter analysed Technique employed Ref 
1 Particle size, morphology and distribution 




Scanning electron microscopy 
[352] 
[351] 
2 Nanoparticle surface charge Zeta potentiometer 






Drug stability and encapsulation inside 
the nanoparticle 
Fourier transform infrared 
resonance and SDS-PAGE gel 
electrophoresis 
[226] 
5 Active nanoparticle surface analysis 
X-Ray diffraction [353] 
6 
Structure and the lattice parameters of the 
nanoparticles 
7 
Bond angles, bond lengths and presence 
of conjugates around the nanoparticle 
surface specimen 
X-ray absorption spectroscopy [351] 
8 
Magnetic nanoparticle surface charge, 
area and magnetic influence 










7.7. Targeted therapy and its applications 
Though NPs have revolutionised the therapeutic research the concept of targeted therapy is 
now attracting attention. Ideally, targeted therapy endows target specific delivery of a drug 
molecule bypassing the barriers retaining the therapeutic activity. For instance, BBB poses 
severe hindrance to the drug penetration and hence modifying the NP surface with a brain 
specific marker would certainly enhance the drug availability. Other added advantage of 
targeted therapy is that normal healthy cells are spared from the drug actions reducing the 
untoward actions [5]. However, fabrication of targeted therapeutics is not a cake walk as 
identifying the targets for site specific delivery is a big issue. Owing to the potential benefits 
of targeted therapy, intense research is being directed towards it with a future hope of clinical 
application. As discussed earlier, drug penetration can be facilitated by opening the BBB 
using agents such as mannitol and retinoic acid. As it involves the disruption of brain milieu 
and its homeostasis, it is not advisable to follow this method [390]. The principal aim of 
targeted delivery is to localise a diagnostic or therapeutic agent to a desired site provided the 
NP is customised with the corresponding site specific marker. If successfully prepared 
targeted delivery offers potential advantages such as: reduced dose of the therapeutic than 
given by conventional delivery due to the enhanced bioavailability and reduced non-specific 
biodistribution abrogating the toxicity reactions. The rate limiting factors to be considered in 
the fabrication of targeted therapeutics are the chemical properties of the NP, its size and the 
availability of the targeting ligand. In addition, a detailed understanding of the PK of the 
targeted therapeutics is essential in evaluating the dose that will further cut down the non-






The application of targeted therapeutics is booming with the understandings of ligand 
identification and nanochemistry. As discussed earlier, transferrin receptor Ab conjugation 
was found effective for the delivery and activity of docetaxel-loaded poly(lactide)-d-α-
tocopheryl PEG succinate NPs in vitro and in vivo [392]. Similarly, the antioxidant tempol 
loaded PLGA NPs were claimed to show effective application against the AD and PD [393]. 
Intriguing results were obtained when the polyamidoamine (PAMAM) dendrimers were 
conjugated with lactoferrin protein. The conjugation showed enhanced permeation through 
the brain endothelium and showed no competition with the endogenous lactoferrin for 
receptor binding [394]. Angiopep-2 peptide is also the much explored conjugate and so as 
PAMAM dendrimers surface modified with it showed selective and enhanced brain delivery.  
The results were promising where a significant improvement was observed in vitro and        
in vivo models of glioma when tested and the mechanism of internalization was reported 
through LRP mediated endocytosis [395]. Another peptide that was tested never before was 
the Pep TGN (a 12-aminoacid peptide). Surface modification of the PEG-PLGA NPs with 
this peptide showed selective and enhanced brain permeation with a minimal non-specific 
distribution in the liver and spleen [396]. Similar results were observed when the chlorotoxin 
modified dendrimers were investigated against the glioma model in vivo [397]. Coenzyme-
Q10 loaded PLGA NPs that were modified with trimethylated chitosan were investigated in 
an in vivo AD model. These NPs were uptaken via adsorptive-mediated transcytosis and were 
observed to have potential neuroprotective activity [398]. Another study reported the 
significant uptake of anti-amyloid antibody (IgG4.1) modified polymeric chitosan NPs, when 




Neuroprotective agents were also tested in vivo AD model where the polymerosomes 
packaged with the neuroprotector S14G-humanin was found to reverse the choline acetyl 
transferase (ChAT) activity [400]. In order to further escalate a dual conjugated polyethylene 
glycol-polycaprolactone di block co-polymer (PEG-PCL) NPs were surface modified with 
Angiopep-2 and EGFP-EGF1. Angiopep provided the permeation through the BBB while the 
EGFP-EGF1 protein (selectively expressed in neuroglial cells) selectively restricted the NP 
accumulation within the glial cells [401]. This nano-complex would certainly benefit the 
glioma therapy if translated at pre-clinical and clinical levels. Conjugation with aptamers is a 
new revolution in the field of targeted therapy. Aptamers represent a class of oligonucleotide 
or peptide molecules that can specifically bind to a molecule that is either a nucleic acid or a 
protein and interferes its function [402]. On similar lines PEG-PLGA NPs loaded with 
paclitaxel were conjugated nucleolin DNA aptamer (AS1411) and tested in a glioma model.  
Nucleolin that is found to be overexpressed in glioma was effectively inhibited and the rats 
were also observed to show significant improvement [403]. Further to this, targeted therapy 
was also directed to abrogate the neuro-inflammation which would address the diseases such 
as MS. Leukemia inhibitory factor (LIF) was the potential ligand identified which has a 
potential role in mediating the anti-inflammatory effects. Some of its potential effects are the 
facilitation of T-regulatory cells maturation and the inhibition of Th17 progression. It has 
been shown that the LIF-modified PLGA NPs directed against the CD4+ T-cells opposed the 
Th17 development and also prolonged the survival of vascularized heart grafts in mice [404]. 
Stroke therapy is also being investigated where  it was found that perfluorocarbon NPs 
conjugated with fibrin-specific urokinase (clot buster) and anti-fibrin antibodies have 
dissolved the clot specifically [405]. Not limiting to the therapeutics, gold NPs modified with 
the anti-tau mAb was applied for diagnostic study.  
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Interestingly, the conjugated NPs showed extreme detection sensitivity of 1 pg/ml of tau 
protein proving the multifunction applications of targeted delivery [406]. Likewise, iron 
oxide NPs customised with sialyl Lewis X, a selectin specific ligand showed increased 
accumulation when observed through MRI in an in vivo experimental autoimmune 
encephalomyelitis model [407]. Thus, a vast application of targeted nanotherapeutics is 
currently being evaluated and translating this research to the clinic is the biggest challenge. 
At present, only few formulations such as the doxorubicin loaded liposomes, albumin coated 
paclitaxel NPs and micelles are available for human use. Overall, the success of managing the 
CNS diseases using targeted therapy depends on the ligand identification and the 


















7.8. Future work 
The current aging population has significant preponderance of neurological disorders 
representing shocking demographic features of the neurodegenerative diseases. Hence, the 
search for new molecules/compounds is highly desirable. The present approach is the first 
lead in testing compounds showing either neuroprotection or neuroproliferation. Since, it has 
been shown that SurR9-C84A has the ability to proliferate the differentiated neurons, future 
work requires assessing its proliferative potential in the neural progenitor cells. In addition, 
SurR9-C84A has proven neuroprotective activity against oxidative stress, T-cell mediated 
inflammatory insults [138, 197] and is also seeming to be beneficial against the β-amyloid 
and T-cell insults. The neuroprotection was evident with a drastic reduction in the apoptotic 
molecules such as the Cyt-c and caspase-3 along with a significant elevation of the survival 
factors such as the survivin, HSP70 and livin. Hence, it would be highly inquisitive to 
investigate the neuroprotective potential of SurR9-C84A in the in vivo models of 
degeneration that can address a range of neurodegenerative diseases such as AD, MS etc. 
Furthermore, the natural milk based proteins, bLf and Fe-bLf showed remarkable 
differentiation in the tumor cells that require careful evaluation in the animal systems. On the 
other hand, treating the neurological disorders is a challenging task due to the discrete 
location of the brain and the presence of a highly regulated blood–brain barrier further 
complicates the therapeutic delivery. To conclude, with the advent of targeted 
nanoformulations, delivery of SurR9-C84A, bLf and Fe-bLf alone or in conjugation with the 
other neuroprotectors not only will enhance the brain permeation but also will yield 
improvised therapeutic outcome. Hence, careful in vivo evaluation of these nanoformulations 
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